

Index

Notes: Page numbers in *italics* indicate figures and those in **bold** denote tables and boxes.

a

- abducens nerve (CN VI) 136
 - anatomy 697
 - examination **24**
 - function 694
 - lesions, corneal reflex deficit 26
 - motor nucleus 697
- aberrations, optical *see* optical aberrations
- abortion
 - aspergillosis 751
 - cryptococcosis 749
 - equine herpesvirus-1 740
 - equine viral arteritis 737
 - leptospirosis 470
 - mare reproductive loss syndrome 766
 - toxoplasmosis 748
- abscess(es)
 - corneal *see* corneal abscess
 - deep stromal *see* deep stromal abscess (DSA)
 - encapsulated 157
 - fungal stromal *see* stromal abscesses
 - iris, fungal 372
 - lacrimal gland 304
 - lymph node, strangles 743, 743, 744
 - orbital 156, 157
 - orbital cellulitis 157
 - Rhodococcus equi* infection 772, 772
 - stromal *see* stromal abscesses
 - ultrasound 108
- abscessation
 - dental arcade trauma 150
 - eyelid, ultrasound 108–109
 - lacrimal gland 304
 - stromal *see* stromal abscesses
- accessory ciliary ganglion 699
- accommodation, lens 629, 644–645, 655
 - chromatic aberrations and 643
 - fine-tuning 645
 - mechanism 442, 644, 645
 - range 644
 - speed 645
 - stimulus for 644, 645
- A-cell 400
- acepromazine, for examination 9, **10**
- Acer rubrum* (red maple) ingestion 768
- acetazolamide
 - glaucoma 556
 - hyperkalemic periodic paralysis 759
- acetylcholinesterase inhibitors, glaucoma 556
- N-acetylcysteine
 - cautions on use 356
 - in corneal bacterial infection 355, **355**, 356
 - neurogenic keratoconjunctivitis sicca 218
- acidic burns, corneal 323
- Acinetobacter* spp., corneal/conjunctival surface
 - microflora 263
- “acoustic shadow”, ultrasound 110
- actinic blepharitis 208, 208
- actinic radiation, adnexal SCC
 - association 228–229
- actinic solar keratitis 227
- Actinomyces*, orbital cellulitis 156
- acute phase proteins 723, 753
- adenine 661
- adeno associated virus (AAV) 480
- adenocarcinoma
 - frontal sinus 163
 - metastases in posterior segment 606, 607
 - nasal 163
 - orbital 162, 163
 - pulmonary 487, 606
- adenovirus infection 742, **742**
- adipocytes 53
- adnexa
 - anatomy and physiology 187–191
 - MRI 99
 - surgery, instruments 55
 - see also* eyelid(s); nasolacrimal system; *other specific structures*
- adnexal diseases/disorders 187–252
 - acquired 203–239
 - congenital 199–203
 - conjunctival *see* conjunctiva
 - economic impact 187
 - eyelid *see* eyelid disorders
 - future research 239
 - importance 187
 - masses, biopsy 54
 - neoplasia 220–239
 - cytology 53
 - frequency and types 220
 - miscellaneous types 238–239
 - referral 220
 - treatment response 220
 - see also specific tumors*
 - prevalence 187
 - see also specific disorders*
- adnexal lymphosarcoma 236–237
- adnexal melanoma 235, 235–236
- adnexal squamous cell carcinoma 226–235
 - age at diagnosis 227
 - aggressive 228, 228, 229
 - atypical pigmented 228
 - breeds associated 227
 - clinical appearance 227–228
 - COX-1/COX-2 and 229–230
 - diagnosis 227–228
 - definitive, methods for 228
 - differential diagnosis 228
 - environmental factors associated 227, 228–229
 - gender predisposition 227
 - genetics 228
 - histology 228, 229
 - invasive 228
 - metastases 189, 226, 235
 - noninvasive 228
 - papillomatous 227, 228
 - pathogenesis and progression 228–229
 - plaque (carcinoma *in situ*) 227, 228
 - prevalence 226, 227
 - prognosis 226
 - recurrence 231, 232, 233, 235
 - sites 227
 - treatment 230–235
 - brachytherapy **230**, 235
 - carbon dioxide laser ablation **230**, 232, 232–233
 - chemotherapy **230**, 233–235
 - cryotherapy **230**, 231–232

- adnexal squamous cell carcinoma (*cont'd*)
- hyperthermia 230, 232
 - immunotherapy 230, 233
 - medical 230
 - photodynamic therapy 230, 233, 234, 235
 - surgical 230, 230–231
 - ultrasound 108
 - unilateral, or bilateral? 227
 - well-differentiated 228
- β -adrenergic blockers, glaucoma 555, 555
- adrenergic receptors 216
- adrenocorticotrophic hormone (ACTH), in PPID
- 759, 761
 - monitoring 762
 - testing 761
- aerial perspective 633–634
- African horse sickness (AHS) 139, 148, 739, 739, 739
- age
- lens changes with 499–500
 - visual acuity with 638
- aged horses *see* geriatric horses
- Agriculture and Agri-Food Canada 793
- air, between skin and calvarium 147
- air embolism 765–766
- clinical signs 765, 765–766
- airflow, reduced, from ipsilateral nostril 147
- akinesia, eyelid 11–12
- alar canal 94
- albinism, ocular 574, 575
- albinotic coat color, undeveloped tapetum fibrosum 19
- albumin, tear film 364
- alcian blue 35
- Alcon pneumotonograph 46
- alignment (vernier) acuity 648
- alkali burns, corneal 323
- alleles 664, 665
- penetrance 665
- allergic blepharitis 208
- allergy 53
- alloantibodies 771
- alloantigen 771
- alopecia
- occult sarcoid 221, 221
 - pemphigus 755
- alphaherpesvirus 739
- alsike clover (*Trifolium hybridum*) 767
- Alternaria* 358
- corneal/conjunctival surface microflora 264, 265
- amacrine cells 566, 691, 692
- amblyopia, deprivation 520
- ambulatory field practice setting *see* field practice
- ambulatory practitioners 3
- American Association of Equine Practitioners (AAEP) 793
- pre-purchase examination guidelines 77
- American Paint horses
- lethal white foal syndrome 681
 - squamous cell carcinoma 675
- American Quarter Horse Association 793, 794
- Official Handbook Show Rules 794
- American Quarter Horses
- hyperelastosis cutis 281
 - regulations regarding ophthalmic disease 794
- American Saddlebred horses, junctional epidermolysis bullosa 680
- ametropia 40, 518, 639
- spherical 639
 - see also* hyperopia (far-sightedness); myopia (near-sightedness)
- amikacin 354
- aminoglycosides 354, 769
- amniotic basement membrane 400
- amniotic membrane (amnion) 400
- anti-inflammatory/anti-angiogenic properties 400, 401
 - antimicrobial/antiviral properties 400
 - epithelium 400
 - grafts *see* amniotic membrane transplants (AMT)
 - harvesting 401
 - homogenates, corneal ulceration healing 356
 - layers/structure 400
 - properties, and growth factors 400
 - proteins, identification map 401
 - storage 401
 - stromal matrix 400
- amniotic membrane transplants (AMT) 271, 400–402
- application methods 401
 - benefits and actions 400
 - complications 402
 - corneal fibrosis reduction 271
 - corneal vascularization prevention 272
 - as disposable dressings 400
 - double-layer, melting corneal ulcer 382
 - epithelialization after, factors involved 400
 - filling-in or layering technique 401
 - harvesting of membrane 401
 - indications 400, 401
 - corneal SCC 289, 290, 298, 402
 - deep corneal ulcer 381
 - destructive keratitis 400, 401
 - keratomalacia (melting ulcers) 340, 341, 380, 381, 382, 386, 400, 401
 - keratomycosis 377
 - ulcerative keratomycosis 365
 - inlay or graft technique 401
 - outcomes 402
 - overlay or patch technique 401
 - patient preparation 402
 - penetrating keratoplasty with 407
 - postoperative care 402
 - principles 400–401
 - as scaffold for epithelial cell migration 401
 - storage of membrane 401
 - superficial keratectomy with 394
 - sutureless techniques 402
 - technique 401, 402
 - versatility 401
 - visual orientation of patch 402
- amphiphilic drugs, corneal diseases 273
- amphotericin B, keratomycosis 374, 376
- ampicillin sodium, orbital disease 164
- amprolium 729
- amyloid L 287
- amyloidosis, corneal 287
- b-amyloid precursor protein 709
- anaerobic infections, corneal ulcers 343
- anaerobic sepsis 153
- analgesia, local, ocular examination 11–15
- Anaplasma phagocytophilum* (*Ehrlichia equi*) 747
- anaplastic sarcoma 161
- anatomy and physiology
- adnexa 187–191
 - globe and orbit 133–138
 - retina 566, 691–693, 692
 - uvea tract 441–444
 - see also* individual structures
- anemia, equine infectious *see* equine infectious anemia (EIA)
- anerobic bacteria, antibiotics against 165
- anerobic infections, corneal ulcers 343
- anerobic sepsis 153
- anesthesia
- cataract surgery 524
 - conjunctival 12–14, 13
 - corneal 12–14, 13
 - corneal surgery 391–392, 394
 - general *see* general anesthesia
 - ischemia/hypoxia, visual deficits after 707
 - local *see* local anesthesia
 - nerve blocks *see* nerve blocks
 - regional 12, 12, 13
 - retrobulbar 14
 - topical *see* topical anesthesia
- anesthetics, topical, ocular surface 13
- angiogenic factors
- deep stromal abscess 388
 - tear film 262
 - vascularization of cornea 263, 388
- angiogenic privilege, corneal 263
- angiography
- sodium fluorescein 125
 - see also* ocular angiography
- angiomatosis 149
- angiosarcoma
- corneal 298, 299
 - eyelid 163
 - orbital 163
- angular aqueous plexus (AAP) 137, 543, 544
- high-resolution ultrasound 550, 551
- anguli oculi vein 190
- aniridic keratopathy 278, 278
- Animal Medicinal Drug Use Clarification Act (AMDUCA) 1994 796–797
- aniridia 444–445, 446, 678–679, 679
- bilateral congenital 679
 - breeds associated 662, 679
 - cataracts 444, 501, 502, 679
 - clinical appearance 444–445, 679
 - congenital 278, 278, 679
 - congenital dermoid with 275, 679
 - inheritance 444, 662, 679
 - pathophysiology 679
- anisocoria 23, 25, 708–709

- dynamic contraction 25
- anisometropia 40
- ankyloblepharon 200, 201, 202
 - amniotic membrane transplant 401
- anophthalmia 141
- anterior chamber 55
 - in acute uveitis 452
 - aqueous humor volume 55
 - in cataract surgery 528, 530
 - fibrin formation after 533, 534, 535
 - collapse, lens capsule rupture 515–516
 - CT 94
 - depth, normal reference range 9
 - examination 30–31, 31
 - foreign bodies 328, 328, 329
 - hyphema, after trauma 607, 607
 - infrared photography 114–115, 115
 - irrigation during cataract surgery 528
 - lens in (ectopia lentis) 503
 - maintenance during corneal surgery 393
 - mass, differential diagnosis 485
 - in penetrating keratoplasty 405
 - red, trauma 150
 - tan-yellow exudates, in MPLS 766
 - therapeutics injection 57
 - in trilaminar clear corneal incision 527, 528
 - ultrasound 103, 105
 - high-resolution 552
- anterior chamber-associated immune deviation (ACAID) 259, 307
- anterior ciliary arteries 136–137
- anterior cortical cataracts 508, 510, 512, 518
- anterior lamellar keratoplasty (ALK) 408
 - indications 408
- anterior lens capsule cysts 505, 505–507, 506
- anterior rectus muscle 140
- anterior segment
 - abnormalities, in MCOA syndrome 585
 - acute uveitis 452
 - angiography 124, 125, 125
 - clinical signs 446
 - embryology 446
 - examination 29–30
 - masses, ultrasound 107, 112
 - ultrasound 104–105
 - see also* cornea; iris; lens
- anterior segment dysgenesis (ASD) 272, 445–446, 670
 - congenital leukoma with 276
 - microcornea association 275, 275
 - see also* multiple congenital ocular anomalies (MCOA) syndrome
- anterior stromal lamellar transplantation (ALK) 408
- anterior synechia *see* synechiae, anterior
- anterior uvea *see* uveal tract, anterior
- anterior uveal cysts *see* uveal cysts, anterior
- anterior uveitis *see* uveitis, anterior
- anti-angiogenic drugs, IMMK therapy 312–313
- anti-angiogenic factors/molecules
 - expression in cornea 263
 - fungi releasing, ulcerative keratomycosis 365
- vascularization of cornea 388
- antibiotics
 - for anerobic bacteria 165
 - bacterial meningitis in neonatal foals 770
 - blepharitis 207
 - botulism 732
- cataract surgery 525
 - post-operative 524, 532
 - pre-operative 524
- conjunctival grafts, for corneal ulcers 395
- conjunctivitis 205
- corneal disease, pulsed delivery 273
- corneal erosion 337–338, 338
- corneal ulceration 353, 354, 356
- corneoconjunctival transposition 399
- empiric, stromal abscesses 389
- equine granulocytic anaplasmosis 747
- equine recurrent uveitis 479–480
 - after facial trauma 154
- keratoconjunctivitis sicca 198
- leptospirosis 479
- Lyme disease 745
- meningitis/meningoencephalitis 729
- nasolacrimal disease 195, 196
- nasolacrimal duct atresia 194
 - postoperative 195
- nasolacrimal duct obstruction 196
- neonatal sepsis 769, 769
- neurogenic keratoconjunctivitis sicca 218
- orbital cellulitis 157
- orbital disease 153, 164–165
- orbital proptosis treatment 156
- parenteral
 - corneal ulceration 354
 - orbital disease 153
- post-direct corneal suturing 393–394
- prophylactic, for
 - orbital disease 164–165
 - recurrent (chronic nonhealing) erosion 337, 338
- recurrent (chronic nonhealing) erosion 337–338, 338
- resistance 353–354
- Rhodococcus equi* infection 773
- sensitivity testing 47–48
- sinus fractures 169
- strangles 744
- stromal abscesses 389, 390
- third eyelid disorders 220
- topical
 - bioavailability 389
 - conjunctivitis 205
 - corneal surgery 394
 - corneal ulceration 353, 354, 356
 - recurrent erosion 337–338, 338
 - ulcerative keratomycosis risk 360
- see also individual drugs*
- antibodies
 - intrathecal production, in EPM 722–723
 - in leptospirosis, ERU pathogenesis 467, 472, 473
 - see also specific antibodies; specific immunoglobulins*
- anticholinergics, topical, uveitis control in corneal ulceration 355
- anticollagenase agents 355, 388
- anti-epileptics 770
- antifungal drugs
 - aspergillosis 751
 - classes 373–374
 - corneoconjunctival transposition 399
 - frequency of treatment 377
 - fungicidal activity 373
 - intralesional/perilesional, stromal abscesses 389–390
 - keratomycosis 377
 - mechanism of action 373–374
 - stromal abscesses 389–390
 - susceptibility 373
 - systemic 374
 - topical 374
 - keratomycosis 373, 375, 376
 - stromal abscesses 389
 - see also individual drugs*
- antigen presentation, ERU 673
- antigen presenting cells (APCs) 258, 259, 261, 262
 - acute corneal graft rejection 415
- cornea
 - epithelial layer 258, 261, 262, 263
 - stroma 259
- germline encoded PRRs expressed 360
- immune-mediated keratitis 307
- keratomycosis incidence and 360
- leptospirosis-associated ERU, pathogenesis 473
- antiherpetic drugs 320
- anti-inflammatory therapy
 - cataract surgery 524
 - conjunctival pseudotumors 238
 - conjunctivitis, cautions 205
 - doxycycline and minocycline action 312–313
 - equine recurrent uveitis 747
 - after facial trauma 154
 - glaucoma 556
 - heterochromic iridocyclitis with keratitis 456
 - lens luxation 511
 - see also individual drugs*
- antimicrobial action, amniotic membrane 400
- antimicrobial proteins (AMPs) 254, 255
- antimicrobial therapy
 - sensitivity testing 47–48
 - see also* antibiotics; antifungal drugs
- antimycotic drugs *see* antifungal drugs
- antinuclear antibody (ANA) 756, 757
- antiproteases
 - amniotic membrane transplant 402
 - chemical injury management 324
 - conjunctival grafts 397, 398
 - corneal bacterial infection treatment 355, 355–356
 - treatment duration 356
- corneoconjunctival transposition 399
- deep lamellar endothelial keratoplasty 412
- for infectious keratitis 355, 355–356
- posterior lamellar keratoplasty 412

- antiproteases (*cont'd*)
 - for recurrent (chronic nonhealing) erosion 337–338
 - topical, corneal ulceration 353, **353**, 355, 355–356
 - ulcerative keratomycosis 377
- antivirals, equine herpesviruses 741
- APCs *see* antigen presenting cells (APCs)
- aphakia
 - bilateral, after phacoemulsification 519
 - post-cataract surgery 518, 519
 - primary 502, 503
- aphakic crescent 511, 514, 523
- Appaloosa horses
 - actinic blepharitis 208
 - adnexal SCC 227, 228
 - cataracts 474
 - coat patterns, CSNB and 667, 669, 674
 - congenital stationary night blindness 140, 141, 586, 586, 666–667, 811
 - equine recurrent uveitis (ERU) 463, 473–474, **662**, 673, 673–674
 - candidate genes 674
 - chronic ocular changes 474
 - economic impact 476
 - frequency 673
 - genetic basis 474, 665, 674
 - genome-wide association study 674
 - insidious 459, 459, 474, 673
 - leptospirosis associated 474
 - pedigrees 674
 - prognosis, blindness 474, **475**, 674
 - TRPM1* gene 674
 - variable expression 665
 - glaucoma 547, 548
 - leopard spots 667
 - normal night vision, coat pattern range 669
 - ophthalmic disease frequency 75
 - pemphigus 755
 - phthisis bulbi 474
 - severe combined immunodeficiency in 681
 - strabismus 140
 - uveitis 474
- applanation tonometry 43
- aqueocentesis, passive 558
- aqueous flare 31, 31, 452, 570
 - green, *Rhodococcus equi* infection 772
- aqueous humor (AH) 55, 441
 - aspiration 55
 - draining structures, embryology 261
 - leakage/loss
 - conjunctival grafts 395, 397
 - corneal perforation, with iris prolapse 417
 - corneal response 270
 - detection *see* Seidel test
 - after direct corneal suturing 393
 - low corneal endothelial cell level 260
 - ocular injury in facial trauma 152
 - perforating lacerations causing 334
 - prevention, in corneal perforation 417
 - reducing, tissue/surgical glue 418
 - microleaks, response 270
 - normal volume 55
 - outflow 442, 543–544, **544**, 551
 - conventional pathway 543–544, **544**
 - high-resolution ultrasound 550, 551, 551, 552, 553
 - into lymphatics 544
 - measurement 46
 - obstruction 545, 551, 553
 - obstruction, gonioimplants to
 - bypass 559, 559–560
 - pulsatile and segmental 544
 - pump-like mechanism 544
 - resistance to 544
 - tonography 46
 - unconventional/uveoscleral pathway 543, **544**
 - procedures performed on 55
 - production 441, **443**, 543–544
 - mechanism 543
 - reduced by carbonic anhydrase inhibitors 555–556
 - removal 174
 - viscosity 543
 - volume in anterior chamber
 - 55, 136
 - aspiration 55, 57
 - normal reference range **9**
- aqueous paracentesis 55–57, 56
 - complications 57
 - therapy injected using technique
 - for 57
- “Arabian fading syndrome” 208
- Arabian horses
 - congenital cataracts 678
 - severe combined immunodeficiency 681
 - vittiligo 208
- area centralis 566, 628, 692, 701
 - areas of 692
 - lesions 565
- area centralis rotunda 646, 692
- area centralis striaeformis 692
- arrectores ciliorum muscle 697
- arteriovenous anastomoses, intracranial 149
- artificial tears
 - facial nerve paresis/paralysis 217
 - after facial trauma 154
 - keratoconjunctivitis sicca 198, 305
- ascorbic acid, in chemical injury management 324
- aspergillosis 750–751
 - clinical signs 750, **750**, 750
 - guttural pouch mycosis 750
 - pulmonary 750–751
- Aspergillus*, infections 358, 750
 - antifungal drugs for 375, 376
 - blepharitis 206
 - conidia 358
 - corneal abrasions due to 361
 - corneal/conjunctival surface microflora 264, **265**, 266
 - in vivo* confocal microscopy 118, 120
 - natamycin efficacy lacking 375
 - precorneal tear film instability associated 360
 - stromal abscesses 387
 - yellow sweet clover infected, ingestion 768
- Aspergillus flavus* 358
- Aspergillus fumigatus* 358
- Aspergillus niger* 358
- aspiration
 - aqueous humor 55
 - with phacoemulsification *see* phacoemulsification
 - with aspiration
- aspirin, equine recurrent uveitis 478, **478**
- asteroid hyalosis 582, 583
- ultrasound 106–107
- astigmatism 41, 253, 639
 - compound hyperopic 639
 - compound myopic 639
 - after foreign body removal 329–330
 - frequency/prevalence 641
 - meridians 639
 - mixed 639
 - simple hyperopic 639
 - simple myopic 639
- astrocytes, retinal 691
- astrocytoma 606
 - optic nerve **598**, 602, 606, 606, 705
- ataxia
 - botulism 732
 - equine protozoal myeloencephalitis **721**, 722
- atrophia bulbi 145
- atropine/atropine sulfate 14–15
 - accommodation inhibition 645
 - cataract treatment 517
 - equine recurrent uveitis **477**, 478
 - glaucoma **555**, 556
 - mydriasis induction 14–15
 - pre-cataract surgery 524
 - prolonged, photophobia 517
 - regulations, for performance animals 794
 - stromal abscesses 390
 - toxic plants 768
 - ulcerative keratomycosis 377
 - uveitis control in corneal ulceration 355
- auriculopalpebral block 11, 12, 45, 104, 152
 - effect on IOP 45
 - enucleation 170
 - posterior segment evaluation 565
- auriculopalpebral nerve 11, 12, 189, 216–217
 - anatomy 697
 - branches 217
 - corneal reflex 703, 703
 - palpebral reflex 701, 703
 - zygomatic branch 697, 701, 703
- autoantibodies
 - in ERU 465, 467, 472, 473, 581, 590
 - leptospira-associated 473
 - in IMMK 307
- autoantigens
 - corneal 307
 - cross-reactivity with leptospira, in ERU 472, 473, 672

- equine recurrent uveitis 463, 464, 465, 467, 468, 587, 672
- autoimmune diseases
- dermatological 754
 - ERU *see* equine recurrent uveitis (ERU)
 - genetics 674, 675
- autologous mesenchymal stem cells (MSCs)
- equine recurrent uveitis 479–480, 673
 - IMMK treatment 313
- autonomic nervous system 214
- anatomy 698
 - disorders 216
 - eyelid supply 697
 - innervation of eye 698–700
 - lacrimal gland supply 700
- autosomal dominant inheritance 666
- autosomal recessive inheritance 666
- autosomal recessive traits 666
- autosomes 664, 665
- Avelignese horse *see* Haflinger horse (Avelignese horse)
- avermectin 751, 766
- avulsion, ocular muscles 137
- AW4 ointment, sarcoids 224
- a-wave, electroretinography (ERG) 41, 667
- axial globe length, normal range 9
- axons, damage by elevated IOP 546
- axoplasmic flow disruption, glaucoma 545, 546
- azithromycin, *Rhodococcus equi* infection 773
- azoles 374, 374, 751
- keratomycosis 374, 376
- ## b
- Babesia caballi* 747
- Babesia equi* (*Theileria equi*) 747
- bacille Calmette–Guérin *see* BCG (bacille Calmette–Guérin)
- Bacillus* spp., corneal/conjunctival surface microflora 263
- bacteria 52
- adhesion 339
 - mucus layer of precorneal tear film 255
 - prevention by glycocalyx mucins 255
 - culture, paranasal sinus samples 139
 - Gram-positive/negative *see* Gram-negative bacteria; Gram-positive bacteria
 - intra-/extracellular, cytology
 - interpretation 52, 52
 - nonpathogenic commensal 338–339
 - ocular surface microflora 263
 - pathogenic 339
 - replication in stroma 339
 - virulence 339
 - see also individual species*
- bacterial infection
- acute uveitis due to 453
 - blepharitis *see* blepharitis
 - conjunctivitis 203
 - corneal ulceration *see* corneal ulceration
 - keratitis *see* keratitis
 - meningitis in foals 770
 - neonatal sepsis 768
 - stromal abscesses 387
 - systemic, ocular manifestations 729, 731, 732, 743–747
 - ulcerative keratitis *see* ulcerative keratitis
 - see also individual bacteria; individual diseases*
- bacterial meningitis, foals 770
- bacterin, leptospiral 477
- Baerveldt gonioimplant 560
- bales, patient support 3, 4, 9, 10
- band keratopathy, glaucoma 549, 550
- band opacities, in glaucoma 549, 550
- barr body 664
- basal cells, corneal 257, 258
- basement membrane (BM)
- amniotic 400
 - corneal, nerve penetration 260
 - corneal endothelium 416
 - corneal epithelium *see* cornea, epithelial
 - basement membrane
 - primary epithelial disease 335
 - structure 258
- base pairs 661
- basilar skull fractures 764, 765
- basioccipital bone, fracture 134, 167
- basisphenoid bone, fracture 134, 167
- bastard strangles 744
- Baum's bumps 109, 110, 110
- BCG (bacille Calmette–Guérin)
- adnexal SCC 230, 233
 - corneal SCC 292
 - sarcoid treatment 224–225, 225
- BCSL *see* bilateral corneal stromal loss (BCSL)
- behavior
- undesirable, ocular disorders causing 615
 - visual deficits and 2, 615, 637
- behavioral studies
- chaining behaviors, visual performance
 - testing 648, 649
 - color perception 653, 653–654
 - color vision 652–653
 - form perception 648, 649
 - visual discrimination, learned 648
- behavior modification 63
- Belgian breed
- congenital cataracts 678
 - junctional epidermolysis bullosa 680
 - squamous cell carcinoma 676
- Belgian Comtois, megalophthalmos 146
- Belgian drafts
- adnexal SCC 228
 - aniridia 444
- Belgian Warmbloods, *DDB2* gene 676
- benign choristomas *see* dermoids
- Bergmeister's papillae 505
- β-adrenergic receptor 216
- β-adrenergic receptor blockers, glaucoma 555, 555
- betadine 391, 524
- beta-irradiation, corneal SCC 293–294, 297
- betalysins 254–255
- bicarbonate ions, transport 443
- biglycan (BGN) 678
- bilateral corneal stromal loss (BCSL)
- breeds, inheritance and gene variants 662
 - Friesian horses 677, 677–678
- binocular depth perception (stereopsis) 633, 634–635
- binocular disparity 629
- binocular vision 655
- panoramic view 631
- bioavailability of drugs, topical
- formulations 273–274
- biofilms 358
- biological materials, in lieu of amniotic membrane
- transplant 400
- biomicroscopy 17–18, 18
- slit-lamp *see* slit-lamp biomicroscopy
- biopsy 54–55
- adnexal masses 54
 - conjunctival 54, 55
 - eyelid margin 55, 56
 - fine-needle aspiration 39
 - orbital mass lesions 139
 - periocular and ocular 54–55
 - surgical, sarcoid diagnosis 221
- Biosist/Amnion 340, 341
- biosynthetic materials, in lieu of amniotic
- membrane transplant 400
- bipedicle grafts, conjunctival *see* conjunctival grafts
- bipolar cells 566, 622, 691
- light adaptation 622
 - number 648
 - structure, location 691
- black locust tree (*Robinia pseudoacacia*)
- ingestion 767
- black walnut tree (*Juglans nigra*) ingestion 768
- bleb fibrosis, gonioimplants, in glaucoma 559
- bleeding diathesis 768
- blepharedema (blepharodema) 157, 205, 206
- causes 206
- blepharitis 189, 206–208
- actinic 208, 208
 - allergic 208
 - causes 203–204, 206, 207, 208
 - clinical signs 203–204
 - differential diagnosis 207, 212
 - immune-mediated 203, 208
 - infectious 203, 206–208
 - clinical appearance 206–207
 - diagnosis 206–207
 - differential diagnosis 207
 - long-term prognosis 208
 - medical treatment 207–208
 - surgical therapy 208
 - in orbital cellulitis 157
- blepharoplastic procedures, in SCC 231
- rhomboid, with cryotherapy 231
- blepharospasm 11, 64
- acute anterior uveitis 452
 - bilateral, enucleation in 817
 - corneal foreign body 326
 - tonometry problem 44
- blindfolding, maze testing 26, 26–27

- blindness/blind horses 798–820, 810
 - acute onset
 - compressive optic neuropathy 706
 - ischemic optic neuropathy 705
 - adaptation to 798–800, 799, 807, 817
 - before training 808
 - anxious behavior 799, 800
 - appearance 814, 814
 - attachment between horses (buddies) 799, 800, 806–807, 807, 808
 - behavior 799, 800
 - after adaptation to vision loss 799, 800, 817, 818
 - blind horses as buddies (i.e. two blind horses) 807, 807
 - broodmares 811, 812
 - with foals 807–808
 - causes 707, 749, 766, 798
 - air embolism 766
 - blunt trauma, optic neuropathy 603
 - chronic vitamin A deficiency 764
 - cryptococcosis 749
 - diseases 798
 - equine recurrent uveitis 457, 474, **475**, 476, 672, 673
 - facial trauma 152
 - Fusarium* infestation of corn 768
 - glaucoma 549
 - ivermectin/pyrantel toxicosis 707, 766, 767
 - lens capsule rupture 515
 - meningioma 163
 - meningitis/meningoencephalitis 729
 - orbital fractures 167
 - orbital neoplasia 162
 - PPID (equine Cushing's disease) 759
 - strangles 743
 - toxic plants 767
 - West Nile virus encephalitis 728
 - cold weather hazards 805, 805, 806
 - communication with trainers 810
 - companion horses for 799, 800, 800, 806, 806–807
 - guidance by 807
 - location, clues to 800, 807
 - complete, regulations affecting 794
 - coping with 803
 - cortical 707, 708
 - ivermectin toxicosis 766
 - postanesthetic 707, 708
 - thiamine deficiency 729
 - toxic plants causing 767
 - debilitating discomfort 816
 - decision-making by owners 800–801, 815, 817
 - dominant sighted horses, bullying 806
 - dressage 813, 814–815
 - electroretinogram in 41
 - enucleation of blind eyes 816–817
 - euthanasia 798, 800
 - failing vision, adaptation 798
 - fight-or-flight responses/temperament 798, 803
 - fluorescein angiography 125
 - foals, congenital adnexal disease 202
 - handlers for 800, 805, 809, 817
 - hazards
 - elimination 804, 804–805
 - training for 809
 - winter 805, 806, 806
 - herd behavior changes 798, 806
 - human-horse partnership 817–818
 - imminent vision loss, concerning facts 798
 - incidence 798
 - as inspiration 817
 - internal GPS 802–803
 - life lessons with 817–818, 818
 - lives lead by 811–815, 817, 818
 - loud noises frightening 798, 804
 - management 798–820
 - tips **818**
 - maze test and 26, 26–27
 - mental maps 801–803, 802, 804
 - neural representation 802–803
 - ophthalmic disease frequency **75**, 76
 - owners, decision-making 800–801, 815, 817
 - owners, patience and love for horse 817–818
 - partnership with handler 817–818
 - as pasture pets 800, 811, 811, 817
 - poll trauma 764
 - postanesthetic cortical 707
 - predictable daily routine 800
 - riding 810, 813, 813, 815, 815, 817
 - safety precautions/concerns 800–801, 804–805, **818**
 - riding 810
 - sanctuaries for horses 807
 - social interactions 806–807
 - spatial navigation 802–803
 - special partnerships 817–818
 - special senses in 803
 - systemic illness causing 723, **723**
 - talking and touching by handlers 800, 805, 809
 - temperament in 800–801, 801
 - in therapeutic equine programs 814, 814
 - as trail horses 813, 813
 - training 808–810, 809
 - commands and cues 808, 809, 810, 815
 - dressage and 813, 814–815, 815
 - nonverbal cues 810
 - positive reinforcement 810
 - for riding 813, 813
 - as trail horses 813, 813
 - for working role 811–813
 - transient 708
 - transitional period 798, 799
 - trapped 798, 803
 - freeing 803, 817
 - turning out 800, 804
 - unilateral
 - intracranial neoplasia 734
 - regulations affecting 794
 - unilateral sight loss *see* unilateral sight loss
 - visual acuity description 636
 - visual cortex neuroplasticity 801–802
 - working role 811–813, 813
 - working with 814
- blind spots 629, 632
 - location 632
- blind staggers 723
- blinking 187
 - absence, in facial trauma 154
 - cataract evaluation 517
 - complete 26
 - dazzle reflex 25, 703
 - form of, facial nerve paralysis 217
 - frequency/normal 25–26
 - incomplete 25–26
 - lesion, menace response deficit 25
 - menace response 701
 - see also* menace response
 - normal 25–26, 190, 191
 - thermal injury, superficial 323
 - see also* palpebral reflex
- blink rate 190
- blink reflex *see* blinking; palpebral reflex
- blood–aqueous barrier 255, 441, 443, 444, 445
- blood–brain barrier, ivermectin toxicosis and 766
- blood flow, Doppler ultrasound 103
- blood–ocular barrier 444, 445
 - disruption 444, 452, 458
- blood–retinal barrier 255, 444, 445
 - activated T cell migration 466
 - CD4+ T cells, in ERU 463, 464
 - disruption, in ERU 463, 464, 466
- blood supply/circulation
 - conjunctiva 191
 - eyelids 189
 - orbital 136
 - uveal tract 444, 445
- blood–tear barrier 255
 - breakdown, effects 255
- blood transfusions 771
- blue-eyed horses 644
 - lethal white foal syndrome 681
- blue wavelength-sensitive (short; S) cone 651
- blunt trauma 606, 607, 764
 - clinical appearance and diagnosis 607, 765
- corneal *see* corneal trauma
- Descemet's membrane, discontinuous
 - rupture 283
- globe 326, 330, 330
- optic neuropathy due to 603–604, 604
- orbital 149, 151, 152
- photography 60
- posterior segment 606–608, 607
- prognosis, vision 516
- retrocorneal fibrotic membrane after 284
- treatment 607–608
- ultrasound 109
- blurring of retinal image *see* retinal image
- B lymphocyte(s) 51
 - adnexal lymphosarcoma 237
 - immunoglobulin production 262
 - lacking, SCID 681
 - lymphocytic nodules, ERU 468, 468
- bone deformation, orbital 148
- bone flaps, sinus surgery 180

- border cells 802
- Borna disease virus (BDV) 595, 605
- Borrelia*, hyalitis and 581
- Borrelia burgdorferi* 470, 744–745
 - outer surface proteins, antibodies to 745
- borreliosis, acute uveitis due to 453
- botulinum antitoxin 732
- botulinum toxin 732
- botulism 731–732
 - causes 732
 - clinical signs 731, 732
 - diagnosis 732
 - treatment, prognosis 732
- bovine papillomavirus (BPV) 222
- Bowman's layer, collagenous pannus replacing 280
- brachytherapy
 - adnexal SCC 230, 235
 - isotopes/radioactive sources 226, 230, 235
 - sarcoids 223, 226, 226
 - side effects 226
- bracken fern (*Pteridium aquilinum*) toxicity 729, 767
- brain
 - anatomy 694
 - color vision 651
 - damage 764
 - neuroanatomic pathways
 - for conscious vision 694–695, 695
 - for menace response 700–701
 - for vestibulo-ocular reflex 696, 696
 - positioning system, blindness 802–803
 - ventral surface 694
- brainstem auditory evoked responses, vestibular disease 731
- brainstem lesion, Horner's syndrome 710
- breed(s)
 - adnexal SCC 227
 - congenital stationary night blindness 586, 587, 662, 666–667
 - corneal SCC 288
 - equine recurrent uveitis 462–463, 473–474, 672, 673
 - at genetic risk 27
 - glaucoma 547
 - inherited ocular diseases 661, 662, 681
 - MCOA syndrome 585, 662, 670
 - retinal degeneration 595
 - sarcoids 221, 222–223
 - USEF rules 795–796
 - visual perspective and field of view 629, 630
 - see also individual breeds
- breeding/breeding advice
 - blind broodmares 811
 - congenital stationary night blindness and 811
 - decisions, genetic testing 681–682
 - hereditary equine regional dermal asthenia 758
 - leopard complex gene, importance 670
 - MCOA syndrome 586, 672, 811
 - neonatal isoerythrolysis prevention 771
 - silver (chocolate) coat color 672, 811
- bright light
 - cones 620
 - multiple pupillary apertures 645, 646
 - pupil shape and visual acuity 645
 - spherical aberrations 642
 - vision in, adaptations to improve 624–625
 - visual acuity in 638, 647
- brinzolamide, glaucoma 555
- bromfenac sodium, ERU 477, 478
- bronchopneumonia 742
- broodmares, blind 811, 812
 - with foals 807–808
- Brucella abortus* 746
- brucellosis 746, 746
- brunescence, lens 507, 507
- buccal cavity 137–138
- buckwheat (*Fagopyrum esculentum*) 767
- buffalo bur 768
- bulbar conjunctiva see conjunctiva, bulbar
- bullae, subepithelial (bullous keratopathy) 279, 309
 - rupture, erosions due to 279
- bullet-hole chorioretinitis 568, 590–591, 591
- bullet-hole lesions/scarring 459, 460, 568, 590–591, 591
 - chorioretinal, ERG evaluation 42
 - chorioretinitis 568, 590–591, 591
 - EHV-1 infection 740
 - multifocal retinopathy 579, 580
 - nontapetal fundus 579, 580
 - trypanosomiasis 733
- bullous keratopathy 278–279, 279
 - optical coherence tomography 123
 - after removal of limbal SCC and irradiation 287
- buphthalmos (hydrophthalmos) 27, 28, 145–146, 146, 545, 547
 - exophthalmos vs. 146
 - glaucoma 146, 549, 549, 550
 - congenital 146
 - laser cyclophotocoagulation 557
 - medulloepithelioma causing 450
- bupivacaine, for examination 10
- burdock bristles 210, 211, 768
 - corneal foreign bodies 324, 328, 329
 - removal 329
- burns, corneal injury 323, 324
- burs (plant), corneal trauma/ulceration 768
- butorphanol tartrate
 - effect on IOP 45
 - for examination 9, 10
- butterfly lesions 459, 460, 587–588, 590, 752
- C**
 - calcification, dystrophic (corneal) 281
 - calcific band keratopathy (CBK) 281, 281, 282
 - calcineurin 312
 - calcineurin inhibitors 301, 312
 - see also individual drugs
 - calcitonin gene related peptide (CGRP) 260
 - calcium crystals, basophilic 53, 53
 - calcium-phosphate crystals, in vitreous 582, 583
 - calcium salts, corneal mineralization 281, 281–282, 348
 - callus, formation, orbital fractures 168
 - CALT (conjunctiva-associated lymphatic tissue) 191, 203, 255, 259
 - lymphocytic cell types 262
 - mucosal immune system role 262
 - calvarium 133
 - fracture 152
 - gas accumulation 154
 - Camargue-type gray-skinned horses, melanoma 236
 - camera images, after mydriasis 14
 - camouflage 654, 655
 - Canadian Pari-Mutuel Agency (CPMA) 792, 793, 793
 - canaliculi 191
 - canaliculorhinostomy 197
 - cancer see neoplasia; individual tumors
 - Candida albicans*
 - in vivo confocal microscopy 118
 - neonatal sepsis 768
 - canthotomy 155
 - canthus, lateral/medial see lateral canthus; medial canthus
 - capillaries
 - choroidal 19, 443, 444
 - ciliary body 443
 - capsule, lens see lens capsule
 - capsulorhexis 527, 528
 - capsulotomy, anterior 527–528, 529
 - carbamate poisoning 768
 - carbamazepine, headshaking 734
 - carbon dioxide laser ablation 294
 - adnexal SCC 230, 232, 232–233
 - advantages/disadvantages 294
 - corneal SCC 294, 295
 - melanoma removal 236
 - sarcoids 224
 - stromal abscesses 391
 - technique 294
 - carbon dioxide laser keratectomy (CDLK), stromal abscesses 391
 - carbonic anhydrase 442, 443, 543
 - carbonic anhydrase inhibitors 759
 - glaucoma 555, 555–556
 - heterochromic iridocyclitis and keratitis 456
 - carcinoma in situ (intraepithelial carcinoma) 289
 - actinic solar keratitis transforming to 227
 - corneal 289, 290, 293
 - carotid artery
 - external, embolization 164
 - internal 139
 - embolization 164
 - occlusion 164
 - rupture 139
 - carotid canal 700
 - carriage driving, regulations 794, 795
 - carriers 666

- caruncle
 - in habronemiasis 207
 - lacrimal *see* lacrimal caruncle
- cataract(s) 499, 507–509
 - aniridia 444, 501, 502, 679
 - anterior cortical 508, 510, 512, 518
 - antibiotics associated 479
 - Appaloosa horses 474
 - asteroid hyalosis with 583
 - bilateral 510, 511, 513
 - causes 507, 509
 - trauma 509, 509, 517, 523, 523
 - uveitis 507, 509
 - in chronic uveitis 455
 - classification 507, 509, 509
 - clinical appearance 507–508
 - congenital *see* congenital cataracts
 - congenital anomalies associated with 504–505
 - cortical
 - anterior 508, 510, 512, 518
 - diffuse 512, 513
 - posterior 105, 508, 518
 - developmental 678
 - diffuse 508, 512, 513, 518
 - evaluation 517
 - equatorial cortical 513
 - in equine recurrent uveitis 458, 459, 461, 462, 479, 508, 524, 678
 - treatment 509
 - evaluation 32, 517
 - examination 16, 16
 - focal central anterior 502, 512
 - focal incipient, evaluation 517
 - genetic basis 678
 - hypermaturation 105, 106, 517, 520
 - retinal detachment and 594, 595
 - immature 507, 508, 518
 - intraocular lens implants *see* intraocular lens (IOL) implants
 - juvenile 507, 509
 - retinal detachment 594
 - late immature 106
 - mature 520
 - mature post-traumatic 509
 - medical treatment 517
 - multipunctate anterior cortical 518
 - nuclear 512
 - after pars plana vitrectomy in ERU 483, 484
 - pathologic glare 644
 - perinuclear 511, 512
 - persistent pupillary membrane association 501, 505
 - posterior capsular geographic 516, 517
 - posterior cortical 105, 508, 518
 - posterior nodal point 644
 - posterior subcapsular 510
 - post-traumatic 509, 509, 517, 523, 523
 - evaluation before surgery 523
 - progression, rate 507
 - retinal detachment 578
 - retro-illumination 16
 - secondary 507
 - anterior capsular lens cysts 505
 - causes 507
 - senile 507, 507, 509
 - surgery *see* cataract surgery
 - trauma-associated 509, 509, 517, 523, 523
 - treatment 509
 - ultrasound 105, 105
 - unilateral, diagnostic testing 537
 - vitreous degeneration with 582
 - cataract surgery
 - age of horse 519–520
 - anesthesia 524
 - antibiotic treatment protocols 524
 - clear corneal incisions *see* clear corneal incisions (CCIs)
 - complications
 - immediate postoperative 533–534, 534
 - intraoperative 533, 533
 - issues present prior to surgery 518, 532–533
 - late postoperative 395, 534–537, 535–537
 - postoperative 533–537
 - secondary infection of globe 524
 - congenital cataracts 520, 522
 - congenital ocular anomalies and 520, 521
 - contraindications 520, 521, 523
 - diagnostic testing after 532, 532, 537
 - diagnostic testing before 521–524, 537
 - difficulties/obstacles during 518
 - draping 524, 526, 526, 527
 - equipment 524, 526, 528
 - ethical issues and liability 517–518
 - in foals 520–521
 - complications 534, 536–537
 - indications and results 520
 - future research 537
 - history taking 522
 - hyperopia after 40–41, 518
 - IOL implant *see* intraocular lens (IOL) implants
 - lens fragments in vitreous 533, 533
 - medications before/after 525, 532
 - in microphthalmos 142
 - owner education 521
 - patient positioning 524, 526, 527
 - patient selection 517–521
 - postoperative management 525, 532
 - SPL systems for 521, 521, 524
 - postoperative vision 518–519, 520, 521
 - preoperative care 509, 525
 - preoperative evaluation 520
 - preparation 524, 526
 - sequelae 532–537
 - techniques 526–532
 - closure 530
 - extracapsular lens extraction 526, 532, 536
 - incisions 526, 527
 - intracapsular lens extraction 532, 532
 - IOL implantation 530, 531
 - “open sky” 536
 - phacoemulsification with aspiration 527–530, 529–531
 - see also* phacoemulsification with aspiration technique
 - viscoelastic material use 528, 530, 533
 - vision results 518–519, 520, 521, 537
 - see also* phacoemulsification
 - β-catenin 258
 - catheters, for nasolacrimal irrigation 62
 - cationic antimicrobial peptides 254
 - cavernous sinus syndrome *see* middle cranial fossa syndrome
 - CCIs *see* clear corneal incisions (CCIs)
 - CD55 255
 - CD59 255
 - CD166 466
 - cefazolin 354
 - ceftiofur
 - Lyme disease 745
 - strangles 744
 - cell phone *see* smartphone
 - cellular retinaldehyde-binding protein (CRALBP) 463, 464, 587
 - cellulitis, orbital *see* orbital cellulitis
 - central corneal thickness (CCT)
 - measurement 46
 - normal reference range 9, 46
 - central nervous system (CNS)
 - disease
 - facial nerve paresis/paralysis 713
 - nystagmus 141
 - infections
 - nystagmus and 141
 - strabismus 140
 - lesions, strabismus 139–140
 - retina as part 692
 - central optic cup (CUP) 545
 - enlargement, advanced glaucoma 545, 546, 546
 - central vestibular disease *see* vestibular disease
 - central vestibular system 695, 696
 - ceratohyoidectomy (CHE) 736
 - ceratohyoid osteotomy (CHO) 736
 - cerebellar disease/lesions 701
 - menace response deficiency 25
 - cerebellar interpositional nucleus (CIN) 701
 - cerebellomedullary angle 695
 - cerebellum, menace response 701
 - cerebral cortex, lesions, visual deficits 707
 - cerebrocortical necrosis 707
 - cerebrospinal fluid (CSF)
 - meningitis/meningoencephalitis 729
 - MRI 97
 - testing in equine protozoal myeloencephalitis 723
 - ceroid accumulation, retinal pigment epithelium 724, 725
 - cetirizine, eosinophilic keratitis/keratoconjunctivitis 317
 - chalazion 302
 - chalazion clamp 210, 231
 - checkerboard illusion 617
 - cheek teeth, maxillary 138
 - chemical burns 323

- chemical injury, corneal 322–324, 323
- chemoattractants, neutrophils 339
- chemokines
- corneal epithelial cell migration 268
 - from corneal epithelial cells 258
 - in precorneal tear film (PTF) 255
- chemosis 158, 203, 204
- foreign body causing 328–329
 - third eyelid 219
- chemotherapy
- adnexal SCC 230, 233–235
 - corneal SCC 292–293, 295
 - lymphoma 763
 - sarcoids 223, 224, 225
- china eyes *see* blue-eyed horses
- chitin 357
- chitosan 357, 358
- chloramphenicol, corneal ulceration 354
- chloramphenicol, stromal abscesses 389
- chocolate (silver) coat color *see* silver (chocolate)
- coat color
- cholesterinic granuloma 708
- chondroitin 4 sulfate (C4S) 258
- chondroitin 6 sulfate (C6S) 258
- chorioamnion 400, 401
- choriocapillaris 568
- posterior 137
- chorion 401
- chorioretinal arteries 137, 137
- chorioretinal neoplasia 607
- chorioretinal scars/scarring 587
- “bullet-hole” 42, 459, 460, 568, 590–591, 591
 - butterfly lesions 459, 460, 587–588, 590, 752
 - “classic” inactive 587–588, 590
 - depigmented 587, 589
 - geographic butterfly-shaped 42
 - hyper-reflective or hyperpigmented 587
 - peripapillary, optical coherence tomography 124, 124
 - in posterior ERU 459, 460
- chorioretinitis 587–592
- active phase, lesions 588
 - bullet-hole (focal) lesions 568, 590–591, 591, 592
 - butterfly lesions 459, 460, 587–588, 590, 752
 - causes 587, 592
 - EHV-1 causing 740
 - systemic diseases 592 - clinical appearance 587–592
 - diagnosis 587–592
 - diffuse 591–592
 - in ERU 587, 589–590
 - immunohistochemistry 589–590
 - inactive focal 591
 - multifocal 587, 588, 591
 - optic nerve degeneration 589, 591–592
 - peripapillary region lesions 587, 588, 588–589, 592
 - prognosis 592
 - RPE hyperplasia, cell migration 590, 591
 - treatment 592
- chorioretinopathy
- focal 590
 - peripapillary 516, 517
- choristoma, corneal (dermoid) 274–275, 275
- choroid
- albinism 574
 - anatomy 442–444, 444, 568, 573
 - blood vessels 33, 442–443, 443, 444, 445, 574, 575
 - bullet-hole lesions, trypanosomiasis 733
 - depigmentation 587, 589
 - dorsal, tapetum *see* tapetum
 - in equine motor neuron disease 597, 597
 - hemorrhage, in pars plana vitrectomy in ERU 484
 - hypopigmentation 574
 - inflammation *see* chorioretinitis; uveitis, posterior
 - melanoma 606
 - neoplastic thickening 607
 - pigmentation 573, 574
 - pigmentation absence 443
 - ultrasound 103
 - venous drainage 137
- choroidal arteries 443, 444
- choroidal arterioles 574
- stars of Winslow 33, 443, 444, 566, 570, 574, 576
- choroidal capillaries 19, 443, 444
- choroidal venous system 137
- choroidal vessels 33, 442–443, 442–443, 443, 444, 445, 574, 575
- infarction, EHV-1 infection 590
- choroiditis
- ultrasound 577, 578
 - see also* chorioretinitis
- chromatic aberrations 642, 643, 643
- accommodation and 643
- chromatids 665
- chromosomes 664, 665
- homologous 664
- Cicuta* (water hemlock) 768
- cicutoxin poisoning 768
- cidofovir 741
- cilia, eyelids 187–188, 188
- aberrant 202, 219
 - ectopic *see* ectopic cilia
 - see also* eyelashes
- ciliary arteries 137, 137
- anterior/posterior 137
- ciliary body
- ablation, chemical (gentamicin) 560, 560
 - anatomy 441–442, 442, 443, 543
 - aqueous humor production 543–544
 - cysts 14, 61, 446, 448, 448–449, 485, 671
 - dimensions 557, 557
 - epithelial cell damage, phthisis bulbi 145
 - ERU, CD3+ T cells 466
 - ERU histopathology 468, 468, 468–469, 469
 - function 441
 - high-frequency ultrasound and UBM 111
 - inflammation *see* iridocyclitis; uveitis, anterior
 - inner surface 441
- lymphocytic nodules, in ERU 468, 468
- medulloepithelioma 450
- melanoma 484–485
- muscles 442, 543
- constriction, AH outflow 544
- nonpigmented epithelium (NPE) 441, 442, 443
- cytoplasmic inclusion bodies, ERU 468–469, 469
 - hyaline membrane, in ERU 468, 469
- pigmented epithelium 441, 442, 443
- posterior view 557
- processes *see* ciliary processes
- shock, corneal perforation, with iris prolapse 417
- ciliary cleft 442, 543
- collapse 551, 552
- anterior uveitis 551, 554
 - glaucoma 551, 551, 552, 553
- elevated IOP effect 545, 551, 552
- glaucoma 551, 553, 554
- high-resolution ultrasound 550, 551, 551, 552, 553, 554
- regions 543
- ciliary disorders 208–211
- ciliary ganglion 699
- accessory 699
 - EHV-2 latency 318–319
- ciliary muscles 644, 645
- accommodation mechanism 644, 645
 - relaxation 355
- ciliary nerves 260, 699
- long 703
 - short 699
- ciliary processes 441, 445, 446, 543
- aqueous humor production 543
 - in ERU 468, 469
 - see also* pars plicata
- ciliary spasm 355
- ciliary veins, posterior 137
- cilioretinal blood vessels 693
- cimetidine, melanoma 236, 299, 486
- ciprofloxacin 389
- resistance 354
- circadian rhythm
- intraocular pressure 45
 - tear production 305
- circle of Hovius 137
- circles and triangles, discrimination 624
- cisplatin
- electrochemotherapy, sarcoids 225
 - intralesional
 - adnexal SCC 230, 233
 - sarcoid chemotherapy 223, 224, 225
- citrate, in chemical injury management 324
- CK 3 (cornea-specific differentiation marker) 258
- CK 14 (cornea-specific differentiation marker) 258
- Cladosporium* 358
- corneal/conjunctival surface microflora 264, 265
- clarithromycin, *Rhodococcus equi* infection 773

- clear corneal incisions (CCIs) 526, 527
 - advantages/disadvantages 527
 - rupture 534
 - three-step (trilaminar) 527, 527, 528, 529, 531
 - two-step (bilaminar) 527
- ClearView II, on smartphone 22, 23
- “Clever Hans” 648
- client education 1
- clinicians, position, for routine ocular examination 7–8
- Clostridium* (spp.), corneal ulceration 343
- Clostridium botulinum* 709, 731
 - serotypes 732
 - toxin 731–732
- Clostridium tetani* 731
- closure *see individual procedures/structures*
- CN (cranial nerves) *see cranial nerve(s)*
- coat, examination 27
- coat color/patterns
 - albino, undeveloped tapetum fibrosum 19
 - Appaloosa horses 667, 669, 674
 - congenital stationary night blindness 667, 668, 668, 669
 - Haflinger horses 675, 675
 - MCOA syndrome 585, 670, 670
 - silver *see silver (chocolate) coat color*
 - subalbinotic, tapetum 19, 569, 572
 - tapetal color variations 574
 - see also individual colors*
- cocaine, Horner’s syndrome testing 216
- Cochet–Bonnet esthesiometer 39
- Cochet–Bonnet esthesiometry 261
- cocklebur 768
- Coggins test 738
- “colitis X” 165
- collagen
 - amniotic basement membrane 400
 - biosynthesis, disorder 281, 680
 - corneal stroma 259
 - repair, after injury 269
 - Descemet’s membrane 259
 - fibrillogenesis, dermatopontin role 401
 - remodelling, corneal wound healing 270
 - type III 259
- collagen cross-linking (CXL), corneal ulcer healing 356
- collagen disorders 678
 - HERDA 757–758
 - see also hereditary equine regional dermal asthenia (HERDA)*
- collagenolysis 339
 - inhibition, corneal bacterial infection 355, 355–356
- coloboma 598
 - eyelid 200, 201, 213
 - iris 449, 449
 - lens *see lens coloboma*
 - optic disc 106, 598, 599
 - optic nerve 568, 598, 598–599, 599
 - optic nerve head 598, 599, 707
 - posterior segment 598
 - retinal pigment epithelium 580, 599, 600
 - types/structures affected 598
 - uveal 449
- color
 - chromatic aberrations 643, 643
 - coat *see coat color/patterns*
 - luminance vs. 620, 621
 - of objects, light wavelength 15
 - perception *see color perception*
 - vision *see color vision*
- color-blindness 652, 653
- color discrimination 648, 653–654
- colored fringes 643
- colorless, perception 652
- color perception 620, 651, 653–654
 - behavioral studies 653, 653–654
 - different colors 653, 654
 - illuminating light affecting 654
 - at neutral point 653–654, 654
- color vision 566, 620, 646, 651–654
 - behavioral tests 652–653
 - central retina 652
 - dichromatic 651, 652, 652, 653, 654, 655
 - adaptive advantage 654, 655
 - implications 653
 - evolution 651, 654, 655
 - horse vs. human 651, 652, 652, 654
 - hues 652, 652
 - at level of brain 651
 - neutral point 652, 653–654, 654
 - significance 654
 - trichromatic 652, 652
- comas (optical aberration) 642
- companion horses, for blind horses 799, 800, 800, 806, 806–807
- competitions, equestrian, blind horses 814–815, 815
- complement factor B 465
- complement regulatory proteins 255
- complement system
 - C3, in ERU 465
 - in equine recurrent uveitis 465, 467
 - precorneal tear film 255
- complete incisional keratectomy 394
- complex inheritance 666
- compliance, topical medication, in corneal diseases 272
- compound hyperopic astigmatism (CHA) 639
- compounding, medications 797
- compound myopic astigmatism (CMA) 639
- compressive optic neuropathy 705, 706
- computed tomography (CT) 92–95
 - advantages/disadvantages 93, 94
 - cone beam technology 93
 - contrast medium 94
 - contrast resolution 93, 94, 94
 - conventional vs. cone-team 93
 - dacryocystorhinography (CT-DCG) 100, 100, 101
 - general anesthesia 93, 93
 - indications/conditions 94, 99
 - exophthalmos 96
 - globe perforation 151
- optic neuropathy 704
- orbital fractures 94, 95, 168, 168
- orbital neoplasia 162, 162
- orbital trauma 94, 95
- sinus and nasal cavity neoplasia 161
- sinusitis 159–160
- trauma 765
- vestibular disease 730
- interpretation 94
- limitations 93
- MRI vs. 94, 99
- normal image, orbit 94
- before orbital procedures/surgery 166
- position of horse 93, 93
- posterior segment examination 578, 579, 580
- principles 92
- radiography vs. 92, 94
- skull, after trauma 765, 765
- spiral/helical 93
- for standing horses 93, 94, 765
- standing units 93
- storage of images 92
- table for, weight and 93
- window settings 93
- Comtois breed, MCOA syndrome 671
- condensing lens, 20-D 570, 571
- cone pigments 651, 651
- cones 566
 - in bright light 620
 - chromatic aberrations and 643
 - color vision 651
 - density, distribution 623, 647, 651, 652
 - distance between 648
 - distribution 623, 651
 - evolution 651
 - function 566
 - location 651
 - loss, in ERU 469, 470
 - number 651
 - photopic state of eye, in ERG 41–42
 - in photoreceptor layer 691
 - subtypes, ratios 651, 652
 - visual acuity 638
- confocal microscopy 118
 - see also in vivo corneal confocal microscopy*
- congenital abnormalities/diseases
 - adnexal 199–203
 - corneal 274–278
 - eyelids 199–203, 200
 - globe size 141–142
 - lens 500–507
 - nasolacrimal system 193–195
 - orbital 148–149
 - retinal 583–585, 584
 - uveal 444–450
 - see also inherited ocular disorders; individual diseases*
- congenital aniridia 278, 278
- congenital cataracts 500, 501, 501–502, 510, 678
 - associated anomalies 501, 504–505
 - breeds associated 663, 678
 - epinuclear 501

- gene variants **663**
 - inheritance 502, **663**, 678
 - nuclear 501, 678
 - perinuclear 501, 502
 - progression 520
 - retinal detachment 594
 - surgery 520
 - surgical candidates 520, 522
 - surgical timing 520
 - congenital diseases *see* congenital abnormalities/
diseases
 - congenital glaucoma *see* glaucoma, congenital
 - congenital retinal detachment 584–585
 - congenital stationary night blindness (CSNB) 140,
140, 520–521, 586–587, 666–670
 - blind horses, breeding and 811
 - breeds associated 586, 587, **662**, 666–667
 - clinical appearance 586, 668
 - diagnosis 586, 668
 - electroretinography 586, 586, 667, 667
 - genetic test 668
 - inheritance mode 587, **662**, 667, 670
 - mutations and effects of 587, **662**, 667, 668,
668, 669
 - pathogenesis 587, 667
 - intron 11 single-nucleotide polymorphism
(Nova-1) 587
 - MGLuR6, mutations 670
 - nyctalopin (NPX) 587
 - TRPM1 gene 587, 667
 - see also* leopard complex gene (LP)
 - retinal lesions 704
 - strabismus in 586
 - treatment 587
 - congenital stationary night blindness 2
(CSNB2) 670
 - breeds, inheritance and gene variants **662**
 - conjunctiva 190–191, 253
 - anatomy 190–191, 203
 - anesthesia 12–14, 13
 - biopsy 54, 55
 - blood supply 191
 - bulbar 190
 - in aqueous paracentesis 55, 56, 57
 - exposure (examination) 10
 - inflammation *see* conjunctivitis
 - procedures, local anesthesia for 14
 - pseudotumors 237–238
 - carcinoma *in situ* 290
 - covering third eyelid 191
 - cytology sample 50, 53, 53
 - depigmentation, *Onchocerca cervicalis*
infestation 321, 322, 751, 751
 - desensitization, anesthesia 12–13
 - edema, PPID (equine Cushing's disease) 759
 - epithelium 397
 - in evisceration procedure 175
 - examination 27–28
 - foreign bodies 324, 326, 328
 - goblet cells 191
 - grafts *see* conjunctival grafts (transplants)
 - in habronemiasis 752
 - hyperemia *see* conjunctival hyperemia
 - icteric, piroplasmosis 748
 - immunoreactivity 262
 - lymphoid follicles 191
 - mucosal immune system role 262
 - pallor, in neonatal isoerythrolysis 771
 - palpebral 188, 190, 191
 - distortion, orbital neoplasia 162
 - ectopic cilia 209
 - inflammation *see* conjunctivitis
 - procedures, local anesthesia for 14
 - prominence, neoplasia 53
 - petechiation, equine granulocytic
anaplasmosis 747
 - pigmented 191
 - removal, in transconjunctival
enucleation 172, 174
 - submucosa, T and B cells 262
 - surface microflora 263–266
 - swelling
 - orbital fat herniation 154–155, 155
 - T-cell lymphoma 763, 763
 - third eyelid 191, 218
 - ulceration, fluorescein staining 36
 - wound healing 266
 - conjunctival-associated lymphatic tissue *see* CALT
(conjunctiva-associated lymphatic tissue)
 - conjunctival diseases/disorders
 - future research 239
 - hemangiosarcoma 298
 - infectious **203–204**
 - inflammatory *see* conjunctivitis
 - inflammatory pseudotumor 237, 238, 238
 - lymphoma 763, 763
 - lymphosarcoma 236, 237
 - melanoma 163, 235, 236
 - pseudotumors 237–238, 238
 - SCC 226, 229, 229, 232, 233, 235, 289, 294
 - systemic illness causing **738**
 - conjunctival fornix 190, 191
 - foreign bodies 326, 328
 - conjunctival grafts (transplants) 395–398
 - 360 degree 396
 - aqueous humor (AH) leakage 395, 397
 - autografts 395
 - bipedicle 395, 396
 - procedure 396, 397
 - bridge 396
 - procedure 396, 397
 - bruising 397
 - bulbar, in corneal SCC **295**, 298
 - bulging 397
 - cell types/blood vessels 395
 - after corneal ulceration 350, 351, 357
 - in deep corneal ulcer 381
 - dehiscence, Friesian horses 677
 - fibrosis, and failure 397, 398
 - free island 396
 - procedure 397, 398
 - harvest location 396
 - hood (advancement) 396
 - procedure 396–397, 398
 - indications 395–396
 - iris prolapse treatment 386, 418
 - island 396
 - in keratomalacia (melting ulcer) 377, 378, 379,
386, 395
 - mechanical trauma 397
 - orientation 396
 - over penetrating keratoplasty 405, 405
 - pedicle 395, 396, 616
 - iris prolapse 379
 - keratomalacia (melting ulcer) 377, 378, 379
 - with penetrating keratoplasty 407
 - procedure 396, 396–397
 - ruptured descemetocoele 379, 380
 - stromal abscesses 391
 - trimming, postoperative 398
 - penetrating keratoplasty 407
 - graft rejection and 415
 - postoperative care 398
 - premature suture dissolution 397–398
 - procedure 396, 396–397
 - retraction, descemetocoele 351
 - selection, factors in 396
 - special considerations 397–398
 - strength 395
 - superficial keratectomy with 394
 - suture material 397
 - tarsopalpebral 396
 - procedure 397, 399
 - tension-relieving sutures 395
 - thinness 397
 - types 395
- conjunctival hyperemia 203, 204, 204
 - acute anterior uveitis 452, 452
 - putative viral keratitis 319
 - superficial IMMK 309
- conjunctivitis 203–205, 204
 - allergic 204
 - caseous discharge 205
 - causes 203–204, **203–204**, 205
 - infectious etiology **203–204**, 205
 - clinical appearance 203
 - clinical signs **203–204**
 - in congenital corneal vascularization 277
 - diagnosis 203–204
 - differential diagnosis 204–205
 - long-term prognosis 205
 - methods for definitive diagnosis 204–205
 - nodular lymphocytic (NLC) 237–238, 238
 - onchocerciasis 321, 751
 - primary 203, **203**
 - secondary 203, **203**
 - treatment 205
- conjunctivosinostomy 197
- connective tissue growth factor (CTGF) 268
- Connemara, *DDB2* gene and squamous cell
carcinoma 676
- consensual light reflex, examination 23–25
- contact lenses 639
 - soft, recurrent corneal erosion 338
- continuous rate infusion (CRI) pump systems, with
SPL systems **353**

- contour 633
- contrast
 - sensitivity 638, 638
 - visual acuity affected by 637, 638
- contrast medium
 - CT 94
 - dacryocystorhinography 99
 - MRI 97
- contusions 606
- convergence 629, 647
- cornea 253, 253–440
 - abnormalities 30
 - abscess *see* corneal abscess
 - in acute uveitis **451**, 452, 453, **454**
 - age-related changes 259, 261
 - anatomy 256–261
 - anesthesia 12–14, 13, 104
 - angiogenesis 388
 - inhibition by glucocorticoids 312
 - angiogenic privilege 263
 - anterior
 - nerve fiber density 260
 - sensitivity 260
 - autoantigens 307
 - bacterial invasion 339
 - host response to 355–356
 - basal cells 257, 258
 - biochemical abnormalities 278–282
 - blood vessel absence (avascularity) 30, 263, 271
 - blood vessel infiltration *see* corneal vascularization
 - calcium salt deposition 281, 281–282, 348
 - caseous plaques 315, 316
 - clarity 256
 - closure, after perforation 152
 - collagenisation, abnormal 276, 276
 - complications of orbital disease 164
 - congenital abnormalities 274–278
 - culture 47–48
 - materials for 47
 - sample collection method 48, 48
 - timing of sample 48
 - in ulcerative keratitis 343, 347
 - cytology 14, 48–49, 53
 - interpretation 50–51, 51, 52, 53
 - primary epithelial disease 306
 - degenerate elements, cytology 53
 - desensitization, anesthesia 12–13
 - dimensions **9**, 256
 - diseases *see* corneal diseases/disorders
 - drug delivery routes 272, 273–274
 - see also* corneal diseases/disorders
 - edema *see* corneal edema
 - embryology 261
 - endogenous reaction to exogenous insult 253
 - endothelial cells/endothelium 257, 257, 259, 270–271
 - abnormal, idiopathic primary edema 278–280
 - abnormality, recurrent erosion 335
 - age-related changes 259
 - barrier function 259
 - basement membrane 416
 - cell density (ECD) 259, 279
 - deep lamellar endothelial keratoplasty 412
 - disease, treatment 279
 - embryology 261
 - healing after injury 270–271
 - hypertrophy 270
 - immune-mediated keratitis 120
 - inflammatory insult, effect 259–260
 - injury, response 270, 271
 - in vivo* confocal microscopy 118, 119
 - ion–water transfer function 259, 260
 - IOP elevation 545
 - lipophilicity 257
 - pigmentation 272
 - sensitivity, cytokines 259
 - source, and functions 259, 260, 261
 - specular microscopy 117, 117
 - structure 259–260, 260
 - thickness, specular microscopy 117–118
 - enlarged (megaloecornia) 275–276, 276
 - enzyme inhibition 267
 - epithelial basement membrane (BM) 258
 - injury 258, 269, 338, 339
 - re-formation 269, 271
 - role 120, 258, 268
 - epithelial cells 50, 51, 51, 52, 257, 261
 - attachment to stroma 258
 - bacterial adherence/invasion 339
 - basilar vs. squamous 52
 - cytokines/chemokines 258
 - cytology 50
 - dedifferentiation after injury 268
 - dysmature, in recurrent erosions 335
 - dysplastic/abnormal 305–306
 - focal degeneration 36, 37
 - fungal adherence 358
 - loss/injury 268
 - membranes, breached 268
 - MHC I /II expression 262
 - migration, healing after injury 266, 268, 269, 335, 337
 - migration rate 269
 - mitosis after injury 337
 - reduced adhesion to BM 335
 - re-epithelialization rate 338
 - turnover 257
 - wound healing 266, 268–269, 337
 - epithelium 257, 257–258
 - abrasion *see* corneal abrasion
 - basal layer 118, 119, 257, 257, 258
 - chemical injury 323
 - contour disrupted 305, 306
 - debridement, in surgery 392, 393
 - defects/injury 268–269, 323
 - dendritic cells 120, 121, 262, 263
 - diamond burr debridement *see* diamond burr debridement
 - disruption/loss 305, 306, 306, 319, 319
 - drug penetration 273
 - dysplasia, SCC after 288, 288
 - embryology 261
 - erosions, recurrent 258
 - glycocalyx *see* glycocalyx, epithelial
 - healing 268–269, 337
 - histology 257, 257, 258
 - in vivo* confocal microscopy 118
 - lacerations 332, 332
 - layers 118, 119, 257
 - lipophilicity 257, 272
 - lymphocytes 262, 263
 - micropuncture wound
 - re-epithelialization 387
 - primary disease 305–306
 - in putative viral keratitis 318–319
 - removal *see* superficial keratectomy (SK)
 - replenishment, stem cells 258
 - secondary disease 305
 - sensitivity to surgical trauma 414
 - stem cells in 258
 - stratified squamous 257, 257
 - suprabasal layer 257
 - thermal injury 323
 - tight intercellular junctions 257, 268
 - topical drug penetration 272, 273
 - transparency 257–258
 - transplantation 407–408
 - trauma, sensitivity, in PK 407
 - ulcers 269
 - wounds, direct suturing 393–394
 - in evisceration 174
 - examination 16, 29, 29–30
 - excoriation, habronemiasis 321
 - fibrosis *see* corneal fibrosis
 - flattening, spherical aberration reduction 642
 - fluorescein staining 35, 36
 - folding, blunt trauma causing 331
 - foreign bodies *see* corneal foreign bodies
 - function 253, 259, 261
 - barrier 259, 261, 339
 - fungal invasion 358
 - “ghost vessels” 272, 308
 - groove formation 349, 350
 - haze *see* corneal haze
 - health, aqueous humor removal 174
 - histology 258, 259
 - homeostasis (tissue) 267
 - horizontal elongation, vision in dim light 623
 - horizontal x vertical diameter **9**
 - hydration 272
 - immune privilege 262, 263, 307, 387, 415
 - mechanisms determining 263
 - immune tolerance 261, 262
 - loss after corneal injury 262
 - immunobiology 255, 261–263, 307
 - adaptive immune system 262–263
 - innate immune system 261–262
 - mucosal immune system 255
 - immunoinflammatory response 307
 - immunophenotypic profile 262–263
 - infections, enucleation 816
 - inflammation 253, 255, 261, 268, 271, 305, 307
 - acute, injury response 266–267, 268, 271
 - after chemical injury 323
 - cytology interpretation 51, 52

- see also keratitis; keratomycosis
 inflammation-counterinflammation
 process 253, 261
 injection (intracorneal) 74, 274
 injury see corneal injury (wounds)
 innervation 260–261
 functions 260
 loss/depletion 260–261
in vivo confocal microscopy 118–120, 119
 irritation see corneal irritation
 lacerations see corneal lacerations
 layers 122, 257, 257
Leptospira, antigenic relationship 472
 lesions see corneal lesions
 limbal 258
 lipophilicity 257, 257, 272
 liquefaction, response to bacterial infection 355
 lubrication, facial nerve paresis/paralysis 713
 microbial invasion 339, 358
 mineralization 281, 281–282
 neovascularization, postsurgical 418
 nutrition 260
 opacity see corneal opacity/opacities
 optical coherence tomography (OCT) 122, 122
 pachymetry, sublayer 122
 pathophysiology 266–268
 fibronectin 267
 growth factors 267–268
 leukocytes, migration, injury
 response 266–267
 proteases on ocular surface 267
 wound healing cascade 266
 perforation see corneal perforation
 peripheral, thickness 256
 pigmentation
 after chronic injury 272
 congenital vascularization and 277–278
 posterior, nerve fiber density 260
 primary epithelial disease see primary epithelial disease
 proteases, excessive 267
 protection
 in entropion 199, 200
 evaporative keratopathy prevention 303
 in facial nerve paralysis 217
 in keratoconjunctivitis sicca 198, 199
 in neurogenic keratoconjunctivitis sicca 218
 tarsorrhaphy see temporary tarsorrhaphy
 proteinases 267
 Purkinje–Sanson reflex 16, 16, 29
 refractive index 15
 remodeling
 after surgery 418
 after ulceration 340, 341, 341, 349
 rupture 325, 417–418
 trauma causing 765
 scarring see corneal scarring
 scraping, in ulcerative keratitis 343
 sensation, loss, neurotrophic keratitis 711
 sensitivity see corneal sensitivity
 sensory denervation, in PK 404
 sensory innervation 26
- slit-lamp biomicroscopy 16, 18, 29
 small (microcornea) 275, 275
 spherical aberration 642
 stem cells 258, 259
 turnover 258
 stroma 257, 257, 258–259
 abscesses see stromal abscesses
 anterior lamellar keratoplasty 408
 axial defects, transposition for 399
 bacteria in/spread 339, 343
 bilateral loss see bilateral corneal stromal loss (BCSL)
 cellular infiltrate, in recurrent erosion 335
 collagen 259
 collagen degradation, corneal perforation 417
 edema 120, 279, 279
 embryology 261
 exposure to tears/AH 270
 extracellular matrix 258, 259, 263
 fibrosis, and reduction 271, 309
 foreign bodies 327, 329
 fungal affinity 358
 fungal infection see keratomycosis
 granulation tissue 342
 groove/furrow 416
 groove in ulcerative keratomycosis 364, 365
 healing 269–270, 270–271
 hydration increase 272, 279
 hydrophilicity 257, 258, 259, 270, 272
 inflammatory cell influx 266, 267
 injection, drugs 274
 injury, response to 269
 keratocyte destruction 339
 keratocyte networks 259
 lacerations 332, 332, 333, 334
 lacunae 309, 309
 loss, in corneal dystrophy 280
 “melting” 267
 mineralization 281, 281–282, 310
 myofibroblasts, wound healing 269–270
 necrosis, after infection 339
 neutrophils 266, 267
 pigmentation 272
 “plasma staining” 309, 310
 remodeling, healing 270, 271, 418
 removal, DALK 408, 408, 409, 409
 scar 270
 sodium fluorescein binding 35, 35
 structure 258–259
 suture placement/depth 392, 392–393
 thermal injury 323
 thickness, optical coherence tomography 122–123
 transparency 259
 ulcers 269, 270
 vertical wound, in PK 403
 wound healing 266, 269–270, 270–271, 337
 subepithelial bullae 279, 309
 subepithelial fibrosis 342, 349
 subepithelial opacity, putative viral keratitis 319, 319
 superficial abrasion 269
- superficial (subepithelial) mineralization 281, 281, 282
 surface 30
 culture of sample 47–48
 surface microflora 263–266
 surgery see corneal surgery
 tattooing 175
 thickness 46, 134, 256–257
 age-related changes 257
 central see central corneal thickness (CCT)
 after injury, edema and 272
 measurement by *in vivo* confocal microscopy 47, 118, 256
 measurement by pachymetry 46–47, 122, 134, 256
 measurement by SD-OCT 47, 122, 256–257
 measurement by specular microscopy 117
 measurement by ultrasound
 biomicroscopy 114
 miniature horses 134, 136, 256, 257
 optical coherence tomography 122
 thinning
 congenital ectasia 276, 277
 progressive, in Friesian horses 677, 677–678
 topical anesthesia 104
 toric (toroidal) 639
 transparency 30
 compromised in acute uveitis 453
 transplantation see corneal transplantation
 ultrasound 103, 104
 vascular infiltration see corneal vascularization
 vulnerability 253
 wounds/wound healing see corneal injury (wounds); corneal wound healing
- corneal abnormalities 30
 congenital 274–278
 corneal abrasion 332, 333
 due to *Aspergillus* 361
 epithelial keratomycosis 361, 361, 362
 epithelial lesions 306, 332, 333
 superficial 269
 in superficial IMMK 309
 corneal abscess
 aspergillosis 750
 corticosteroids associated 357
 habronemiasis causing 321
 high-resolution ultrasound 113, 114
 corneal amyloidosis 287
 corneal anesthesia 12–14, 13, 104
 corneal confocal microscopy see *in vivo* corneal confocal microscopy
 corneal degeneration (CD)
 focal 36, 37
 mineralization 281, 281–282
 corneal dermoids 274–275, 275
 corneal diseases/disorders 253–440
 congenital abnormalities 274–278
 degenerative 281–288
 dystrophic 278–281
 edema see corneal edema
 epithelial diseases 305–306
 immune-mediated 306–318

- corneal diseases/disorders (*cont'd*)
 - infections 816
 - inflammatory 263, 302–324
 - medical therapy 272, 273–274
 - periocular injection 272, 274
 - principles 272
 - systemic 272, 274
 - topical *see* corneal diseases/disorders, topical therapy
 - neoplastic 288–302
 - optical coherence tomography 123
 - parasitic infestations 320–322
 - prevalence 253
 - primary epithelial 305–306, 306
 - secondary epithelial 305
 - topical therapy 272, 273–274
 - bioavailability 273–274
 - improving penetration 273
 - optimal volume 273
 - pulsed delivery 273
 - trauma/foreign bodies *see* corneal foreign bodies; corneal trauma
 - ulceration *see* corneal ulceration
 - see also* keratitis; keratopathy; *individual diseases/tumors*
- corneal dystrophy 278–282, 280–281
 - diagnosis 280
 - Friesian horses 280–281, 677, 677
 - management and prognosis 280–281
 - optical coherence tomography 123–124
 - pellucid 280, 280
- corneal ectasia 280
 - congenital 276, 277
- corneal edema 258, 259, 327
 - acute glaucoma 548, 549
 - chronic glaucoma 550
 - after deep lamellar endothelial keratoplasty 414
 - after deep ulcer 350, 351
 - differential diagnosis 286
 - diffuse
 - blunt trauma causing 330, 330, 331
 - causes 279
 - differential diagnosis 286
 - after endothelial injury 270
 - endotheliitis 309–310, 311, 311
 - in equine recurrent uveitis 458, 459, 462, 462
 - after evisceration 175, 175
 - focal, differential diagnosis 286
 - foreign body causing 328
 - idiopathic primary 278–280
 - IMMK 308
 - infrared photography 115
 - after injury 272, 330, 330, 331, 331
 - IOP elevation causing 545
 - lightning strike 765
 - melting ulcer with 340
 - non-lacerating blunt trauma causing 330, 330, 331, 331
 - in onchocerciasis 321
 - optical coherence tomography 123, 123, 124
 - pathologic glare 644
 - after penetrating keratoplasty 407
 - after phacoemulsification cataract surgery 395
 - primary glaucoma and 547
 - specular microscopy 118
 - stromal 258, 259, 279, 279
 - lacerations causing 332, 333
 - non-lacerating blunt trauma causing 330, 330
 - recurrent erosion 335, 335, 336
 - after strontium irradiation 287, 288
 - thermal keratoplasty for 394
 - after transscleral cyclophotocoagulation 558
 - after traumatic iris prolapse 326
 - uveal melanoma 484
 - vertical, in glaucoma 549
 - vertical band, Descemet's membrane rupture 330
- corneal endotheliitis 309–311, 311
 - in vivo* confocal microscopy 120
- corneal epithelial dysplasia, SCC after 288, 288
- corneal erosion 269, 279, 333
 - in corneal sequestrum 284
 - fluorescein staining 347
 - recurrent (chronic nonhealing) 305, 335–338
 - clinical appearance 335, 335–336
 - differential diagnosis 337
 - etiology and pathogenesis 335
 - prognosis 338
 - treatment 337–338, 338
 - re-epithelialization rate 338
 - small, putative viral keratitis 319, 319
 - superficial nonhealing 335
- corneal esthesiometry 26, 39, 704
- corneal fibrosis 271, 450
 - corneal SCC vs. 292
 - after evisceration 175, 176
 - after surgery for corneal SCC 289, 290
- corneal folds 534
- corneal foreign bodies 324, 326–330, 328
 - diagnosis 326–329
 - high-resolution ultrasound 113–114
 - inorganic/inert 328, 329
 - in vivo* confocal microscopy 120, 329
 - multiple 327–328
 - particulate debris removal 329
 - pathogenesis 324
 - penetrating 327, 328, 328
 - management 329
 - prognosis 330
 - presenting clinical signs 326, 327
 - prognosis 329–330
 - removal 328, 329
 - slit-lamp biomicroscopy 329, 330
 - solitary 326, 327
 - stromal 327, 329
 - superficial 326, 327, 328, 329
 - treatment/management 329
 - types/pathogenesis 324, 328
 - ultrasound biomicroscopy 329
- corneal globosa 27, 275–276, 671
- corneal grafting *see* corneal transplantation
- corneal haze 134, 269, 271, 285
 - after chemical injury 323, 323
 - in epithelial keratomycosis 362
 - after superficial lacerations 334
 - after ulceration healing 342, 349
- corneal hemangioma 297
- corneal hemangiosarcoma 297, 298
- corneal hydrops 309, 311
- corneal hypoesthesia 303
- corneal injury (wounds) 261, 269
 - chemical 322–324, 323
 - clinically important sequelae 271–272
 - dehiscence 394
 - direct suturing 393–394
 - edema after 272
 - extent, stromal remodeling 270
 - fibrosis after 271
 - full thickness, healing 270–271, 337
 - full thickness, suturing 393, 394
 - healing *see* corneal wound healing
 - immune-mediated keratitis after 307
 - lacerations *see* corneal lacerations
 - penetrating wounds 764
 - pigmentation after 272
 - response 259, 261, 266–267
 - acute inflammation 266–267, 268, 271
 - dendritic cells and MHC II upregulation 262
 - healing cascade after 266
 - MMP-9 expression 267
 - sequestrae after 283
 - thermal 323–324
 - vascularization after 269, 271–272, 388
 - see also* corneal trauma
- corneal irritation
 - in entropion 199
 - foreign bodies causing 324
 - incorrect closure of eyelid laceration 213
- corneal keratosis 289, 292
- corneal lacerations 151, 152, 324, 332–335
 - deep penetrating 332–333, 333, 335
 - management 334
 - diagnosis 332–333
 - epithelial flap 332, 332
 - full thickness, healing 270–271
 - iris prolapse after 417
 - management 333–334
 - outcome/prognosis 417
 - penetrating 324, 417
 - extensive 333, 334
 - management/prognosis 334
 - perforating 324, 333, 334
 - prognosis 334–335, 417
 - Seidel test 38, 38, 332–333, 333
 - size, outcome 417
 - superficial 332, 332
 - management 333
- corneal lesions
 - examination 30
 - fluorescein dye 35
 - high-frequency ultrasound and UBM 111
 - lavage 13
 - see also* corneal injury (wounds); corneal lacerations
- corneal lymphangioma 297
- corneal lymphangiosarcoma 297

- corneal lymphoma 301–302
 - B-cell 301
 - in vivo* confocal microscopy 120
- corneal mast cell tumor 300–301, 301
- corneal melanoma 298–300, 299, 300
 - medical treatment 299
 - surgical treatment 299–300
 - unpigmented 298, 299
- corneal necrosis, anterior 283
- corneal neoplasia 288–302
 - cytology 53
 - see also individual tumors*
- corneal opacity/opacities
 - in acute anterior uveitis 452
 - band, in glaucoma 549, 550
 - causes 387
 - chemical injury 323
 - foreign bodies 326
 - non-lacerating blunt trauma 331
 - vascularization 30, 263, 271
 - examination for 17, 29
 - focal (leukoma) 276, 277
 - healing after injury and 270, 271
 - in IMMK 308
 - infrared photography 114, 115
 - linear, in glaucoma (stria) 545, 549, 550
 - linear refractile 282, 282
 - persistent pupillary membrane 446
 - in putative viral keratitis 319, 319, 320
 - refractile, in glaucoma 283
 - retro-illumination 17, 17
 - subepithelial
 - in keratomycosis 362–363, 363
 - in putative viral keratitis 319, 319
 - after surgery 418
 - ultrasound 105
- corneal perforation 333, 416, 417–418
 - in bacterial infections 343
 - in corneal dystrophy 280
 - full thickness 270–271
 - globe perforation 150, 151
 - iris movement in response 417
 - with iris prolapse 324, 325, 368, 417–418
 - lacerations 324, 325, 333
 - management 329
 - red-tan material from 150, 151
 - in ulceration 152, 417
 - see also corneal lacerations*
- corneal reflex 26, 39, 703, 703–704
 - assessment 39, 703, 703–704
 - neuroanatomic pathway 39, 698, 703, 703–704
 - see also blinking*
- corneal scarring 270
 - amniotic membrane graft outcome 402
 - chronic eyelid laceration causing 213
 - conjunctival grafts 395
 - after corneal transplantation 416
 - extent/density, reducing over time 341, 341, 342
 - postsurgical, reducing 418
 - reduction, methods 271, 418
 - after traumatic corneal perforation 326
 - treatment, trypan blue assessment 38
- corneal-scleral prosthesis 177, 177, 178, 179
- corneal scraping, in ulcerative keratitis 343
- corneal sensitivity 260, 261, 704
 - central axial area 39
 - in foals 261
 - PPID (equine Cushing's disease) 759, 761
 - quantification 261
 - reduced in keratitis 261
 - testing (touch threshold) 39
- corneal sequestrum 283–284, 284
- corneal squamous cell carcinoma 288–299
 - adjunctive treatment 293–294, **295–296**
 - carbon dioxide laser therapy 294, **295**
 - cryotherapy 293, **295**, 297
 - diode laser with infracyanine green 294
 - radiation therapy 291, 293–294, **296**, 297
 - radiofrequency hyperthermia 294, **295**
 - breeds associated 288
 - chemotherapy 292–293, **295**
 - clinical appearance 289, 289–292
 - COX-2 overexpression 288–289, 293, 676
 - diagnosis 292
 - differential diagnosis 292, 292
 - grading 289
 - histopathology 289
 - invasive 289
 - medical treatment 292–293, **295**
 - pathogenesis 288–289
 - prevalence 288
 - prognosis 294, 299
 - proliferative 290
 - of limbus 289
 - recurrence 297
 - risk factors 288
 - stromal invasive (CSI-SCC) 289, 292
 - surgical treatment 232, 293, 297
 - amniotic membrane transplant 289, 290, 298, 298, 402
 - keratectomy 289, 290
 - postoperative appearance 289, 290, 291
- corneal stria, glaucoma 545, 549, 550
- corneal surgery 391–416
 - anesthetic blocks 391–392
 - anterior chamber maintenance 393
 - conjunctival grafts *see* conjunctival grafts (transplants)
 - direct corneal suturing 393–394
 - complications 394
 - epithelial debridement 392, 393
 - epithelial irrigation 392
 - equipment 391, 392
 - see also individual procedures*
 - general anesthesia 394
 - hemostasis 393
 - magnification 392
 - patient preparation 391–392
 - postoperative care 393–394
 - procedures 392–416
 - general considerations 392–393
 - standing sedation 391
 - surgical site preparations 392
 - suture material 391, 397
 - suture placement 392–393
 - depth 392, 392–393
 - suture selection 391
 - topical local anesthetic 391
 - see also individual procedures*
- corneal sutures 334, 391
 - depth 392–393
 - direct corneal suturing 393–394
 - material 391, 397
 - penetrating keratoplasty 403, 404
 - placement 392, 392–393
- corneal tissue welding 286
- corneal touch threshold (CTT) 39, 261, 704
 - factors affecting 39
 - normal reference range **9**
- corneal transplantation 118, 152, 279, 402–407
 - autologous partial-thickness (lamellar) graft 399–400
 - component 407
 - see also lamellar keratoplasty (LK)*
 - cosmetic 403
 - after deep perforating lacerations 334
 - donor cornea preservation 405, 414, 415–416
 - frequency/number 402
 - frozen donor cornea 405, 414
 - full-thickness 402–407
 - penetrating keratoplasty *see* penetrating keratoplasty (PK)
 - full-thickness homologous graft 399
 - general concepts 402–403
 - graft failure 415
 - graft opacification 414
 - graft rejection 414, 415
 - indications 402
 - for noninflammatory dystrophic conditions 415
 - optical 402
 - outcome 414, 415
 - procedures 403
 - future prospects 415–416
 - lamellar keratoplasty *see* lamellar keratoplasty (LK)
 - PK *see* penetrating keratoplasty (PK)
 - targeted epithelial layer lamellar transplantation 407–408
 - split thickness 403, 407, 409
 - procedures 403
 - technical observations 414
 - tectonic 402–403
 - terminology (vs. corneal transplantation) 404
 - therapeutic 402
 - see also individual procedures*
- corneal trauma 324
 - blunt 324, 325, 417
 - diagnosis 330–331
 - management 332
 - non-lacerating 330, 330–332, 331
 - prognosis 332
 - ultrasound 330, 331
 - chemical and thermal 322–324, 323
 - classification (by depth) 324
 - fungal invasion after 360
 - lacerating *see* corneal lacerations

- corneal trauma (*cont'd*)
 - management 329, 332, 333–334
 - micropuncture wounds 387
 - penetrating 324, 332–333, 333, 334, 335
 - perforating 324, 325, 333, 334, 334
 - see also* corneal perforation
 - stromal abscess pathogenesis 387
 - superficial 324, 332, 332, 333
 - tissue plasminogen activator 329, 332, 417
 - see also* corneal injury (wounds)
- corneal trephine, penetrating keratoplasty
 - 405, 406
- corneal ulceration 206, 269, 335–360
 - aspergillosis 750
 - axon reflex uveitis in 354
 - bacterial 338–357
 - amniotic membrane homogenate use 356
 - antiprotease therapy 353, **353**, **355**, 355–356
 - clinical appearance 340, 343
 - collagen cross-linking 356
 - collagenolysis inhibition **355**, 355–356
 - common species involved 339, 343, **344–347**
 - contraindicated therapy 357
 - diagnostic techniques 343, 347, 350, 352
 - differential diagnosis 343
 - discontinuation of medical therapy 356–357
 - Gram-negative species **344–345**, 354
 - Gram-positive species **346–347**, 352, 354
 - medical therapy 341, 352–357, **353**
 - pathogenesis 339, 341
 - prevalence 343
 - prognosis 341, 357
 - reducing MMP activity 352, 355
 - repair processes 340, 341, 341, 357
 - sterilization of ulcer 353–354
 - superficial 348
 - surgical treatment 340, 341, 357
 - topical corticosteroids, later healing stage 357
 - topical cycloplegics **353**, 355, 357
 - uveitis control 354–355
 - see also* ulcerative keratitis, bacterial
 - bacterial and fungal (mixed) 339, 351
 - after cataract surgery 532, 534, 535
 - causes 270
 - cellular infiltrate 341
 - corneal sequestrum and 284
 - deep, fluorescein staining 350
 - enucleation 816
 - in eosinophilic keratitis 315, 316
 - erosion *see* corneal erosion
 - in evaporative keratopathy 303
 - evisceration and 174
 - in facial nerve paralysis 217
 - in facial trauma 152
 - fluorescein staining 35, 348, 349, 350
 - foreign body causing 328
 - frequency 75, 75
 - Friesian horses 677, 677
 - fungal 341, 357–360, 363, 363, 364, 368
 - DSA *see* deep stromal abscess (DSA)
 - see also* ulcerative keratomycosis
 - healing 266, 269, 341, 341, 342, 354
 - granulation tissue 341, 348
 - intraocular prostheses and 174
 - iris prolapse 417
 - large, infected 340
 - limbal, eosinophilic keratitis with 315
 - melting *see* keratomalacia (melting ulcers)
 - mineralization 282
 - noninfected 340, 348, 349
 - onchocerciasis 321
 - optical coherence tomography 123
 - pain 352
 - pathogenesis 262, 268–269
 - pathophysiology 339, 341–362
 - in pellucid dystrophy 280
 - perforation 152
 - iris prolapse with, outcome 417
 - PPID (equine Cushing's disease) 761
 - rose bengal staining 38
 - subpalpebral lavage system for 64
 - superficial 204, 348
 - in bullous keratopathy 279
 - calcium deposition 348
 - chemical injury 323, 323
 - noninfected 348
 - putative viral keratitis 319, 319
 - remodeling after 349
 - treatment, healing 348, 349
 - superficial indolent 335, 336
 - recurrence 336
 - surgical treatment, conjunctival grafts 395
 - temporohyoid osteoarthropathy 736
 - thermal injury 323, 324
 - after transscleral cyclophotocoagulation 558
 - treatment 348
 - goals 352
 - trichiasis causing 209
 - ultrasound 104
 - West Nile virus encephalitis 728
 - see also* ulcerative keratitis
- corneal vascularization 30, 263, 271–272, 307
 - in aniridia 444
 - in bacterial ulceration 343
 - causes/patterns 271–272, 453
 - congenital 277–278, 278
 - corneal graft rejection and 415
 - cyclooxygenase/lipoxygenase pathways 390
 - after evisceration 175
 - foreign bodies causing 326
 - fungal plaques 366
 - in IMMK 307, 308, 308
 - induction 263, 271
 - inflammatory response 263, 271
 - mechanism, growth factors 263, 271
 - in medulloepithelioma 450
 - postsurgical 418
 - process 271–272
 - rate 269
 - response to injury 269, 271–272, 388
 - role 272
 - in stromal abscesses 388
 - superficial ulcer with 335, 348
 - after ulceration 341, 342
 - in ulcerative keratomycosis 365
- corneal vascular tumors 297–298
 - differential diagnosis 297–298
 - treatment and prognosis 298
- corneal wound(s) *see* corneal injury (wounds)
- corneal wound healing 266, 267, 268
 - cell migration 266, 268
 - collagen remodeling 270, 418
 - contracture, myofibroblasts 269–270
 - epithelial 268–269, 337
 - fibronectin role 267
 - full thickness 270–271, 337
 - growth factor role 267–268
 - keratocyte apoptosis initiating 266, 269
 - lumican role 401
 - “master regulators” 266
 - postsurgery 418
 - stromal 266, 269–270, 270–271, 418
- cornea-specific differentiation marker (CK 3) 258
- cornea-specific differentiation marker (CK 14) 258
- corneal conjunctival squamous cell carcinoma, high-resolution ultrasound 112
- corneal conjunctival transposition 399–400
 - complications 399–400
 - indications 399
 - postoperative care 399
 - procedure 399, 403
- corneolimbic squamous cell carcinoma 228
 - CO₂ laser ablation 232, 232
 - medical treatment 292
 - photodynamic therapy **230**
 - surgical treatment 293
 - amniotic membrane transplant 402
- corneal scleral histiocytic sarcoma 302, 302
- corneal scleral lacerations, circumferential 333
- corneal scleral lymphosarcoma (LSA) 301–302
- corneal scleral neoplastic diseases, corneal vascular tumors vs. 297–298
- corneal scleral prosthesis, after trauma 607
- corneal scleral rupture, circumferential 324
- corneal scleral trabecular meshwork (CSTM) 543, 551
- corneal scleral transposition 399–400
 - limitations 399
- corpora nigra 32, 441, 442, 446
 - atrophy 455, 458, 459, 462
 - bright light vision 625
 - cataract surgery complications 533
 - cysts 108, 446–447, 447, 485
 - high-resolution ultrasound 113, 113, 447
 - treatment 447
 - detachment 509
 - high-frequency ultrasound and UBM 111
 - normal 24
 - polishing 548
 - prolapse 533
 - pupil segments (two) 625, 625, 642
 - ultrasonography 578
- cortical blindness *see* blindness/blind horses, cortical
- cortical bone defects, MRI 99

- cortical cataracts *see* cataract(s)
- corticosteroids
- cataract surgery **525**
 - contraindicated in corneal bacterial infections **357**
 - deficiency, critical illness-related, neonatal sepsis **769**
 - eosinophilic keratitis/keratoconjunctivitis **317, 317**
 - keratoconjunctivitis sicca **199**
 - nasolacrimal duct atresia, postoperative **195**
 - onchocerciasis **752**
 - orbital proptosis **155–156**
 - pemphigus foliaceus **756**
 - postoperative, cataract surgery **532**
 - PPID (equine Cushing's disease) **761**
 - subconjunctival injections, equine recurrent uveitis **478, 478**
 - in thermal injury management **324**
 - topical **418**
 - contraindicated in corneal bacterial infections **357**
 - corneal infections, risks **418**
 - eosinophilic keratitis/keratoconjunctivitis **317, 317**
 - equine recurrent uveitis **477, 478**
 - fungal infection risk **358, 360**
 - idiopathic primary edema **279**
 - risks associated **418**
 - side effects **478**
 - West Nile viral encephalitis **728**
 - see also individual drugs*
- corticotropin-like intermediate lobe peptide (CLIP) **759**
- cortisol **759, 761**
- Corynebacterium* spp., corneal/conjunctival surface microflora **263**
- cosmetic conformer **177, 177–178**
- permanent **178, 178**
- cosmetic issues
- corneoscleral prosthesis after trauma **607**
 - enucleation **170, 177**
 - evisceration **174, 175, 176**
 - intrasccleral prosthesis **174, 175**
 - orbit/globe diseases **133, 139**
 - see also* prosthesis
- cosmetic shell, in phthisis bulbi **145**
- counting fingers vision **636**
- cow cockle (*Vaccaria pyramidata*) **767**
- COX-2 *see* cyclooxygenase
- COX-2 inhibitors **293**
- cranial cervical ganglion (CCG) **699, 700**
- cranial fossa
- middle **693, 696, 697, 699, 700**
 - rostral **693, 693**
- cranial nerve(s)
- anatomy and function **694–697, 695, 696**
 - equine protozoal myeloencephalitis **721**
 - examination **23, 24**
 - eye movements and globe position **694–697**
- cranial nerve II *see* optic nerve
- cranial nerve III *see* oculomotor nerve
- cranial nerve IV *see* trochlear nerve
- cranial nerve V *see* trigeminal nerve
- cranial nerve VI *see* abducens nerve
- cranial nerve VII *see* facial nerve
- cranial nerve VIII *see* vestibulocochlear nerve
- cranial trauma, optic neuropathy due to **603–604, 604**
- C-reactive protein (CRP) **723**
- crossing over, genetic material **664**
- “crossmodal” sensory processing **801–802**
- crossmodal task processing **802**
- cryopreservation, donor corneas **405**
- cryosurgery, enophthalmia **145**
- cryotherapy
- adnexal SCC **230, 231–232**
 - corneal SCC **293, 295, 297**
 - distichia (extra cilia) **210**
 - liquid nitrogen **210, 225, 293**
 - nitrous oxide **225, 293**
 - eyelash disorders **210**
 - principles **225**
 - sarcoids **225–226**
- cryptococcal meningitis **606**
- cryptococcosis **749, 749**
- Cryptococcus*, orbital cellulitis **156, 157**
- Cryptococcus mirandi* **206**
- Cryptococcus neoformans* **729, 749**
- crystallins, in cornea **257**
- CT *see* computed tomography (CT)
- culture
- aerobic, corneal sample **48**
 - antimicrobial sensitivity testing **47–48**
 - bacterial, paranasal sinus samples **139**
 - corneal *see* cornea, culture
 - equine herpesvirus-2 (EHV-2) **48**
 - fungal **48**
 - of ocular surface **47–48**
 - materials for **47**
 - in orbital cellulitis **139**
 - in orbital mass lesions **139**
 - sample collection **28**
 - specimen collection **47, 48, 48**
 - see also* cytology
- Cushing's disease, equine **759–762**
- see also* pituitary pars intermedia dysfunction (PPID)
- cutaneous habronemiasis **752, 752–753**
- cutaneous lupus erythematosus **756, 756, 756–757**
- cx43 **258**
- cyclocryosurgery, glaucoma **556**
- cyclooxygenase **390, 676**
- COX-1 **229, 230, 676**
 - COX-2 **229, 230, 676**
 - overexpression, corneal SCC **288–289, 293, 676**
 - inhibitors **293, 390**
 - after cataract surgery **536**
 - SCC pathogenesis **229–230, 235**
- cyclophilin **312**
- cyclophilin B **281, 680**
- cyclophilin B gene (PPIB) **680**
- cyclophotocoagulation, laser *see* laser cyclophotocoagulation
- cyclopia **142**
- cycloplegics
- stromal abscesses **390**
 - topical, corneal ulceration **353, 355, 357**
- cyclosporine A (CsA) **480**
- actions, IL-2 transcription block **480**
 - corneal scarring reduction **271**
 - episcleral implants **274, 313**
 - equine recurrent uveitis **480–482**
 - IMMK treatment **312, 312, 313**
 - implants
 - cyclosporine-silicone matrix implants **274**
 - dislocation, after cataract surgery **533**
 - heterochromic iridocyclitis with keratitis **456**
 - keratoconjunctivitis sicca **305**
 - lacrimostimulant effect **305**
 - mechanism of action **312, 312**
 - postsurgical **418**
 - suprachoroidal sustained-release
 - devices **480–482**
 - drug level and results **481–482**
 - technique **481, 481**
 - sustained-release devices **480, 481**
 - complications **480**
 - contraindications **480**
 - equine recurrent uveitis **480–482**
 - keratoconjunctivitis sicca **305**
 - post-operative medications **481**
- topical
- eosinophilic keratitis/keratoconjunctivitis **317**
 - idiopathic primary edema **279**
 - keratoconjunctivitis sicca **198, 199**
- Cylindrocapsa* spp. **358**
- cyproheptadine **762**
- headshaking **734**
- cyst(s)
- anterior lens capsule **505, 505–507, 506, 516**
 - anterior uveal *see* uveal cysts, anterior
 - ciliary body *see* ciliary body
 - corpora nigra *see* corpora nigra, cysts
 - dentigerous **160**
 - dermoid *see* dermoids
 - exophthalmos due to **142, 143**
 - hydatid *see* hydatid cysts
 - iridal **446, 447–448, 448, 485**
 - maxillary sinus **160**
 - in MCOA syndrome **585, 671, 671**
 - nasal **160**
 - periocular sinuses **142**
 - retrobulbar dermoid **148**
 - sinus **160**
 - ultrasound **108**
 - uveal *see* uveal cysts
- cytobrush **49, 49, 50**
- cytokeratin, cytology slide interpretation **50, 52, 52**
- cytokine(s)
- amnion stromal matrix **400**
 - from corneal epithelial cells **258, 268**
 - corneal wound healing **266, 267, 268**
 - keratocyte mitosis/migration **269**
 - in precorneal tear film (PTF) **255**
 - pro-inflammatory

- cytokine(s) (*cont'd*)
- corneal response 261, 262, 388
 - downregulation, IMM treatment 312
 - effect on corneal endothelium 259
 - in equine recurrent uveitis 463
- cytokine modulators, corneal wound healing 266
- cytology
- adnexal neoplasia 53
 - bacteria 52, 52
 - cell phone images 58, 59
 - cellular elements 50–52, 51, 52, 52
 - common cellular elements 50–52, 51, 52, 52
 - conjunctival samples 49, 53, 53
 - corneal *see* cornea, cytology
 - corneal epithelial cells 50–51, 51, 52, 52
 - corneal neoplasia 53
 - corneal ulceration 49, 51
 - degenerate corneal elements 53
 - eosinophilic keratitis/keratoconjunctivitis 315, 316–317
 - fine-needle aspiration 139
 - foreign bodies (corneal) 53
 - fungal hyphae *see* fungal hyphae
 - indications 50
 - interpretation 50–53, 51, 52
 - keratomycosis 52, 371, 371, 373
 - materials for 47
 - neoplasia 53
 - noncellular elements 53
 - sample
 - slides and handling 49–50, 50
 - types 50
 - sampling procedure 28, 48–50, 49
 - corneal conditions 14, 48–50
 - cytobrush use 49, 49
 - position of patient 49
 - tools for 49, 49
 - slide preparation 49, 50, 50
 - staining 50
 - in ulcerative keratitis *see* ulcerative keratitis
- cytoplasmic inclusion bodies, ERU 468–469, 469
- “cytoplasmic streaming” 53
- cytosine 661
- d**
- dacryoadenitis
- acute 304
 - immune-mediated 198, 304
 - ultrasound 108–109
- dacryocystitis 196, 197
- seasonal 197
 - secondary bacterial 193
- dacryocystorhinography 59, 99, 99–100
- advantages/disadvantages 100
 - antegrade 99
 - contrast medium 99
 - CT (CT-DCG) 100, 100, 101
 - horse position for 99
 - MRI (MR-DCG) 100
 - nasolacrimal duct atresia 194, 194
 - nasolacrimal duct obstruction 99, 194
 - retrograde injection 99
- dacryohemorrhage 196
- DALK *see* deep anterior lamellar keratoplasty (DALK)
- damage-associated molecular patterns (DAMPs) 360
- damaged DNA binding protein 2 (DDB2) gene *see* DDB2 gene
- damage-specific DNA binding protein 2 (DDB2) *see* DDB2 protein
- dappled coat 670
- dark adaptation 620–622
- normal curve 42
- darkness, perception by horses 616
- Datura stramonium* (jimson weed) 768
- dazzle (light), cataract evaluation 517
- dazzle reflex 25, 703
- glaucoma 549
- DDB2 gene 288
- missense mutations 676
 - squamous cell carcinoma 676
- DDB2 protein 228
- functions, DNA repair 676
- debridement
- corneal epithelium 392, 393
 - corneal recurrent erosion 338
 - diamond burr *see* diamond burr
 - debridement (DBD)
 - eyelid lacerations 212
 - soft-tissue damage 169
- deceleration injury 705–706
- decompression, in orbital proptosis 155
- decorin gene 271
- dedicator of cytokinesis 8 (DOCK8) 464
- deep anterior lamellar keratoplasty (DALK) 340, 408–409, 409
- descemetocelles 408, 408, 416
 - indications 403, 408
 - keratomalacia (melting ulcers) 381, 382
 - outcome 409, 409
 - procedure 408–409
 - stromal abscesses 389
 - ulcerative keratomycosis 365
- deep facial vein 137
- deep lamellar endothelial keratoplasty (DLEK) 407, 409, 412–414
- advantages 412
 - complications 414
 - deep stromal abscess 369, 383, 407, 409, 412, 414–415
 - fungal 368, 369
 - indications 403, 412
 - keratomycosis 377
 - modification, standing surgery 414
 - outcomes 369, 407, 412, 414
 - postoperative care 412
 - stromal abscesses 391
 - surgical procedure 412, 413
- deep stromal abscess (DSA) 340, 341, 380, 409, 409, 410, 414
- adhesions and 414
 - corneal vascularization 389, 390
 - diagnostic evidence of infection 387
- fungal 367–368, 367–370, 367–371, 383, 388–389, 390
- causes 367, 369
 - healing 368, 369, 370, 371
 - histology 369, 373
 - outcome 369, 390
 - treatment 368, 368, 381, 383, 384, 389–390
- healing, signs 390
- limbal, deep lamellar endothelial keratoplasty 403
- medical treatment 389, 390, 409
- outcome 390, 410
- ocular pain 416
- pathogenesis 387–388
- prevalence 388
- surgery 390–391, 404, 405, 407
- deep lamellar endothelial keratoplasty 369, 383, 407, 409, 412, 414–415
 - penetrating keratoplasty 405, 409
 - posterior lamellar keratoplasty 384, 403, 407, 409, 410, 414–415
 - technical observations 414–415
- α-defensins, precorneal tear film 254
- deferoxamine mesylate 771
- degeneration
- corneal *see* corneal degeneration (CD)
 - optic nerve *see* optic nerve (CN II)
 - pellucid marginal (PMD) 280, 677–678
 - retinal *see* retinal degeneration
 - vitreal *see* vitreal degeneration
 - zonular ligaments, lens luxation 510
- dehydration, foals 199
- demecarium bromide, glaucoma 556
- demodex infestation 206
- dendritic cells
- in corneal epithelium 120, 121, 262, 263
 - TLR-ligand binding 262
- denervation hypersensitivity 216, 709
- density of optical texture 634
- dental arcade
- assessment in trauma 150
 - cysts from 160
- dental disease 137, 144
- orbital disease due to 150, 180
- dental surgery 180
- dentigerous cysts 160
- deoxyribonucleic acid (DNA) 661, 664
- deoxyribose 661
- depigmentation
- causes 208
 - chorioretinal scars/scarring 587, 589
 - choroid 587, 589
 - conjunctiva, *Onchocerca* infestation 321, 322, 751, 751
 - iris *see* iris, depigmentation
 - lateral canthus, in CLE 756
 - nontapetal (ventral) fundus 577, 579, 600
 - peripapillary region 574, 577, 588, 589, 592, 601, 602
 - retinal pigment epithelium 33, 579
 - vitiligo 208, 209
- depression fractures 92, 92

- deprivation amblyopia 520
 depth perception 620, 629–635, 655
 binocular (stereopsis) 633, 634–635
 threshold 634–635
 deprivation 635
 development 635
 diplopia 633
 field of view 629–635
 human comparison 633, 634, 635
 integration of binocular visual inputs 632–633
 motion and 635
 with one functional eye (monocular) 633–634, 634, 816
 variations 633
 visual perspective, breed differences 629, 630
 dermal hair 187, 188, 188
 dermatitis, periocular 70, 71
 dermatologic disorders 754–757
 dermatopontin 401
 dermoids 679
 conjunctival 202
 corneal 274–275, 275
 eyelid 200
 orbital 148
 perilimbal 502
 retrobulbar 148
 descemetocoeles 270, 343, 350, 351, 409, 416
 anterior lamellar keratoplasty 408, 409
 bacterial growth and 48
 deep anterior lamellar keratoplasty 408, 408
 definition/description 35, 270, 343, 416
 fluorescein staining 270, 347
 formation 270, 416
 medical therapy 416, 416
 optical coherence tomography 123, 123
 pre-descemetocoele 270, 350, 350, 352
 ruptured, iris prolapse 379
 surgery 380, 416
 Descemet's membrane 30, 31, 35, 257, 259, 270–271, 416
 anatomy 416
 breaks
 chronic IOP elevation 545
 glaucoma 548, 549, 549
 severe IOP elevation 548, 549
 bulging 416, 416
 deep anterior lamellar keratoplasty 408
 deep melting ulcer 351
 detachment 285–286, 286
 blunt trauma causing 330, 330
 corneal edema and glaucoma 547
 differential diagnosis 286
 discontinuous rupture 283
 duplication 285–286, 286
 embryology 261
 endothelium–Descemet's membrane complex 123
 exposure *see* descemetocoeles
 injury, restoration 270
 in vivo confocal microscopy 118
 microperforation, in DALK 409
 opacity, after blunt trauma 331
 optical coherence tomography 122–123, 123
 progressive duplication and detachment 285
 rupture, corneal trauma 330, 330
 sectioning, retrocorneal fibrotic membrane after 284
 structure 257, 259
 thickness 122–123, 416
 thinning, linear keratopathy 283, 283
 transplantation 409
 detachment
 Descemet's membrane *see* Descemet's membrane
 retinal *see* retinal detachment
 detergent 170
 detomidine/detomidine hydrochloride 578
 effect on IOP 45
 for examination 9, 10
 deworming, inadequate 158
 dexamethasone
 adnexal lymphosarcoma 237
 chemical ciliary body ablation 560, 560
 equine recurrent uveitis 477, 478
 IMMK treatment 312, 313
 mechanism of action 312
 pemphigus foliaceus 756
 dexamethasone suppression test (DST) 761
 diagnostic procedures/tests 33–58
 aqueous paracentesis *see* aqueous paracentesis
 corneal esthiometry 26, 39, 704
 culture *see* culture
 cytology *see* cytology
 dyes (ophthalmic) 35–39
 electroretinography *see* electroretinography (ERG)
 field practice 5
 fine-needle aspiration *see* fine-needle aspiration (FNA)
 molecular 54
 most common diagnoses 74–76, 75
 normal reference ranges 9
 periocular and ocular biopsy 54–55
 phenol red thread test 34–35
 retinoscopy *see* retinoscopy
 Schirmer tear *see* Schirmer tear test (STT)
 tear film breakup time *see* tear film breakup time (TFBUT)
 tonography 46
 tonometry *see* tonometry
 ultrasonic pachymetry *see* pachymetry, ultrasonic
 diamond burr debridement (DBD) 280, 394–395
 complications 395
 corneal mineralization 282
 eosinophilic keratitis/keratoconjunctivitis 317
 recurrent corneal erosion 338
 diapedesis 266
 diarrhea, neonatal sepsis 768
 dichlorphenamide, glaucoma 556
 diclazuril 723
 diclofenac sodium, equine recurrent uveitis 477, 478
 DICOM viewing software 92–93
 diet, hyperkalemic periodic paralysis 759
 diethylcarbamazine 753
 difference-to-brightness discrimination 648
 Diff-Quik stain 52, 53
 Diff-Quik stain jars, cytology samples 50
 diffraction 642
 digital camera, eye comparison 616–617, 618
 digital photography 621
 ocular region 58, 59, 60, 61
 digital single-lens reflex camera (DLSR) 58
 dilator muscles, of iris 700
 dimethyl sulfoxide (DMSO) 158, 208
 dim light
 adaptations to improve vision 622, 623–625, 655
 rods, function 620, 691
 visual acuity in 637, 638, 648, 655
 diode laser
 corpora nigra cysts 447
 cyclophotocoagulation, glaucoma 557
 with intracyanine green, corneal SCC 294
 photoblation, nasolacrimal duct atresia surgery 194
 retinopexy 594–595
 uveal melanoma treatment 486
 diopter 639
 dioptric power, lens 639
 diplopia (double vision) 633
 direct corneal suturing 393–394
 direct illumination, ciliary body cyst 14
 direct ophthalmoscope 19
 lenses 20
 power source 19–20
 direct ophthalmoscopy *see* ophthalmoscopy
Dirofilaria immitis 753–754, 754
 disc, optic *see* optic nerve head (ONH)
 discharge, ocular
 caseous, conjunctivitis 205
 mucopurulent *see* mucopurulent discharge
 orbital cellulitis 157
 strangles 743
 “disposable dressing” *see* amniotic membrane transplants (AMT)
 distichia (extra cilia) 209, 209
 diagnosis/examination 210
 in Friesian horses 676–677, 677
 multiple 210
 treatment 210–211
 see also ectopic cilia
 distichiasis 208, 210, 676–677, 677
 breeds, inheritance and gene variants 662
 diuretics 770
 diurnal variation, Schirmer tear test (STT) values 34
 divergent eye movements 629, 645
 DLEK *see* deep lamellar endothelial keratoplasty (DLEK)
 DNA (deoxyribonucleic acid) 661, 664
 UV-induced damage 288
 DNA-protein kinase (DNA-PK), mutation 681
 DNA repair gene, DDB2, mutation 288, 676
 DOCK8 464
 doll's eye reflex *see* vestibulo-ocular reflex (VOR)
 dominant traits 666
 donkey factor 771
 donkeys, ocular disease frequency 75

dopamine agonist 762
 dopaminergic innervation 759
 Doppler shift 102
 Doppler ultrasound 102, 103
 dorsal oblique muscle 697
 dorsal rectus muscle 697
 dorzolamide, glaucoma 555, **555**, 555–556
 double vision (diplopia) 633
 doxorubicin 764
 doxycycline 313
 corneal ulceration 354
 equine recurrent uveitis 479
 IMMK treatment 312–313
 orbital disease 164
Draschia (spp.), intermediate host/vector 321
Draschia megastoma 206, 321, 752
 keratitis due to 321
 dressage horses
 blind horses 813, 814–815, 815
 training and cues 815
 USEF rules **795**
 drug(s) 2
 compounding 797
 extralabel use 794, 796–797
 parenteral, for orbital disease **153**, 164–165
 for performance animals 794
 regulations **796**, 796–797
 systemic, corneal diseases 272, 274
 topical *see* topical medication
 see also individual drugs
 drug delivery
 periocular, systems, corneal diseases 272, 274
 systemic, corneal diseases 272, 274
 topical, preparations, corneal diseases 272, 273–274
 see also topical medication
 dry eye syndrome 302–303
 see also keratoconjunctivitis sicca (KCS)
 dummy foal syndrome 770
 dyes, ophthalmic 35–39
 dynamic contraction anisocoria 25
 dysautonomia, equine 709, 709
 dyscoria, uveal melanoma 485
 dysphagia, botulism 732
 dystrophic diseases, corneal *see* corneal diseases/
 disorders

e

ear, external, viscous yellow fluid in 152
 ear mite 733
 ear tick infestations, bilateral third eyelid
 elevation 219
 Eastern equine encephalitis **726**, 726, 726–727
 eastern tent caterpillar (ETC), ingestion 766
 ECA1 (equine chromosome 1) 664, 667, 674, 747
 ECA13 677
 ECA18 675, 678
 ECA20, ERU and 674
 E-cadherin 258
 echinocandins 376
Echinococcus granulosus 157, 754, **754**
 echolocation 803

ectoderm 275
 ectopia lentis 503
 ectopic cilia 209, 209, 210
 diagnosis 210
 third eyelid 219
 treatment 211
 see also distichia (extra cilia)
 ectropion 201
 cicatricial 303
 edema
 corneal *see* corneal edema
 hemorrhagic, African horse sickness 148
 Edinger Westphal nucleus (human) 698
EDNBR gene, mutation 681
 EDTA
 chemical injury management 324
 corneal bacterial infection 355, **355**, 356
 serum, synergistic action 356
 in corneal mineralization 282
 microcellulose sponge method 282
 ulcerative keratomycosis 377
 education, of owners 1
Ehrlichia equi (*Anaplasma phagocytophilum*) 747
 elastin, staining for 284
 elastomeric balloon pump devices 69
 elastomeric infusion pump, after cataract
 surgery 521
 electroacupuncture, facial nerve paralysis 713
 electrocautery
 distichia (extra cilia) 210
 low-voltage, thermal keratoplasty 394
 electrochemotherapy, sarcoids 225
 electrodiagnosis, photic trigeminal mediated
 headshaking 715
 electromagnetic spectrum 15, 619, 619, 620
 electromyography, hyperkalemic periodic
 paralysis 758
 electrophysiology tests 42
 electroretinography (ERG) 41–42
 amplitudes 41
 before cataract surgery 520, 521, 523, 523
 components 41
 congenital stationary night blindness 586, 586
 dark adaptation, normal curve 42
 equine motor neuron disease 725
 extrinsic factors affecting 41
 flash ERG 41, 42, 767
 flicker-photometry 42
 general anesthesia for 41
 implicit times 41
 indications 41
 intrinsic factors affecting 41–42
 ivermectin toxicosis 767
 negative, in CSNB 586, 586, 667, 667
 optic neuritis 606
 pattern 42
 photopic (light-adapted) state 41
 photoreceptor hyperpolarization, a-wave 667
 posterior segment examination 578
 scotopic (dark-adapted) state 41
 in standing horse 41, 42
 waveforms (a-, b-, c-) 41, 42, 667

ELISA
 botulism 732
 equine infectious anemia 738
 equine protozoal myeloencephalitis 723
 Lyme disease 745
 West Nile viral encephalitis 728
 embryology
 cornea 261
 lens 499
 pupillary membrane 446
 emergencies, ocular examination 1
 emmetropia 15, 40, 639, 641
 accommodation 644
 prevalence 639, 641
 emphysema 147
 after facial trauma 152–153
 after skull/orbital fractures 169
 subcutaneous 147, 147, 152–153
 empyema, guttural pouch 164, 744
 encephalitis
 Eastern equine **726**, 726–727, 727
 Venezuelan equine **726**, 726–727
 Western equine **726**, 726–727
 West Nile viral *see* West Nile virus encephalitis
 endocrine disorders 759–762
 endolymph 695
 endophthalmitis 451
 cataract surgery complication 534, 536
 causes 516
 differential diagnosis 516
 after formalin injection 164, 164
 fungal 371
 infectious **451**, **454**
 organic foreign bodies in anterior chamber 329
 septic, uncontrolled 156
 endoscopic cyclophotocoagulation (ECP),
 glaucoma 558, 558–559
 endophthalmitis, corneal 120, 309–311, 311, 313
 endothelin-B receptor gene (*EDNBR*), mutation
 681
 endotheliopathy 412
 endothelium, corneal *see* cornea
 enophthalmos 144–145
 entropion secondary to 199, 211, 211
 Horner's syndrome 215, 215
 neonatal foals 144, 145
 treatment 145–145
 enrofloxacin
 equine recurrent uveitis 479
 orbital disease 164–165
Enterobacter spp., corneal/conjunctival surface
 microflora 263
Enterococcus, neonatal sepsis 768
 entropion 199, 199–201, **200**
 in adult horses 211, 211–212
 “anatomic component” 199
 causes 199, 211
 cicatricial 211
 clinical appearance 199, 211
 conformational (anatomic) 211
 diagnosis 211
 differential diagnosis 199, 211

- in foals 199–201
- genetic predisposition 199
- long-term prognosis 211–212
- pathogenesis 211
- postoperative management 201
- secondary 211
- spastic 199, 211
- treatment 199–201, 211
 - medical 200
 - permanent surgical repair 201, 201, 202, 211
 - temporary surgical repair 200, 200
- enucleation 169–174
 - alternatives to 170
 - of blind eyes 816–817
 - closure 173, 174
 - complications 174
 - corneal thickness after 257
 - cosmetic alternatives 170
 - cosmetic appearance after 177
 - decision-making 816
 - exenteration after 175, 176
 - general anesthesia 170
 - glaucoma 560–561, 816–817
 - globe perforation 152
 - indications 169–170, 816
 - intraorbital prosthesis 170, 172, 172, 173
 - complications 173
 - placement and sizing 172–173
 - in keratoconjunctivitis sicca 199
 - in microphthalmos 142
 - ocular pain 816–817, 817
 - orbital cellulitis 156, 157
 - orbital proptosis 156
 - performance of horses after 793–794
 - periorbitum retention 134
 - postoperative performance 793–794
 - preparation 170
 - retrobulbar nerve block 170
 - in secondary entropion 211
 - standing sedation 170
 - surgical site infection risk factors 170
 - techniques 170
 - temperament improvement after 816, 817, 817
 - transconjunctival approach 170–173, 171
 - transpalpebral approach 170, 173–174
- environmental control
 - ERU reduction 476, **476**
 - habronemiasis 207–208
 - nasolacrimal duct obstruction 198
- eosinophil(s) 51, 51
 - in corneal sample 51, 51, 52
 - cytology interpretation 52, 52
- eosinophilic inflammation
 - eosinophilic keratitis 316
 - mast cell tumors 300
- eosinophilic keratitis/keratoconjunctivitis (EK) 37, 204, 205, 307, 315–318
 - clinical appearance 315, 316
 - cytology 315, 316–317
 - diagnosis 315, 316–317
 - differential diagnosis 317
 - histology 316, 316–317
 - medical treatment 317, **317**
 - pathogenesis 316
 - prevalence 315–316
 - prognosis 318
 - recurrence 316
 - surgical treatment 317
- epibulbar melanoma 298, 299
- epibulbar neoplasia, ultrasound 108
- epidermal growth factor (EDF) 267, 268
- epidermis, separation from dermis 680
- epinephrine
 - in corneal surgery 393
 - intracameral, lens capsule rupture 516
- epiphora 139, 147, 192–193, 198
 - bilateral 193
 - causes 192, 197
 - corneal foreign body 326
 - chronic 192
 - diagnosis 193, 197
 - examination 192–193, 197
 - mild, management 198
 - in nasolacrimal duct atresia 193
 - in putative viral keratitis 319
 - seasonal 197
 - treatment 193
- episclera, piroplasmiasis 748
- episcleral blood vessels 147
 - dilation, acute anterior uveitis 452
 - enlargement 147–148, 148
- episcleral sustained-release implants 274, 313
- episclerokeratitis 307, 314, 314
- epistaxis 149, 167, 734
- epithelial cells, corneal *see* cornea, epithelial cells
- epithelial dysplasia, SCC after 288, 288
- epithelial keratomycosis *see* keratomycosis, epithelial
- epithelial keratopathy 305
 - see also* immune-mediated keratitis (IMMK), superficial
- epithelium
 - amniotic membrane 400
 - corneal *see* cornea, epithelium
- epitope spreading 463, 473
- epizootic lymphangiectasia 749
- epizootic lymphangitis 749, 749, 749–750
- EPM *see* equine protozoal myeloencephalitis (EPM)
- equestrian competitions
 - blind horses 814–815, 815
 - unilateral sight loss 816, 816
- equine adenovirus type 1 (EAdV1) 742
- equine arteritis virus (EAV) 737
- equine degenerative myeloencephalopathy (EDM) 726
- equine dysautonomia (equine grass sickness) 709, 709, 732–733
 - acute, clinical signs 732
 - clinical signs 709, 709, **732**, 732–733
 - diagnosis 709, 733
 - prognosis 733
- equine epitheliogenesis imperfecta *see* junctional epidermolysis bullosa (JEB)
- equine granulocytic anaplasmosis 747, **747**
- equine granulocytic ehrlichiosis 747, **747**
- equine grass sickness *see* equine dysautonomia (equine grass sickness)
- equine herpesvirus(es) 739–742
 - clinical signs 740, 741
 - putative viral keratitis 318, 319
 - treatment 741
- equine herpesvirus-1 (EHV-1) 739–740
 - chorioretinal lesions 590, 740, 740
 - clinical features of infection 319, 740, **740**
 - experimental infection 740, 740
 - neurologic form of disease 740
 - putative viral keratitis 318
 - vaccine 741–742
 - white chorioretinal lesions 577
- equine herpesvirus-2 (EHV-2) 740–741
 - culture of sample 48
 - latency, sites 318–319
 - ocular signs 740, 741, 741
 - PCR tests 54, 741
 - putative viral keratitis 318, 319, 320, 740, 741
- equine herpesvirus-4 (EHV-4), vaccine 741
- equine herpesvirus-5 (EHV-5) 740–741
 - cutaneous and ocular lymphoma 763
 - keratoconjunctivitis 741
 - ocular signs 740, 741
 - putative viral keratitis 318, 319, 320
- equine infectious anemia (EIA) 139, 738–739
 - clinical signs 738, **738**
 - quarantine 739
- equine influenza 742, 742–743
- Equine Injury Database (EID) 793
- equine leukocyte antigen (ELA) 673
 - see also* major histopathology complex (MHC)
- equine leukoencephalomalacia 723–724, **724**
 - clinical signs 724
 - white matter, liquefactive necrosis 724, 724
- equine motor neuron disease (EMND) 597, 724–725
 - ceroid/lipofuscin accumulation 724, 725
 - clinical appearance, diagnosis 597, 597, **724**, 724–725, 725
 - prognosis 725
- equine protozoal myeloencephalitis (EPM) 139, **721**, 721–723
 - clinical sign 217
 - diagnosis 722–723
 - facial nerve dysfunction 721, **722**
 - ocular manifestations 721–722, **722**
 - prevention 723
 - treatment 723
- equine recurrent uveitis (ERU) 451, 457–484, 672–675
 - acute/active 458, **458**, 461, 461
 - histopathology 468, 468–469, 469
 - age at diagnosis 463
 - in Appaloosa horses *see under* Appaloosa horses
 - blindness 474, **475**, 672, 673
 - blood–retinal barrier disruption 463, 464, 466
 - breeds associated 462–463, 473–474, **662**, 672, 673, 747

- equine recurrent uveitis (ERU) (*cont'd*)
- butterfly lesions 588
 - cataracts 458, 459, 461, 462, 479, 508, 524, 678
 - treatment 509
 - causes 457–458, 587
 - historical views 458
 - chorioretinitis 587, 589–590
 - chronic 462, 462
 - suprachoroidal CsA sustained-release device 480
 - classic 458, **458**, 461, 461, 672
 - effect of repeated episodes 458, 459
 - clinical appearance 458–461, 459, 460, 461, 672, 747
 - clinical classification/types **458, 458–462**
 - clinical signs 451, 452, 672
 - decreased TIMP2 activity 467
 - differential diagnosis 463
 - early, vesicles associated 508
 - end-stage **458**, 461, 462, 462
 - experimental autoimmune uveitis model 464, 465, 466
 - extracellular matrix remodeling 467
 - genetics 463, 473, **662**
 - in German Warmblood horses 674–675, 747
 - glaucoma, secondary to 462, 547, 548
 - pathogenic mechanisms 547–548
 - histopathology 468, 468–470, 469, 470
 - anterior uvea 468, 468–469, 469
 - optic nerve head 470, 470
 - posterior segment 469, 469–470, 470
 - historical aspects 458
 - hyalitis (inflammation of vitreous) 581
 - immunohistochemistry, in
 - chorioretinitis 589–590
 - immunology of 463–465, 672–673
 - adaptive immune system 464–465, 467, 473
 - antigen presentation and MHC 474, 673
 - autoantigens 463, 464, 465, 467, 587, 672
 - autoantigen-specific CD4+ T cells 463, 464, 465, 590, 672
 - complement system 465, 467
 - cytokines 672
 - dysregulated, retinal autoantigens 463, 464, 465, 467, 468, 590
 - genetic variants, IL-17A and IL-17F 463
 - granulocyte activation 465
 - IgA, in vitreous 581
 - IgG levels 467, 590
 - IgM autoantibody response to NF-M 467
 - IgM levels, vitreous 467
 - innate immune system 465, 467
 - leptospira initiating autoimmunity 472, 473, 672
 - priming of autoimmune reaction 465
 - target organs 466–468
 - T cell activation 465
 - Th1 cells role 464, 466, 467, 672
 - Th17 cells, inflammation 464, 466, 672
 - Treg cells, remission of inflammation 464, 465
 - inheritance and gene variants **662**
 - insidious **458**, 458–459, 459, 461, 463, 672
 - Appaloosa horses 459, 459, 474, 673, 673
 - kininogen 466
 - leptospirosis-associated 458, 460, 463, 470–473, 672, 746
 - antibiotic therapies 479
 - antigenic relationship cornea/*Leptospira* 472, 473, 672
 - experimental disease work 472
 - genetics and 747
 - geographical distribution 470–471, 471
 - hyalitis and 581
 - immunohistochemistry 589–590
 - intraocular antibody analysis, C-value 473
 - Leptospira* Pomona 471, 472, 672
 - pars plana vitrectomy 482, 484
 - pathogenesis, immune-mediated 472, 473, 672, 746
 - prevalence and geography 472, 746
 - prognosis 474
 - testing, interpretation 473, **473**, 581
 - time course of ERU 472
 - vaccination 477
 - membrane proteoma analysis 467
 - moon phases, association 458
 - pars plana vitrectomy *see* pars plana vitrectomy (PPV)
 - pathogenesis 463–468, 672–673
 - autoantibodies 467, 473, 672
 - immune system *see above*
 - leptospirosis-associated ERU *see above*
 - pathophysiology 458, 463–468, 672
 - PEDF decrease 466
 - pineal gland and 467, 470
 - posterior 459, 460, 461, 565, 672
 - histopathology 469, 469–470, 470
 - posterior primary **458**
 - posterior synechiae in 458, 459, 461, 462, 548
 - practical and stable-management
 - practices **476**, 476–477
 - prevalence 457, 565, 672
 - prevention, stable-management **476**, 476–477
 - after primary uveitis 457
 - prognosis 474, 476, 479
 - Appaloosa horses 474, **475**
 - non-Appaloosa horses 474, **475**, 476
 - quiescent 451, **458**, 461
 - quiescent periods 457, 458
 - autoantigen-specific CD4+ T cells 464
 - pars plana vitrectomy 482
 - T regulatory cells and 464, 465
 - retinal damage, immunological cause 589–590
 - retinal Müller glial cell (RMG) role 463, 467, 487
 - risk after uveitis 458
 - risk factors 457
 - serum proteins 465–466
 - stage of chronicity **458**
 - surgical management, vitrectomy 608
 - target organs 466–468
 - retina and vitreous 466–468
 - retinal pigment epithelium 466
 - treatment 747
 - antibiotics 479–480
 - autologous mesenchymal stem cell therapy 479–480, 673
 - decisions 476–477
 - goals 476, 477
 - immunosuppressive gene therapy 480
 - lens removal surgery 523
 - medical **477**, 477–479
 - pars plana vitrectomy 482–484
 - suprachoroidal CsA sustained-release devices 480–482, 481
 - systemic medications 478, **478**
 - topical medications 478, **478**
 - unilateral or bilateral 463
 - vaccinations, spacing of 476
 - vitreous, effector role 566, 608
 - equine viral arteritis 148, 737–738
 - abortion syndrome 737
 - causative virus and transmission 737
 - clinical signs 737, **737**
 - management and prevention 738
 - respiratory syndrome 737
 - equine vision *see* vision
 - equipment/instruments
 - adnexal surgery 55
 - cataract surgery 524, 526
 - corneal surgery 391, 392
 - for ocular examination *see* examination, ocular
 - ophthalmic 15–23
 - periocular/ocular biopsy 55, **55**
 - tonometry 43
 - Equisetum arvense* (horsetail) 767
 - Equus caballus* papillomavirus 2 (EcPV-2) 229
 - ERG *see* electroretinography (ERG)
 - ERU *see* equine recurrent uveitis (ERU)
 - erythrocytes 51
 - Escherichia* (spp.), corneal/conjunctival surface microflora 263
 - Escherichia coli* 768, 770
 - ESwab® 48, 48
 - ethmoidal foramen 134, 134
 - ethmoidal hematomas 138
 - ethmoidal masses 158
 - ethmoidal sinuses 139
 - ethmoid labyrinth, CT 94
 - ethmoid turbinates 138
 - traumatic injury 149
 - eumelanin 670
 - eustachian tube, diverticulum (guttural pouch) 139
 - euthanasia
 - blind horses 798, 800
 - after facial trauma 152
 - evaporative keratopathy 302–303, 303
 - eventing, USEF rules **795**
 - evisceration 174–175
 - complications 174, 175
 - contraindications 174
 - cornea appearance after 175, 175, 176
 - description 174
 - indications 174
 - after lens capsule rupture 517

- preparation 174–175
- procedure 175
- evolution, color vision 651, 654, 655
- examination, ocular 1–89, 90
 - adnexa 27–29, 28, 29
 - analgesia for 11–15
 - anterior chamber 30–31, 31
 - anterior segment (cornea, sclera) 29–30
 - appointments 2
 - before cataract surgery 522–523
 - clinical position 7, 10
 - complete 7, 27–33
 - discipline of 7
 - order of steps 7, 7, 27
 - physical examination 3, 7, 27
 - see also individual steps/structures*
 - conditions in ambulatory field setting 3, 3–5
 - conjunctival anesthesia for 12–14, 13
 - corneal anesthesia for 12–14, 13
 - in emergencies 1
 - equipment 2, 3, 5, 5, 15, 523
 - ambulatory field practice setting 3, 4, 4
 - field practice 4, 5, 6
 - ophthalmic instruments 15–23
 - eyelid akinesia 11–12, 12
 - eyelid analgesia 11–12, 12
 - eyelids 2
 - field practice *see* field practice
 - findings (prepurchase), significance 78, 78
 - first, with presenting complaint 615–616
 - foals *see* foals
 - geriatric horses 1
 - globe position and orbit 27, 28
 - handler position 7, 9, 10
 - head support 4, 9–11, 10, 11
 - history 1–2
 - illumination techniques 15, 16, 523
 - indications 1, 3
 - instruments 5, 5, 15
 - iridocorneal angle 30
 - iris 31–32
 - lens 32
 - light reflection and 15–16
 - local analgesia/anesthesia 11–15
 - minimum ophthalmic database 203, 204
 - mydriasis for 14, 14, 523
 - nasolacrimal system 29, 30
 - neonatal 1
 - nerve blocks for 11–12, 12
 - in neurological disturbances 1
 - neuro-ophthalmic 23–27
 - see also neuro-ophthalmology*
 - normal appearance 2
 - patient positioning 7–9, 9
 - physical restraint 9–11, 10
 - posterior segment 32–33
 - prepurchase 1, 77
 - pupillary light reflexes 23–25
 - pupils 28, 32
 - reference ranges for common tests 9
 - in referral institutions 2
 - retrobulbar anesthesia for 14
 - routine 3, 7, 7
 - second opinion 79
 - sedation 7–9
 - smartphone use 14, 22–23, 23
 - in specialty practices 2
 - tests before mydriasis 14
 - urgent, indications 1, 3
 - see also specific conditions/diseases*
- examination report, standardized 7
- examination room 2, 3
 - ambulatory field practice setting *see* field practice
 - in specialty practice, facilities 4
- examination sheet (clinical report) 7, 8
- exenteration 175–176
 - closure and analgesia after 176
 - complications 176
 - drain sites 176
 - enucleation expansion 176
 - after eyelid laceration/removal 214, 214
 - general anesthesia 176
 - indications 166, 175–176
 - orbital disease 166
 - preparation, procedure 176
 - prosthesis contraindication 176
- Exmoor ponies, congenital cataracts 678
- exons 661, 664
- exophthalmos 28, 142–144
 - causes 142, 142–143
 - CT 96
 - differential diagnosis 108
 - in episcleral vessel enlargement 147–148
 - evaporative keratopathy and 303
 - exenteration for 166
 - globe retropulsion assessment 144
 - hydatid cyst disease 754
 - hydrophthalmos (buphthalmos) *vs.* 146
 - identification 144
 - intracranial neoplasia 734
 - intradiploic hematoma of frontal bone 160
 - in nasal cavity neoplasia 161
 - in nontraumatic orbital disease 149
 - orbital cellulitis causing 144
 - orbital dermoids causing 148
 - orbital masses causing 142, 142
 - orbital neoplasia causing 161, 161, 162, 162, 163
 - in orbital vascular abnormalities 148
 - prognosis 144
 - pulsatile 148
 - in sinusitis 159
 - in sinus neoplasia 161
 - after skull fracture 765
 - subtle 144, 144
 - systemic disease causing 740
 - third eyelid in 147
 - ultrasound 101, 108
- exotic diseases 139
- experimental autoimmune uveitis (EAU) 464, 465, 466
 - autologous MSC therapy 479
- expressivity 665
- external limiting membrane, retina 691, 692
- external ophthalmic artery 137
- external ophthalmoplegia 713
- extracapsular lens extraction, cataracts 526, 532, 536
- extracellular matrix (ECM)
 - corneal epithelium 258
 - corneal stroma 258, 259, 263
 - remodeling in ERU 467
- extraconal masses 166
- extracortical nuclei 694
- extralabel (off-label) prescribing 794, 796–797
- extraocular muscles 136, 136, 136, 696
 - avulsion 137, 140, 169
 - CT 94
 - functions 136
 - innervation 136, 696, 696–697
 - post-inflammatory stricture 140–141
 - reattachment 169
- extrapulmonary disorders (EPD), *Rhodococcus equi*
 - infection 772
- exudative optic neuritis 598, 604, 605
- eye(s)
 - autonomic innervation 698–700
 - digital camera comparison 616–617, 618
 - disease, frequency (by condition) 74–76, 75
 - motor nerve supply 697
 - movements 626, 694–697
 - cranial nerves involved 694–697
 - divergent 629, 645
 - fixation system 626–627
 - motion detection and 626
 - reflexive systems 627
 - synchronous 629
 - “vergence” 629
 - visual acuity affected by 637
 - voluntary 628
 - normal appearance 2
 - position 629, 793
 - binocular vision and 634–635
 - radius 547
 - sensory nerve supply 697–698, 698
 - size 623, 642, 793
 - surface *see* ocular surface
- eyeball *see* globe
- eyedrops 62, 63
 - application 273
 - for corneal disease 273
- eyelashes (eyelid cilia) 187–188, 188
 - aberrant 202, 219
 - disorders 208–211
 - clinical appearance 209, 209–210
 - definitive diagnostic methods 210
 - diagnosis/examination 209–210
 - differential diagnosis 210
 - long-term prognosis 211
 - pathogenesis/progression 210
 - treatment 210–211
- ectopic *see* ectopic cilia
- examination 27
- extra lashes *see* distichia (extra cilia)
- normal 2, 29
- in ocular pain 29

- eyelashes (eyelid cilia) (*cont'd*)
 - orientation/direction 2, 27, 29
 - resting tone, innervation and 697
 - turned inward *see* trichiasis
 - eyelid(s)
 - abscessation, ultrasound 108–109
 - agenesis 201, 202
 - akinesia 11–12
 - anatomy and physiology 187–191
 - autonomic nerve supply 697
 - blinking *see* blinking
 - blood supply 189
 - cilia *see* eyelashes (eyelid cilia)
 - closure 190, 213, 214
 - distortion, orbital neoplasia 162
 - edema/swelling 205
 - examination 27–28, 29
 - function/role 187
 - fusion *see* ankyloblepharon
 - in habronemiasis 752
 - hair 187, 188
 - aberrant follicles 202
 - inflammation *see* blepharitis
 - innervation 189, 189, **190**
 - lacerations *see* eyelid lacerations
 - layers 187
 - ligaments 190
 - lower, denervation 12
 - lymphatic drainage 189
 - margin 188, 188
 - biopsy 55, 56
 - closure, biopsy site 55
 - defects, facial trauma 154
 - eversion, assessment 28
 - inversion *see* entropion
 - motor nerve supply 697
 - muscles 189, **190**, 190
 - normal position 190
 - ocular health, importance to 187
 - opening, avoidance in corneal lacerations 332
 - ptosis 189
 - radical resection 176–177
 - resting tone, innervation and 697
 - scarring, in eyelash disorders 209, 210
 - sebaceous glands (tarsal) 188, 188–189
 - separation 202
 - spastic, examination 11
 - support, loss
 - in enophthalmia 144–145
 - entropion in 211
 - surgical repair 169, 212–214, 213
 - swelling around, strangles 743
 - swollen drooping 205
 - tacking, entropion management 199, 200, 200
 - tattooing, SCC protection 230
 - tension, raised IOP 45
 - third *see* third eyelid
 - trauma *see* eyelid trauma
 - turning in *see* entropion
 - upper
 - analgesia, examination 11
 - anesthesia, for examination 11–12
 - droopiness (ptosis) 215
 - grass sickness (dysautonomia) 732–733
 - nerve blocks 11, 12, 12
 - eyelid disorders
 - acquired 211–218
 - angiosarcoma 163
 - coloboma **200**, 201, 213
 - congenital abnormalities 199–203, **200**
 - entropion *see* entropion
 - future research 239
 - inflammation *see* blepharitis
 - lymphosarcoma 236, 237
 - masses, pseudotumors vs. 237
 - melanoma 235, 235–236
 - neurologic 214–218
 - sarcoids 221
 - squamous cell carcinoma 213, 226, 227, 227, 235
 - cryotherapy 231, 232
 - lacerations vs. 213
 - papillomatous 227, 227–228
 - surgical treatment 231, 231
 - superficial venous malformations 149
 - third eyelid *see* third eyelid, disorders
 - turning in of margins *see* entropion
 - eyelid lacerations 154, 188, 212, 212–214
 - clinical appearance 212, 212, 213
 - diagnosis 212
 - differential diagnosis 212
 - long-term prognosis 214
 - pathogenesis/progression 212
 - ripping 212
 - surgical repair 212, 213, 213–214, 214
 - treatment 212–214, 213
 - eyelid trauma 207
 - blepharitis due to 206, 206
 - blunt 189
 - lacerations 212
 - defect, closure 56
 - management 207
 - penetrating, lacerations 212
 - trichiasis due to 209
- f**
- face masks, photic head shaking 715
 - facial canal 697
 - facial crest 139
 - facial hypalgesia/analgesia 711
 - facial lacerations 150
 - facial motor nucleus, lesions 712
 - facial nerve (CN VII) 216–217, 303
 - anatomy 216–217, 695, 697, 701, 712
 - auriculopalpebral branch 697
 - buccal branches, compression, paralysis 713
 - caudoventral bend (“knee”) 697, 700
 - course 216–217
 - dazzle reflex 25
 - dysfunction
 - hypothyroidism 762
 - keratoconjunctivitis sicca 198
 - systemic illnesses causing 721, **722**
 - equine protozoal myeloencephalitis 721
 - examination **24**, 701
 - eyelid innervation 189, 189
 - in facial trauma, effects 154
 - lesions
 - corneal reflex deficit 26
 - sites 217
 - menace response 701
 - palpebral branch
 - blocking, eyelid akinesia 11, 12
 - menace response deficit 25
 - paresis/paralysis *see* facial nerve paresis/paralysis
 - somatic motor nucleus 697
 - temporohyoid osteoarthropathy 735, **735**, 735
 - trauma
 - keratoconjunctivitis sicca in 198, 199
 - neurogenic keratoconjunctivitis sicca 218
 - zygomatic branch 697
 - facial nerve paresis/paralysis 148, 216–217, 304, 712–713
 - causes 217, 712, 713
 - lesions causing 712
 - trauma 764
 - chronic 712
 - clinical appearance 217, 217, 712, 713, 721
 - diagnosis 217
 - differential diagnosis 217
 - in equine protozoal myeloencephalitis 721, 722
 - examination 712
 - long-term prognosis 217
 - methods for definitive diagnosis 217
 - neurogenic keratoconjunctivitis sicca with 712
 - peripheral vestibular disease with 730, **730**, 730
 - in polyneuritis equi 737
 - in temporohyoid osteoarthropathy 735, **735**
 - treatment 217, 713
 - in West Nile virus encephalitis 728
 - facial neuropathy, trauma 711
 - facial nuclei 701
 - facial paralysis 711, 712
 - chronic 712
 - idiopathic 713
 - neurogenic keratoconjunctivitis sicca with 712
 - see also* facial nerve paresis/paralysis
 - facial skin, equine 231
 - facial trauma
 - facial nerve paresis/paralysis 713
 - ocular injury associated with 152–154
 - orbital cellulitis risk 156
 - factor B 465
 - factor VIII-related antigen (FVIII-RAg) 297
 - fading vision zebrafish pigmentation 671
 - Fagopyrum esculentum* (buckwheat) 767
 - falls, rotational 793
 - far point 40
 - far-sightedness *see* hyperopia (far-sightedness)
 - Fas ligand 259
 - fat
 - mobilization, sites 144
 - orbital *see* orbital fat
 - supraorbital fossa 144
 - fat pad, third eyelid 191

- Federal Food, Drug and Cosmetic Act (FFDCA) 792
- Fédération Equestre Internationale (FEI) 792, 793, 794
- Federation of International Polo Rules 794, 816
- feline herpesvirus 1 316
- fenbendazole 158
- fencing, paddocks, for blind horses 804
- fetal head compression 583
- fibrin 270
 - band, after surgery for corneal perforation 325
 - deposits in zonular ligaments 514
 - formation in AC, after cataract surgery 533, 534, 535
 - high-resolution ultrasound 111
 - intraocular, neonatal sepsis 769
 - from iris vessels, corneal perforation 417
 - pupil margin, fungal infection 371
 - septic uveitis, neonatal foals 768, 769
 - small penetrating corneal lacerations 333, 334, 334
 - ultrasound hyperechogenicity 105
- fibrin clot 111, 334, 334
- fibrin tissue glues, amniotic membrane transplant 402
- fibroblast(s)
 - corneal fibrosis 271
 - wound 259, 337
- fibroblast growth factors (FGFs) 263
- fibronectin 267, 467
- fibrosis, corneal *see* corneal fibrosis
- field of view 629–635, 655
 - horizontal 645
 - panoramic 629, 631, 655
 - vertical 645
- field practice
 - barn, and conditions in 3, 3–4
 - challenges of examination in 4
 - diagnostic tests 5
 - digital photography 58, 58, 59, 60, 61
 - examination
 - barn aisle/stall size 4
 - equipment 4, 5, 6
 - folding tables 3, 4
 - handler position 7, 9, 10
 - head support, passive 4, 9, 10, 11
 - instruments 5, 5, 15
 - lighting 5, 6, 15
 - room optimization 4–5
 - tote box and consumable supplies 4, 4
 - examination conditions 3–5
 - examination room 3, 3–4
 - creating 3, 4
 - maze testing in barn 26, 26
 - ophthalmic imaging 58–61
 - radiography 59, 61
 - ultrasound 58–59, 61
 - therapy 5
 - intracorneal injection 74
 - medications needed 5
 - nasolacrimal duct irrigation 61–62, 62, 62, 63
- SPL insertion *see* subpalpebral lavage (SPL) system
- subconjunctival injections 73, 73–74
- supplies needed 5
- topical medication 62–64, 63, 63
- fight-or-flight behavior, blind horses 798, 803
- fimbriae 339
- fine-needle aspiration (FNA) 53–54, 139
 - orbital dermoids 148
 - procedure 54
 - sarcoids, not recommended for 222
- Finnoff transilluminator 17, 17, 19, 21
- cataract examination 517
- corneal examination 30
- iridocorneal angle examination 30
- iris examination 32
- posterior segment examination 33, 570, 571
- firocoxib, nasolacrimal disease 196
- fistulous withers 746
- fixation system 626, 627
- fixed point of reference 635
- FK506 (tacrolimus) 312
- flash electroretinography 41, 42, 767
- flashing, third eyelid, tetanus 731
- flash-stimuli visual evoked potential (FVEP) 42
- flicker-photometry, ERG 42
- “flight response”, periocular trauma 212
- floaters 33, 460, 582
- fluconazole 374, 376, 749
- flucytosine 374
- flunixin meglumine 355
 - equine recurrent uveitis 478, 478
 - intraocular inflammation control 355
 - nasolacrimal disease 196
 - onchocerciasis 752
 - stromal abscesses 390
 - ulcerative keratomycosis 377
- fluorescein angiography 125
 - chorioidpapillary phase 578
 - indications/uses 125
 - posterior segment examination 578, 580, 580
 - retinal vascular phase 578, 580
- fluorescein stain/staining 35, 35–36, 256
 - corneal abrasions 362
 - corneal erosions 333, 347, 352
 - recurrent 335, 335, 336
 - corneal ulcer
 - bacterial 347
 - deep/deep melting 350, 352
 - noninfected 340, 348, 349
 - superficial indolent 335
 - descemetocoeles 347
 - effect on microbiologic culture 36
 - epithelial keratomycosis 361, 361, 362
 - indications 35, 36
 - Jones test 36, 38, 39
 - keratoconjunctivitis sicca 305
 - putative viral keratitis 319, 319
 - strips/containers and application 36, 36
 - tear film breakup time 35–36, 46
 - ulcerative keratomycosis 364
- see also* Seidel test
- fluoroquinolones 354
- fluoroscopy, neocanalization guided by 195
- 5-fluorouracil (5-FU) 234
 - adnexal SCC 234
 - corneal SCC 293
 - sarcoid chemotherapy 225
- fly masks 70, 70
- fly repellent, chemical keratitis 323, 323
- foals
 - aniridia 444–445
 - blind broodmares with 807–808
 - botulism 732
 - cataracts 500, 501, 501–502
 - see also* congenital cataracts
 - cataract surgery 520
 - complications 534, 536–537
 - diagnostic testing before 521–522
 - results 520
 - classification by gestation/foaling history 770
 - congenital corneal abnormalities 274
 - congenital glaucoma 547
 - corneal sensitivity 261
 - depth perception 635
 - entropion 199
 - see also* entropion
 - equine viral arteritis 737
 - examination 1
 - patient positioning 8, 9
 - eyelid disorders 199–203, 200
 - HERDA 757
 - immune-mediated hemolytic anemia 771
 - ivermectin toxicosis 767
 - lens disorders 500–507
 - MCOA syndrome 276
 - neonatal
 - bacterial meningitis 770
 - corneal touch threshold 39
 - deaths, mare reproductive loss syndrome 766
 - encephalopathy 770, 770
 - enophthalmia 144, 145
 - fundus 577
 - isoerythrolysis *see* neonatal isoerythrolysis (NI)
 - junctional epidermolysis
 - bullosa 773, 773–774
 - maladjustment syndrome 770, 770
 - Rhodococcus equi see Rhodococcus equi* infection
 - sepsis *see* sepsis, neonatal
 - systemic disease, ocular manifestations 768–774
 - ocular disease/abnormalities frequency 74
 - persistent hyaloid artery 580–581
 - retinal detachment 593
 - retinal hemorrhages 582, 583, 583
 - rib fractures 770
 - Schirmer tear test (STT) values 33
 - septic meningoencephalitis 729
 - strabismus 140, 140
 - subconjunctival hemorrhage 202, 203
 - subpalpebral lavage (SPL) system 65, 65
 - visual deficits 522
 - see also* congenital abnormalities/diseases

- focus adjustment 644
- Food and Drug Administration (FDA) 792, 793, 794
- extralabel (off-label) prescribing 796–797
- foramen lacerum 693, 700
- foramina, orbital *see* orbit, foramina
- forced duction tests 139, 140
- foreign bodies
- anterior chamber 328, 328, 329
 - conjunctival 324, 326, 328
 - corneal *see* corneal foreign bodies
 - corneal cytology 53
 - globe, management 154
 - iris depigmentation 328
 - lens capsule 330
 - nasolacrimal duct obstruction 196
 - orbital, penetrating 154, 158
 - organic, orbital 154
 - retained, eyelid laceration and 214
 - in tear film 327
 - third eyelid 326, 329
 - ultrasound 104, 108, 109
 - vitreous 327
 - wooden, orbital 154
- formalin 164, 164
- formin-like 1 (FMNL1) deficiency 464
- form perception 648–654
- behavioral studies 648, 649
 - color vision and *see* color vision
 - orientation 650, 650–651
 - from 2D photos 648
- fornix *see* conjunctival fornix
- Fourier-domain optical coherence tomography *see* spectral-domain optical coherence tomography (SD-OCT)
- fovea (lacking in horses) 626, 637, 646
- cone:ganglion cell ratio 647
 - motion detection 625–626
- fractionous horses, treatment 63
- fractures
- basilar 764, 765
 - depression 92, 92
 - frontal bone 149, 765
 - lacrimal bone 167
 - maxillary bones 149
 - orbital *see* orbital fractures
 - orbital rim 167, 167, 168
 - sinus *see* sinus fracture
 - stylohyoid 735
 - zygomatic arch 149
 - zygomatic process 167, 167
 - see also* skull fractures
- frame overo pattern 681
- free radicals, corneal ulcer healing 356
- frequency-domain optical coherence tomography *see* spectral-domain optical coherence tomography (SD-OCT)
- frequency of ocular disease 74–76, 75
- fresh frozen plasma (FFP) 355–356
- Friesian horses
- bilateral corneal stromal loss 677, 677–678
 - corneal dystrophy 123–124, 280–281, 677, 677
 - distichia (extra cilia) 676–677, 677
 - nonocular conditions 678
- frontal bone 133, 134, 135
- fractures 149, 167, 765
 - intradiploic hematoma 160
 - zygomatic process *see* zygomatic process, frontal bone
- frontal cortex 701
- frontalis muscle 189, 190, 190
- frontal nerve 12, 189
- anatomy 697
 - block 11–12
- frontal sinus 139
- adenocarcinoma 163
 - drainage 139
 - fracture 139
 - trauma, subcutaneous emphysema 147
 - trephination 179
- frontonasal osteoplastic flap 160
- Fuch's endothelial dystrophy 407
- full-sightedness *see* hyperopia (far-sightedness)
- fully penetrant diseases 666
- fumonisin B1 768
- functional annotation of animal genomes (FAANG) 664
- fundic reflex 40
- direct ophthalmoscopy 20
 - retinoscopy 40
- fundus 693
- albinotic eye 574, 575
 - color-dilute horse 569, 574, 576, 577
 - dorsal tapetal section *see* tapetum
 - examination 14, 32–33, 569
 - direct ophthalmoscopy 19–20, 20, 21–22
 - indirect ophthalmoscopy 570
 - interpretation 573–577
 - optic neuropathy 704
 - smartphonoscopy 572–573, 573
 - newborn foals 577
 - nontapetal (ventral) 574, 575
 - bullet-hole lesions 579, 580
 - color 571, 574, 576
 - depigmentation 577, 579, 600
 - examination 571
 - hyperpigmentation, senile
 - retinopathy 596, 596
 - pigment clumping, chorioretinitis 587
 - pigment deposits, EMND 597, 597
 - normal 573–574, 574, 575, 576
 - normal variations 568, 569, 573, 574
 - peripapillary 575
 - anatomy 567, 568, 569
 - subalbinotic 19, 569, 572, 575, 576
 - tapetal *see* tapetum
 - transillumination 16, 17, 19
 - see also* specific structures
- fungal-associated precorneal tear film
- instability 360, 360–361, 361
- fungal culture 48
- fungal hyphae 52, 357
- confocal microscopy, keratomycosis 372, 372
- cytology interpretation 50, 51, 51, 52–53
- basiphilic cytokeatin vs. 53
- dead, slow removal 373
- iris abscess 372
- keratomycosis 358, 361, 362, 364, 372, 372
- smartphone photograph 59
- staining of cytology slides 50, 52
- stromal abscesses 367, 373, 387
- fungal infections
- blepharitis 203, 206
 - conjunctivitis 203
 - corneal ulceration 341, 357, 360
 - endophthalmitis 371
 - keratitis, *in vivo* confocal microscopy 118, 119–120, 120
 - lens 371, 372
 - meningitis due to 729
 - neonatal sepsis 768
 - rose bengal staining 37
 - sample collection and culture 48
 - stromal abscesses *see* stromal abscesses
 - systemic 724, 749–751
 - see also* keratomycosis; *individual diseases; individual fungi*
- fungal plaque 341, 342
- in aspergillosis 750, 751
 - thick pigmented 366, 366, 367
- fungal spores 52
- fungi 357
- corneal/conjunctival surface microflora 264
 - hyphae *see* fungal hyphae
 - keratopathogenic species 358, 359, 387
 - lens and 371, 372
 - ocular microflora 358
 - pathogenic species 359
- Fusarium* 358
- antifungal drugs for 375, 376
 - conidia 358
 - corneal ulceration 364, 384
 - corn infected with, blindness due to 768
 - deep melting ulcer 386
 - in vivo* confocal microscopy 118
 - keratomycosis 375, 376
 - natamycin effectiveness 375
 - stromal abscesses 387
- Fusarium verticillioides* (*Fusarium moniliforme*) 724
- g**
- gabapentin 734
- gadopentetate dimeglumine 97
- gain-of-function mutation 665
- galectin-3 255
- gametes 664
- mutations in DNA 665
- gamma-glutamyl transferase (GGT) 724, 767
- gammaherpesviruses 318, 740
- ganglion cell layer 691, 692, 692
- gaze 19, 23
- in congenital stationary night blindness 586

- fixation 626, 627
- saccades and 628
- star gazing 140, 586, 586
- Gedoeftia* 321
- clinical features of infestation 322, 322
- host, larvae 321
- keratitis due to 321, 322
- gelatin zymography 267
- gels (drug), bioavailability 273
- gene(s) 661, 664
 - expression 664, 665
 - inheritance 664
 - mutations *see* mutations
 - sex-linked 664
- general anesthesia
 - cataract surgery 524
 - corneal surgery 394
 - CT 93, 93
 - electroretinography 41
 - enucleation 170
 - examination and 2
 - exenteration 176
 - position effect on IOP 45
 - protracted, evaporative keratopathy after 303
 - risks 41
- gene splicing 664
- gene therapy
 - corneal haze reduction, after surgery 418
 - equine recurrent uveitis 480
- genetic code 661
- genetic disorders *see* inherited ocular disorders
- genetic diversity 664
- genetic risk, breeds at 27
- genetics, concepts/terminology 661, 664
- genetic testing 681–682
 - breeding decisions 681–682
 - laboratories offering 682
- genetic variation 664–665
 - structural variants (SVs) 665
- geniculate nucleus 700
- genome 661
 - horse, base pair number 661, 664
 - sequencing 661
- genome-wide association study (GWAS)
 - Appaloosa horses, ERU in 674
 - distichiasis 677
 - ERU in German Warmbloods 675
 - squamous cell carcinoma 676
- genotype 665
- gentamicin 354
 - chemical ciliary body ablation 560, 560
 - equine recurrent uveitis 479
 - intravitreal injection 479
 - nasolacrimal disease **196**
 - orbital disease 164
- gentocin 479
- geriatric horses
 - enophthalmos 144, 145
 - exenteration for orbital disease 166
 - melanoma 235–236
 - ocular examination 1
- ophthalmic disease frequency 75
- optic nerve atrophy 600
- senile cataracts 507, 507, 509
- senile retinopathy (retinal degeneration) 596, 596
- vitreous syneresis 581–582
- German Warmblood horses
 - cataracts 678
 - ERU 674–675, 747
- “ghost vessels”, corneal 272, 308
- glands, tarsal (meibomian) *see* meibomian glands
- glands of Moll (ciliary glands) 188
- glands of Zeiss 188
- glare 638, 644
 - accidents and 638, 644
 - adaptations to reduce 624–625, 625
 - pathologic, causes 644
 - protective mechanisms 644
- glaucoma 543–568
 - acute/active 548, 549
 - clinical signs 548, **548**, 549
 - idiopathic primary edema vs. 279
 - anatomy and physiology 543–545
 - breeds associated 547
 - cataract surgery complication 536
 - cause 543
 - chronic 548–549
 - clinical signs **548**, 548–549, 550
 - lamina cribrosa deformation 545, 546, 546
 - optic nerve atrophy 601, 602
 - optic nerve degeneration 601
 - chronic ERU causing 462, 547–548
 - ciliary cleft collapse 551, 551, 552, 553
 - clinical signs 145, 548, **548**, 548–549, 550
 - congenital 28, 142, 547, 547
 - hydrophthalmos in 146
 - definition 543
 - diagnosis 548–550
 - high-resolution ultrasound 550–552, 551, 552, 553
 - early, diagnosis 548, 549
 - enucleation 816
 - in ERU, pathogenesis 547–548
 - etiology 547–548
 - future research 561
 - globe size increase 146, 549, 549, 550
 - IOP 45, 46, 543, 545
 - after Baerveldt gonioimplant 560
 - drugs reducing 554–557, **555**
 - elevated 45, 46, 543, 545
 - after endoscopic cyclophotocoagulation 558
 - fluctuations 548
 - measurements 44, 46, 548
 - target IOP in treatment 554
 - after transscleral cyclophotocoagulation 558
 - see also* intraocular pressure (IOP)
 - iridocorneal angle 544, 550–551, 551, 552, 553
 - lamina cribrosa deformation 545, 546, 546
 - laminar plate compression 546, 546
 - medical treatment 554–556
 - β -adrenergic blockers 555, **555**
- anti-inflammatories 556
- carbonic anhydrase inhibitors **555**, 555–556
- goals, and choice 554–555
- parasympathomimetic drugs **555**, 556
- prostaglandin analogs **555**, 556
- topical mydriatics/atropine **555**, 556
- optic nerve atrophy 546, 546
- pathophysiology 545–547
- prevalence 547, 561
- primary 514, 547
 - diagnosis 548, 552
 - diffuse corneal edema 547
- prognosis 554
- prognostic factors 551, 552
- refractile corneal opacities 283
- secondary 547, 550
 - acute anterior uveitis 453
 - ciliary cleft 553
 - equine recurrent uveitis 462, 462, 547–548, 548
 - high-resolution ultrasound 553
 - subacute, clinical appearance 548
- surgical treatment 556–561
 - chemical ciliary body ablation 560, 560
 - choice, options 556
 - endoscopic cyclophotocoagulation 558, 558–559
 - enucleation, intrascleral prosthesis 560–561
 - goals 557
 - gonioimplants 559, 559–560
 - gonioimplants with cyclophotocoagulation 559
 - laser cyclophotocoagulation 556, 557, 557–559, 558
 - micropulse transcleral cyclophotocoagulation 559
 - transscleral cyclophotocoagulation 557, 557, 558, 558, 566
- trabecular meshwork **544**
- treatment 554–561
 - goals 554–555
 - vision, control of IOP 554–555
 - vision loss, and resistance to 546–547, 568
- glia, radiating 691
- glial cells, Müller *see* Müller cells
- gliomas 606
- gliosis, in glaucoma 546
- globe 133–186
 - acquired diseases 149–156
 - anatomy 27, 134, 136
 - artificial 174
 - attachment to orbital rim 134, **136**
 - axis 133
 - color, light reflection 15
 - compression/entrapment 139
 - developmentally small (microphthalmos) 141–142
 - deviation *see* strabismus
 - dimensions 133
 - diseases
 - preventive management 139
 - topical medications **156**

- globe (*cont'd*)
- displacement 139, 155
 - anterior *see* exophthalmos
 - from orbit *see* orbital proptosis
 - evaluation after facial trauma 152
 - examination 27, 28
 - in facial trauma 152
 - prepurchase 77
 - external wall 134
 - foreign bodies, management 154
 - function abnormalities 141–146
 - hemorrhage into 150
 - hypotony 151
 - inferior, exposure (examination) 10–11
 - internal volume 136
 - lacerations 151, 152
 - location 133
 - location abnormalities 141–146
 - see also* enophthalmos; exophthalmos
 - motion
 - assessment 139
 - involuntary 141
 - oscillatory *see* nystagmus
 - perforation 150–152
 - blunt trauma 150, 151, 152
 - clinical appearance 150
 - diagnosis 109, 151
 - fluid leakage 150
 - prognosis 152
 - treatment 152
 - position 27, 133, 139–140, 140, 694–695
 - abnormalities 27, 28, 139–140
 - foals 140, 140
 - repair of ocular muscle avulsion 169
 - see also* strabismus
 - preservation, aim 615
 - radical resection 176–177
 - recession (enophthalmos) 144–145
 - refractive index 15
 - retraction, in hyperkalemic periodic paralysis 758
 - retraction reflex 136
 - retropulsion 146, 155
 - assessment 144
 - painful/nonpainful, diseases causing 144
 - ruptured 109, 150–152
 - see also* globe, perforation
 - shape 133
 - shrinkage *see* phthisis bulbi
 - size 133
 - size abnormalities 27, 28, 141–146
 - congenital 141–142
 - enlarged 145–146
 - reduction in size 145, 149
 - surgical removal *see* exenteration
 - symmetry 28
 - trauma 150, 152
 - blunt 326, 330, 330
 - see also* globe, perforation
 - ultrasound 104, 104
 - vascular abnormalities 148–149
- globe retraction reflex 136
- glucocorticoid(s)
- IMMK 309, 311–312, 313
 - mechanism of action 311–312
- glucocorticoid receptor (GR) 311–312
- glucose, cornea, supply to 260
- glutamate receptor 667
- glycocalyx, epithelial 254, 255, 257
 - barrier function 255, 257
 - corneal injury, healing 268
 - mucins 255, 256
- glycosaminoglycan (GAG) 258
- goblet cells 53, 191
- Goldmann–Witmer coefficient (C-value) 473, 745
- gold salts, injectable 756
- gonioimplants, glaucoma 559, 559–560
- graft(s)
- amnion *see* amniotic membrane
 - transplants (AMT)
 - conjunctival *see* conjunctival grafts (transplants)
 - corneal *see* corneal transplantation
- graft rejection
 - conjunctival grafts (transplants) 415
 - corneal transplantation 414, 415
 - penetrating keratoplasty 403, 407
- Gram-negative bacteria 339
 - antibiotic sensitivity 354
 - corneal/conjunctival surface 263, **264**
 - corneal ulceration 339, **344–345**, 354
- Gram-positive bacteria
 - antibiotic sensitivity 354
 - corneal/conjunctival surface 263, **264**, 338
 - corneal ulceration 339, **346–347**, 352, 354
 - stromal abscesses 387
- granula iridica (GI) 24, 441, 442, 644, 645
- granular dermatitis *see* habronemiasis
- granulation tissue
 - corneal ulceration healing 341, 342, 348
 - sarcoid diagnosis and 221–222
- granulocytes, activation, in equine recurrent uveitis 465, 466
- granulomas
 - cholesterinic 708
 - habronemiasis 752
 - orbital cellulitis 157
 - parasitic orbital disease 157, 158
- grass sickness *see* equine dysautonomia (equine grass sickness)
- grating acuity 635
- “gray line” 189, 213
- greater petrosal nerve (GPN) 700
- green wavelength-sensitive cones 651
- grid cells 802
- grid keratotomy, recurrent corneal erosion 338
- griseofulvin, complicated microphthalmos associated 141
- GRM6 gene 587
- growth factors
 - amniotic membrane 400
 - corneal angiogenic privilege 263
 - corneal vascularization 263, 271
 - corneal wound healing 267–268
 - ocular surface 267–268
- see also* individual factors
- guanine 661
- Gundersen flaps 395
- Gundersen inlay conjunctival graft 279, 286
- gunshot, in orbit 154
- guttural pouch 139, 699, 700
 - empyema 164, 744
 - fungal plaque 750
 - lesion, Horner's syndrome 710
- guttural pouch disease 164
 - causes 139
 - direct extension 149
- guttural pouch mycosis 164, 705, 734, 750
 - treatment 751
- ## h
- Haab's striae 145, 283, 514, 545
- Habronema*
 - blepharitis 206–207, 207, 752
 - clinical features of infestation 322
 - intermediate host/vector 321
 - orbital cellulitis 156
- Habronema microstoma* 206, 752
- Habronema muscae* 206, 321, 752
- habronemiasis 157, 206–207, 321
 - blepharitis 206, 207, 207, 752
 - clinical appearance 206–207, 207, 752, **752**
 - corneal 321, 322
 - cutaneous **752**, 752–753
 - diagnosis 207, 752–753
 - differential diagnosis 322
 - environmental control 207–208
 - keratitis 321, 321, 322
 - mucocutaneous junctions/sites 207
 - treatment 207, 322, 753
 - working horses, developing world 76
- Hackney, USEF rules **795**
- Haflinger horse (Avelignese horse) 675
- DDB2 gene 676
- squamous cell carcinoma 675, 676
 - adnexal 227, 228
 - corneal 288
 - limbal 675, 676
- hair
 - dermal 187, 188, 188
 - eyelid 187, 188
 - aberrant follicles 202
 - halicephalobiasis 157, 158
- Halicephalobus gingivalis* (*Halicephalobus deletrix*) 157, 158, 592, 729, 754
 - clinical signs 754, **754**
 - treatment and prognosis of infection 158, 754
- halogen lamp, Finnoff transilluminator 17, 17
- handlers, for blind horses 800, 805, 809, 817
- hand motion vision 636
- hard cup hoods 70–71, 71
- hay, moldy/contaminated 724
- haze, corneal *see* corneal haze
- head
 - movement
 - acceleration-deceleration 695
 - aversive 64

- positioning, effect on IOP 45
- stabilization, ocular examination 9
- support
- for examination 4, 9–11, 10, 11
 - passive, for examination 9, 10
- tremors, butorphanol tartrate inducing 9
- weight 9
- head direction cells 802
- headshaking 714–715, 733–734
- causes 733, 734
 - examination 733–734
 - idiopathic 733
 - management 734
 - photic 598
 - see also* photic trigeminal mediated headshaking
- head tilt posture
- unilateral sight loss 815
 - vestibular disease 730, 730
- head trauma 764
- middle cranial fossa syndrome after 714
- hearing, blind horses 803
- hemangiomas, corneal 297
- hemangiosarcoma
- conjunctival 298
 - corneal 297, 298
 - limbal 298
 - orbital 163
- hematoma
- ethmoidal 138
 - frontal bone intradiploic 160
- hemolytic anemia, immune-mediated, in foals 771
- hemorrhage
- cataract surgery 533
 - nasolacrimal duct atresia surgery 194
 - subconjunctival 200
- hemostasis, corneal surgery 393
- hepatic encephalopathy 707
- hepatic failure 767, 771
- hepatoencephalopathy 767
- herbal substances, sarcoid therapy 224
- HERDA *see* hereditary equine regional dermal asthenia (HERDA)
- herd animals, visual cues, ignoring impact 798
- herds, blind horses in 798, 806
- adaptation 798–800
- hereditary equine regional dermal asthenia (HERDA) 47, 281, 679–680, 757–758
- breeds associated 663, 679, 757
 - clinical appearance 679, 757, 757, 757
 - diagnosis 758
 - inheritance and gene variants 663, 680, 757
 - management/breeding and 758
 - pathogenesis 680, 757
 - Schirmer tear test 1 758
- hereditary junctional mechanobullous disease *see* junctional epidermolysis bullosa (JEB)
- hereditary ocular disorders *see* inherited ocular disorders
- herniation, orbital fat 154–155
- herpes keratitis, corneal touch threshold
- decrease 39
- herpes simplex virus (HSV) 318, 320
- herpes stromal keratitis (HSK) 263, 318
- heterochromia iridis 23
- heterochromic iridocyclitis 311, 616
- heterochromic iridocyclitis with keratitis (HIK) 451, 454, 455–456
- causes 456
 - chronic persistent uveitis due to 455
 - clinical appearance 455–456, 456, 616
 - diagnosis and treatment 454
 - histology 456, 457
 - pathogenesis 456
 - secondary keratitis, optical coherence tomography 123
 - treatment and prognosis 456–457
- heterozygous individuals 665, 666
- high-frequency diathermy, cataract surgery 528, 529
- high-frequency ultrasound 110–114
- see also* high-resolution ultrasound
- high-frequency ultrasound biomicroscopy (UBM) 59, 102, 110–114
- see also* ultrasound biomicroscopy (UBM)
- high-resolution ultrasound 102, 110, 551, 552
- anterior chamber 552
 - aqueous humor outflow 550, 551, 551, 552, 553
 - central corneal thickness measurement 114
 - ciliary cleft 550, 551, 551, 552, 553, 554
 - corneal abscess 113, 114
 - corneal dermoids 275
 - corneal foreign body 113–114
 - corneoconjunctival SCC 112
 - corpora nigra cyst 113, 113, 447
 - fibrin clot 111
 - glaucoma 550–552, 551, 552, 553
 - indications 110–111
 - iridocorneal angle (ICA) 550, 551, 552
 - iris hypoplasia 112
 - iris melanoma 112
 - keratomycosis 113, 114
 - limitations 550
 - normal appearances in 110–111, 111
 - systems available 550
 - uveal cyst 113, 113
- hindlimb ataxia 728
- hindlimb paresis 728
- hirsutism 759, 760
- histiocytic sarcoma 302
- corneoscleral 302, 302
- histopathology
- corneal SCC 289
 - ERU *see* equine recurrent uveitis (ERU)
 - retinal disorders 584
 - sarcoids 222
- Histoplasma farciminosum* 206, 749
- HLA typing (humans) 673
- homozygous individuals 665, 666
- hood(s), hard cup 70–71, 71
- hood (advancement) conjunctival graft *see* conjunctival grafts (transplants)
- hooves
- examination 27
 - striped 668
- horizontal cells 566, 691, 692
- structure 691
- Horner's muscle 190
- Horner's syndrome 146, 189, 214–216, 708–709
- bilateral 710
 - causes 215, 215–216, 708
 - systemic illness 721, 722
 - trauma 764–765
 - clinical appearance 215, 215, 708, 709, 710
 - diagnosis 215
 - differential diagnosis 215, 710
 - in equine protozoal myeloencephalitis 721
 - first-order 709, 710
 - lesions location 709, 710
 - long-term prognosis 216
 - methods for definitive diagnosis 215
 - miosis 215, 215, 708
 - neurological signs 216
 - pharmacologic testing 216
 - postganglionic lesion 215, 216, 709
 - preganglionic lesion 215, 216, 709
 - second-order 709, 710
 - third-order 709, 710
 - treatment 216
 - vestibular disease 730, 730
- horses, suitability for specific uses 615
- horsetail (*Equisetum arvense*) 767
- Hotz–Celsus procedure 201, 201, 202
- Hounsfield Unit (HU) 92
- H-plasty, for eyelid SCC 231, 231
- hyaline membranes, iris/ciliary body, in ERU 468, 469, 469
- hyalitis *see* vitreous, inflammation (hyalitis)
- hyaloid artery 504, 580
- persistent 504, 580–581
 - regression 504, 580
 - remnants 505, 577, 580, 581
- hyaloid remnant 505, 577, 580, 581
- hyaluronic acid
- corneal surgery 393
 - dermatopontin effect 401
- hyaluronic acid substitutes 418
- hydatid cysts 157, 754
- treatment and prognosis 158
- hydrodissection 528
- hydrogen protons, MRI 95
- hydropthalmos *see* buphthalmos
- hydroxyamphetamine, Horner's syndrome testing 216
- hydroxyapatite orbital implantation 152, 177, 177–178, 178, 179
- hyoscine 768
- hyoscyamine 768
- hyperacuity 648
- hyperacuity-like phenomena 648
- hyperbilirubinemia 767, 771
- hyperelastosis cutis (HC) *see* hereditary equine regional dermal asthenia (HERDA)
- hyperemia
- in acute anterior uveitis 452, 452
 - conjunctival *see* conjunctival hyperemia
 - optic nerve *see* optic nerve (CN II)
- hyperfibrogenemia 773

- Hypericum perforatum* (St John's wort) 767–768
hyperimmune plasma, *Rhodococcus equi* infection 773
hyperkalemic periodic paralysis (HYPP) 680, 758–759
breeds associated 663, 680, 758
clinical signs 758, 758
inheritance and gene variants 663, 680, 758
treatment 759
hyperopia (far-sightedness) 40, 639, 641
after cataract surgery 40–41, 518
prevalence 641
hyperosmotic preparations, in idiopathic primary edema 279
hyperpigmentation
iris *see* iris, hyperpigmentation
nontapetal retina 595, 595
tapetum 587
hyper-reflective chorioretinal scars 587
hyper-reflectivity, tapetum 573, 584, 587, 595
hypersensitivity
denervation, law of 216
to *Habronema* 207, 752
type IV response, eosinophilic keratitis 316
hypertension
intraocular, retinal hemorrhages 583
post-cataract surgery 533–534, 534
hyperthermia
adnexal SCC 230, 232
corneal SCC 294
sarcoïd treatment 226
hyphae *see* fungal hyphae
hyphema 150, 151
blunt ocular trauma, iris prolapse 417
hypopigmentation, *PMEL* mutations 671
hypopyon 105, 384, 414
hypo-reflectivity, tapetum 588
hypothyroidism 762, 762
hypotony, corneal perforation, with iris prolapse 417
hypovitaminosis A 764, 764
hypoxia, neonatal maladjustment syndrome 770
hypoxic ischemic encephalopathy (neonatal maladjustment syndrome) 583, 770
- i**
iatrogenic orbital diseases 164
Icelandic Horses
EHV-2 and EHV-5 in 318
insidious ERU 674
idiopathic corneal edema *see* corneal edema
idiopathic facial paralysis 713
idiopathic headshaking 733
idiopathic pachymeningitis 705
idiopathic primary edema (corneal) 278–280
idoxuridine 318
putative viral keratitis 320
ill-fitting harnesses 76
illumination, for examination 2, 15, 16
direct 14, 16, 16
lens evaluation 32
field practice 5, 6, 15
principles 15–17
supplemental lighting 5, 6
transillumination *see* transillumination
illusion, visual 616, 616, 617
ilomast 355, 355
imaging techniques 90–132
advanced 90–132
equipment for 2
in the field 58–61
future/research methods 125, 180
see also individual techniques
imidazoles 374
imidocarb dipropionate 748
IMMK *see* immune-mediated keratitis (IMMK)
immune defence *see* cornea, immunobiology
immune-mediated blepharitis 203, 208
immune-mediated conjunctivitis 203
immune-mediated corneal diseases 306–318
immune-mediated dacryoadenitis 198, 304
immune-mediated ERU *see* equine recurrent uveitis (ERU)
immune-mediated hemolytic anemia, in foals 771
immune-mediated keratitis (IMMK) 120, 306–313
antigens causing 307
causes 307
clinical presentation 308
clinical spectrum 120, 307
corneal layers involved 120, 307
corneal lymphoma after 301
diagnosis 307–308
endothelial form (endotheliitis) 120, 309–311, 311
medical therapy 313
epithelial form 120, 305, 307, 308, 308
immunoinflammatory response 120, 307
in vivo confocal microscopy 120, 121
medical therapy 311–313
cyclosporin A and tacrolimus 312, 312
doxycycline and minocycline 312–313
glucocorticoids 311–312
guidelines 311, 313
NSAIDs 312
mid-stromal 307, 309, 309
optical coherence tomography 123
pathogenesis 307
pathology 120, 121, 306
presumptively 313–314, 314
prevalence 307
spontaneous resolution 311
stromal 307, 309, 309, 310
medical therapy 313
superficial 307, 308, 308–309
clinical presentation 308, 308
medical therapy 313
treatment 309
superficial stromal 120, 121
surgical therapy 311, 313
treatment 311–313
unilateral 307, 308
immune-mediated keratopathies 313–314
immune privilege, eye 261, 464
cornea *see* cornea, immune privilege
immune response
blood–ocular barrier limiting 444
corneal *see* cornea, immunobiology
mesenchymal stem cells modulating 479
pathological 357
see also immune system
immune surveillance
by conjunctiva and CALT 262
by cornea 261
by precorneal tear film (PTF) 255, 256
immune system
adaptive 262–263
in equine recurrent uveitis 464–465, 467
cornea role 261–263
in immune-mediated keratitis 307
innate *see* innate immune system
mucosal 255, 262
see also cornea; immune response
immunodeficiency, severe combined *see* severe combined immunodeficiency (SCID)
immunodiagnostic tests, equine protozoal myeloencephalitis 722–723
immunoglobulin(s), in precorneal tear film 254
immunoglobulin A (IgA) 255, 581
secretory 255
immunoglobulin G (IgG), in equine recurrent uveitis 467, 590
immunoglobulin M (IgM), in equine recurrent uveitis 467
immunohistochemistry
adnexal neoplasia 222, 229, 237
chorioretinitis, in ERU 589–590
immunophenotypic profile 262–263
immunosuppressive drugs
cyclosporin A and tacrolimus 312
doxycycline and minocycline 312–313
in equine recurrent uveitis 477, 478
immunosuppressive gene therapy, equine recurrent uveitis 480
immunotherapy
adnexal SCC 230, 233
sarcoïds 223, 224–225
implants
episcleral sustained-release 274, 313
gonioimplants, glaucoma 559, 559–560
IOL *see* intraocular lens (IOL) implants
iridium¹⁹², sarcoïd 226, 226
orbital 177, 177–178, 178
hydroxyapatite 152, 177, 177–178, 178, 179
integrated 173
importation restrictions 139
impression smear 50
incompletely dominant traits 666
incomplete penetrance 665
indel 665
Indian army horse, ocular disease frequency 74–75
indirect fluorescent antibody test (IFAT) 723
indirect ophthalmoscopy *see* ophthalmoscopy
indocyanine green, angiography 124, 125, 125
infection
bacterial *see* bacterial infection

- fungus *see* fungal infection
 - parasitic *see* parasitic infections
 - protozoal *see* protozoal disease
 - see also individual diseases and infection sites*
- infectious blepharitis *see* blepharitis, infectious
- infectious orbital diseases 156–158
- inflammation
 - choroid *see* chorioretinitis; uveitis, posterior
 - ciliary body *see* uveitis, anterior
 - conjunctival *see* conjunctivitis
 - corneal *see* cornea, inflammation; keratitis
 - DAMPs promoting 360
 - decreased by amnion stromal matrix 400
 - eosinophilic *see* eosinophilic inflammation
 - in ERU *see* equine recurrent uveitis (ERU)
 - exophthalmos due to **142, 143**
 - eyelids *see* blepharitis
 - infectious pathogen-induced 360
 - iris *see* iris, inflammation
 - lens 105
 - nasolacrimal duct 196, 197
 - orbital (noninfectious) 158–159
 - retinal *see* chorioretinitis
 - sinus *see* sinusitis
 - third eyelid 219
 - uveal tract *see* uveitis
 - vitreous *see* vitreous, inflammation
- inflammatory mediators
 - acute uveitis 452, 453
 - see also* cytokine(s)
- inflammatory response, systemic, neonatal sepsis 768
- influenza, equine **742, 742–743**
- information overload, vision 618
- information processing, vision 616–618, 617, 635, 647
 - chromatic aberrations and 643
 - ganglion cell types/number effect 647
 - packaged in “topics” 618
 - saccades and 628
- infracyanine green, diode laser with, corneal SCC 294
- infraorbital canal 134, 135
- infraorbital foramen 134, 135
- infraorbital nerve 134, 714
 - analgesia, photic trigeminal mediated headshaking 715
 - anatomy 697
 - damage, in trephination of maxillary sinus 179
- infrared ocular thermography 116, 116–117
 - applications 116–117
 - normal 116
 - as physical fitness indicator 117
 - physiological stress assessment 117
 - pyrexia, screening for 116
 - use in human ocular disease 117
- infrared photography 114–115
 - indications/uses 114–115
 - iris 114, 114, 115
 - monitoring/documenting pigmented lesions 115
 - uveal cyst 115
- infrared radiation 114, 115, 116
- infratrochlear nerve 12, 13, 189
 - block 12, 13
- infratrochlear notch (incisura infratrochlearis) 13
- “inguinal nodules” 484
- inheritance, modes 666
 - complex 666
- inherited ocular disorders 1, 661–690
 - basic concepts and terminology 661–665
 - breeding decisions 681
 - breeds associated 661, **662–663**
 - diseases caused by known mutations 679–681
 - disorders with suspected genetic basis 677–679
 - elimination/reducing 681–682
 - genetic testing 681–682
 - list of, inheritance, gene variants **662–663**
 - see also* congenital abnormalities/diseases; *individual diseases (see pages 662–663)*
- innate immune system 261–262, 360
 - chitin activating 357
 - constraint and control 261–262
 - in equine recurrent uveitis 465, 467
 - keratomycosis incidence and 360
 - linking to adaptive 262
 - pattern recognition receptors (PRRs) role 360
- instruments *see* equipment/instruments
- insulin-like growth factor-1 (IGF-1) 260
- integrated orbital implant 173
- interferons
 - equine herpesvirus infections 741
 - types 741
- interferon- α 320, 741
- interferon- γ 463, 464
- interferon- γ -induced protein 10 (IP10) 464
- interleukin-1 (IL-1) 266, 388
- interleukin-10 (IL-10), gene therapy 480
- interleukin-17 (IL-17), ERU 463, 464
- internal acoustic meatus 697, 701
- internal carotid artery *see* carotid artery, internal
- internal carotid nerve 700
- internal ophthalmoplegia 713, 714
- international regulations 792–797
- interneurons
 - amacrine cells 692
 - horizontal cells 691
- interphotoreceptor retinoid-binding protein (IRBP) 463, 464, 466
- intracapsular lens extraction (ICLE) 526, 532
 - for cataracts 526
 - for lens luxation 511
- intracarotid injection, blindness after 707
- intracorneal injection 74, 274
- intracorneal lymphoma 301
- intracranial neoplasia **734, 734–735**
 - clinical signs 734, **734**
 - investigations 734
- intracranial pressure, increase 577, 765
- intraocular hemorrhage, after trauma 764
- intraocular inflammation, trauma 516
- intraocular lens (IOL) implants 521, 522
 - cataract surgery 521, 522
 - implantation procedure 530, 531
 - development progress 521
 - displacement 533, 534
 - future research 537
 - haptics positioning 530, 531
 - types available 526, 531
 - vision after 519
- intraocular masses
 - lymphoma 486–487
 - ultrasound 101, 107–108, 108
- intraocular melanoma *see* melanoma
- intraocular pressure (IOP) 136, 545
 - aqueous humor outflow, effect 46, 442
 - auriculopalpebral block effect 45
 - body position effect, general anesthesia 45
 - circadian rhythm 45
 - constant, control mechanisms 555
 - corneal perforation/rupture 417
 - corneal thickness, after injury 272
 - elevated 442, 543, 545
 - blunt trauma causing 607
 - chronic 545
 - cornea, features 545
 - glaucoma *see* glaucoma
 - pathophysiology 545–547
 - vision, and resistance to loss 546–547, 568
 - episcleral vessel enlargement 147
 - head position effect 45
 - measurement 42–46, 548
 - see also* tonometry
 - normal, despite AH leakage 152
 - normal reference range **9**
 - ocular injury in facial trauma 152
 - orbital cellulitis 157
 - reduced/reduction
 - acute uveitis 452
 - corneal lacerations, iris prolapse 417
 - glaucoma treatment goal 554
 - medications 45, 554–557, **555**
 - sedatives affecting 45
 - target, in glaucoma treatment 554
 - units 42–43
- intraocular silicone prosthesis, blunt trauma 607
- intraorbital masses 139
- intraorbital pressure 545
- intraorbital prosthesis (ISP) 170, 172, 172, 173
 - complications 173
 - migration avoidance 172–173
 - placement 172
 - silicone, glaucoma 560, 561
 - size, measurement 172
- intraretinal hemorrhages 582
- intrascleral plexus (ISP) 543, 544
- intrascleral prosthesis (ISP) 145, 174–175, 177
 - glaucoma 560–561
 - procedure 175
 - risks/complications 174, 177
 - selection/size 175
- intravascular papillary endothelial hyperplasia 239
- intravenous fluids 770

- introns 661
 - mutations affecting 665
 - in vivo* corneal confocal microscopy 118–120
 - advantages 120
 - central corneal thickness measurement 47, 118
 - clinical applications 118–120
 - corneal epithelium 118
 - corneal foreign bodies 120, 329
 - corneal lymphoma 120
 - corneal thickness measurement 47, 256
 - fungal keratitis 118, 119–120, 120, 372, 372
 - immune-mediated keratitis 120
 - keratomycosis 372, 372
 - laser scanning 118
 - normal features 118, 119
 - principles and confocal microscope design 118
 - sedation/general anesthesia 118
 - ionizing radiation, exposure risk 92
 - iontophoresis 356
 - IOP *see* intraocular pressure (IOP)
 - IP-10 (IFN γ -induced protein 10) 464
 - iridal cysts 446, 447–448, 448, 485
 - treatment 448
 - iridal hypoplasia *see* iris, hypoplasia
 - iridectomy, sector, in melanoma 486, 486
 - iridium¹⁹² implants, sarcoid 226, 226
 - iridocorneal angle (ICA) 30, 31, 543, 544
 - examination 30
 - high-resolution ultrasound 550–551, 551, 552
 - obstruction, secondary glaucoma 548
 - optical coherence tomography 122
 - iridocyclitis
 - corneal graft rejection 415
 - corneal perforation, with iris prolapse 417
 - ERU *see* equine recurrent uveitis (ERU)
 - full-thickness fungal stromal abscess 367
 - heterochromic 311, 616
 - heterochromic with keratitis *see* heterochromic iridocyclitis with keratitis (HIK)
 - stromal fungi death leading to 377
 - in ulcerative keratitis 354
 - in ulcerative keratomycosis 377
 - iridonesis 32
 - iris 616
 - absence 444, 678–679
 - anatomy 441, 442
 - aniridia 444–445
 - blue, hypoplasia 449, 449
 - cataract surgery complications 533
 - chronic inflammation 505
 - chronic rubbing, in anterior capsular lens
 - cysts 505
 - color 23, 31–32
 - color changes, ERU 461
 - cysts *see* iridal cysts
 - dark, bulging area 449, 449
 - depigmentation
 - chronic uveitis 455, 455
 - foreign body and 328
 - heterochromic iridocyclitis with keratitis 456
 - dilator muscles, innervation 700
 - equine recurrent uveitis, CD3+ T cells 466
 - ERU histopathology 468, 468–469
 - examination 31–32
 - functions 441
 - fungal abscess 372
 - greater arterial circle of 137
 - high-frequency ultrasound 111
 - hyperemia, acute anterior uveitis 452, 452
 - hyperpigmentation 548
 - chronic uveitis 455
 - equine recurrent uveitis 458, 459, 462
 - hypoplasia 446, 449, 449–450, 485, 678–679
 - congenital 278, 278
 - congenital dermoid with 275
 - high-resolution ultrasound 112
 - MCOA syndrome 671
 - melanoma vs. 485
 - inflammation 447, 505
 - chronic 505
 - neonatal sepsis 769
 - see also* iridocyclitis; uveitis, anterior
 - inflammatory changes 447
 - infrared photography 114, 114, 115
 - in insidious equine recurrent uveitis 459
 - instability, lens luxation/subluxation 510
 - ischemic damage, elevated IOP causing 545
 - lymphocytic nodules, in ERU 468, 468
 - melanoma 450, 484, 484–485, 485
 - differential diagnosis 449
 - high-resolution ultrasound 112
 - optical coherence tomography 123
 - melanotic epithelial cells 441, 442
 - movement, in corneal perforation 417
 - neoplasia
 - hypoplasia vs. 449, 450
 - optical coherence tomography 123
 - neoplastic changes 447
 - normal anatomy 24
 - outer surface 31
 - persistent pupillary membrane 446, 446
 - prolapse *see* iris prolapse
 - protrusion 449
 - size, autonomic system regulating 698
 - stroma 441, 442
 - aqueous humor flow 543
 - hypoplasia 449, 449
 - surface 31, 32
 - yellow/green, in equine recurrent uveitis 461
 - iris coloboma 449, 449
 - atypical 449
 - iris dilator muscle 441, 442, 698, 700
 - sympathetic system control 698
 - iris prolapse 324, 327, 368, 379, 417–418
 - cataract surgery 533
 - causes/pathogenesis 417
 - corneal lacerations 417
 - perforating 333, 334, 334, 335, 417
 - corneal perforation 324, 333, 334, 335, 368, 417
 - corneal trauma 324, 417
 - corneal ulceration 385, 417
 - deep stromal abscess 324
 - definition 368
 - descemetocoele, ruptured 379, 416
 - globe perforation 150, 151
 - keratomycosis 371
 - melting ulcer 340, 386, 417, 418
 - outcomes 418
 - pathogenesis 417
 - prognosis 417
 - red-tan material from 150, 151
 - surgical repair 371, 417–418, 533
 - trauma 324, 325, 326, 335, 417
 - iris sphincter muscle 441, 442, 698, 700
 - contraction, mechanism 699
 - damage, elevated IOP causing 545
 - dilation, mechanism 699
 - parasympathetic system control 698
 - spasm, acute anterior uveitis 452
 - iritis *see* iris, inflammation
 - irrigation
 - during cataract surgery 528
 - corneal chemical injury 323
 - in corneal surgery 392
 - nasolacrimal duct *see* nasolacrimal duct (NLD)
 - irrigation fluids, cataract surgery 528
 - irritation
 - chronic
 - adnexal SCC and 228–229
 - corneal pigmentation after 272
 - entropion 211
 - eyelash disorder causing 209
 - ischemia
 - during anesthesia, visual deficit after 707
 - neonatal maladjustment syndrome 770
 - ischemic optic neuropathy 598, 602–603, 705, 734
 - clinical appearance 705, 734, 734
 - island grafts 396
 - isoerythrolysis, neonatal *see* neonatal isoerythrolysis (NI)
 - itraconazole 374, 376
 - keratomycosis 376
 - ivermectin
 - habronemiasis 207–208, 753
 - Halicephalobus gingivalis* infection 158
 - ocular onchocerciasis 322, 751, 752
 - Onchocerca cervicalis* prevalence decline 320
 - parasitic orbital disease 158
 - toxicosis 707, 766, 766–767
- j**
- jaundice 29
 - jimson weed (*Datura stramonium*) 768
 - Jockey Club 793
 - Jones test 36, 38–39, 39, 62, 193, 197
 - Juglans nigra* (black walnut tree) ingestion 768
 - junctional epidermolysis bullosa (JEB) 680
 - breeds 663, 773
 - clinical signs 773, 773
 - diagnosis and management 774
 - foals 773, 773–774
 - inheritance and gene variants 663, 680, 773

k

- kallikrein–kinin system 466
- KCS *see* keratoconjunctivitis sicca (KCS)
- keratectomy
- complete incisional 394
 - complications 394
 - corneal dermoid removal 275
 - cryotherapy after 293
 - in IMMK 311, 313
 - partial incision 394
 - postoperative care 394
 - superficial *see* superficial keratectomy (SK)
 - suture placement 393
- keratic precipitates (KPs), pigmented 455, 456
- keratin pearls 228, 229
- keratitis
- bacterial 343
 - clinical appearance 343
 - diagnostic techniques 343, 347, 350, 352
 - differential diagnosis 343
 - prevalence 343
 - ulcerative *see* corneal ulceration; ulcerative keratitis
 - chemical 322, 323, 323, 324
 - chronic 37
 - avoidance, by eyelid laceration repair 212
 - corneal vascularization 272
 - destructive, amniotic membrane
 - transplant 400, 401
 - eosinophilic *see* eosinophilic keratitis/keratoconjunctivitis (EK)
 - epithelial, foreign body causing 327
 - exposure, glaucoma 549
 - fungal 358
 - causative species 358
 - cytology 52, 371, 371, 373
 - diagnosis 372–373
 - differential diagnosis 372–373
 - pathogenesis 358, 360
 - prevalence 358, 360
 - seasonal influence 358
 - see also* keratomycosis
 - heterochromic iridocyclitis and *see* heterochromic iridocyclitis with keratitis (HIK)
 - immune-mediated *see* immune-mediated keratitis (IMMK)
 - infectious
 - bacteria causing 339
 - culture of corneal surface 47–48
 - fungi causing 358
 - serine proteases and MMPs 339
 - VEGF-A and PEDF balance 388
 - see also* keratitis, bacterial; keratitis, fungal
 - neuroparalytic 148
 - neurotrophic 711–712, 712
 - onchocerciasis 320, 321, 751
 - parasitic 320–322
 - causative agents 320–321
 - clinical appearances 321, 321–322, 322
 - diagnosis 321–322
 - differential diagnosis 322
 - pathogenesis 321
 - prevalence 320–321
 - treatment and prognosis 322
 - perilimbal nonulcerative 278, 278
 - pigmentary 314, 314
 - Pseudomonas* 262
 - pupil dilation and 14
 - putative viral 305, 318–320
 - diagnosis 319
 - medical treatment 318
 - pathogenesis 318–319
 - prevalence 318
 - prognosis 320
 - treatment/management 320
 - types, clinical appearance 319
 - secondary, Friesian corneal dystrophy and 124
 - subepithelial punctate 307
 - superficial corneal vascularization and 278
 - superficial viral, rose bengal staining 36
 - suppurative 366
 - temporohyoid osteoarthropathy 736
 - ulcerative *see* ulcerative keratitis
 - vascular 308
 - see also* cornea, inflammation
- keratitis sicca 37
- keratoconjunctivitis
- EHV-2 causing 741
 - EHV-5 causing 741
 - eosinophilic *see* eosinophilic keratitis/keratoconjunctivitis (EK)
 - parasitic 316
 - vernal (VKC) 316
- keratoconjunctivitis sicca (KCS) 34, 148, 191, 198–199, 303, 709
- acute 199
 - after basilar skull fracture 765
 - bilateral, causes 304
 - causes 198, 303–304
 - chronic 199
 - clinical appearance 198
 - congenital 304
 - corneal sequestrum and 284
 - diagnosis 198, 304–305
 - differential diagnosis 198
 - fractures associated 304
 - hypothyroidism 762
 - long-term prognosis 199
 - medical treatment 305
 - methods for definitive diagnosis 198
 - neurogenic *see* neurogenic keratoconjunctivitis sicca (NKCS)
 - pathogenesis 303
 - prevalence 198, 303
 - Schirmer tear test 198
 - in temporohyoid osteoarthropathy 304, 735
 - treatment 198–199
- keratocyte(s) 259
- “activated”, after stromal injury 269
 - apoptosis 269
 - corneal wound healing initiation 266, 269
 - corneal fibrosis 271
 - death, corneal stromal injury 269
 - destruction after microbial invasion 339
 - in full thickness corneal perforation 270–271
 - mitosis and migration 269
 - replenished after stromal injury 269
- keratomalacia (melting ulcers) 151, 267, 341, 343, 351
- anterior uveitis with 389
 - bacteria infecting 340, 386
 - descemetocoele formation 416
 - Fusarium* causing 386
 - medical therapy 351
 - Pseudomonas*, amnion grafts 402
 - rupture, iris prolapse after, treatment 340, 386, 417, 418
 - Streptococcus* causing 380
- after surgical laser, *Pseudomonas* infection 323, 324
- surgical treatment 340, 341, 377, 378, 379, 380
- amnion graft outcome 402
 - amnion grafts 340, 341, 380, 381, 382, 386, 400, 401
 - conjunctival grafts 395
 - DALK and amnion grafts 381, 382
 - deep anterior lamellar keratoplasty 408
 - penetrating keratoplasty 386, 404
- ulcerative keratomycosis 363, 364, 365, 377, 386
- conjunctival graft 377, 378, 379
- keratometry 41
- keratomycosis
- corneal vascularization inhibition 272, 388
 - deep corneal ulcer 350
 - diagnosis 371–372, 373
 - differential diagnosis 372–373
 - epithelial 304, 306
 - nonulcerative 119, 361, 361, 362, 363
 - ulcerative *see* ulcerative keratomycosis
 - false-negative cytology/culture results 371
 - high-resolution ultrasound 113, 114
 - horses predisposed to, mechanism 360
 - in vivo* confocal microscopy 118, 119, 372, 372
 - iris prolapse with 371
 - melting ulcers 363, 364, 365, 377, 378
 - treatment 377, 378, 381–383, 386
 - pathogenesis 358, 360
 - prognosis 387
 - risk
 - with corticosteroids, area of high incidence 418
 - nasolacrimal duct atresia surgery 195
 - nasolacrimal duct obstruction treatment 197
 - rose bengal staining 37, 361, 361
 - slow healing, inflammation and 373
 - subepithelial 119, 120, 362, 362–363, 363
 - superficial 361
 - therapy 373–377, 377–386
 - combination therapy 375, 375
 - indications 377
 - medical (antifungals) 373–377, 374, 375
 - surgical 377, 378–386

- keratomycosis (*cont'd*)
 thick pigmented fungal plaques 366, 366, 367
 ulcerative *see* ulcerative keratomycosis
 variant forms 360–371
- keratopathy
 aniridic 278, 278
 band, glaucoma 549, 550
 bullous *see* bullous keratopathy
 corneal opacification after treatment 418
 corneal scarring prevention after surgery 418
 epithelial *see* immune-mediated keratitis
 (IMMK), superficial
 evaporative 302–303, 303
 exposure 302
 immune-mediated 313–314
 linear 282, 282–283, 283
 penetrating keratoplasty 404
 pigmentary 314, 314
 punctate *see* immune-mediated keratitis (IMMK),
 superficial
 radiation-induced 287–288
 stromal 53, 53
 tear-deficient *see* tear-deficient keratopathies
 ulcerative, penetrating keratoplasty 404
- keratoplasty *see* individual procedures
- keratotomy, grid, recurrent corneal erosion 338
- kernicterus 771
- ketamine, effect on IOP 45
- ketoconazole 374
- kicks
 corneal injuries 324
 extraocular lens displacement 765
 orbital fractures 149, 167
 prolapse of uveal tract 607
 trauma due to 764, 765
- kimura spatula 49, 49
- kininogen, equine recurrent uveitis 466
- knots, surgeon's 393
- Knott's test 753
- kochia weed (*Kochia scoparia*) 767
- L**
- lacerations
 corneal *see* corneal lacerations
 eyelid *see* eyelid lacerations
 facial 150
 globe 151, 152
 nasolacrimal duct 169
 third eyelid 219, 220
- lacrimal bone 134, 135
 fractures 167
- lacrimal canal 191
 damage 197
- lacrimal canaliculus 192
- lacrimal caruncle 2, 188, 190
 enlarged 190
- lacrimal gland 133
 abscessation 304
 adenitis 198, 199
 anatomy and function 191
 innervation 218, 303, 700
 disruption, keratoconjunctivitis sicca 303
 removal, enucleation 172, 174
- lacrimal nerve 12, 13, 697, 700
 block 12, 13
- lacrimal process, caudal 13
- lacrimal puncta 191
 atresia 193, 194
 surgical opening 194–195
see also nasolacrimal puncta
- lacrimal sac 139, 190, 191, 192
- lacrimal system *see* nasolacrimal system
- lacrimal veins 137
- lacrimation, increased, causes 192, 215
 acute anterior uveitis 452
- lacrimumstimulation 305
- lactated Ringer's solution (LRS) 323
- lactoferrin, in precorneal tear film 254, 255
- lagophthalmos 154, 157, 164, 199
 in entropion repair 201
 evaporative keratopathy association 302
 facial nerve paralysis 217, 217
 management 164
- LAMA3 gene 680
- LAMB3 gene 680
- LAMC2 gene 680
- lamellar keratoplasty (LK) 407–409
 aim/principle 407
 split-thickness, principle 391, 407, 409
 stromal abscesses 391
 targeted anterior stromal 408
 targeted epithelial layer 407–408
 targeted posterior stromal 409
- lamina cribrosa 545–546, 545–546, 566, 568
 elevated IOP effect 545, 546, 568
 functions 545–546, 546
 in glaucoma 546, 546, 549, 568
 laminar beam compression 546, 546
 optic nerve after, anatomy 693
 posterior displacement 545, 546, 546
 scleral 568
- laminar plate compression, glaucoma 546, 546
- laminar pores 546, 546
- laminin 400
 gene mutations 680
- laminin 5, genes encoding 773
- laminitis
Juglans nigra (black walnut tree) ingestion 768
 PPID (equine Cushing's disease) 761
 steroids, risk with 756
- Langerhans cells 258, 262
- Larmor frequency 95
- laser cyclophotocoagulation 556
 glaucoma 557, 557–559, 558
- laser retinopexy 594–595
- laser scanning confocal microscopes 118
- latanoprost, glaucoma 555, 556
- lateral canthal (palpebral) ligament 190
- lateral canthus 188, 189
 depigmentation, in CLE 756
 normal 2
- lateral geniculate nucleus (LGN) 694, 694
- lesions 704, 707–708
- lateral rectus muscle 697
- law of denervation hypersensitivity 216
- L cone 651
- lectins, C-type 255
- LED light, dazzle response 25
- legend drugs 794
- lens 499–542, 616
 abnormalities 105, 566
 accommodation *see* accommodation, lens
 anatomy and physiology 499–500, 500
 anterior translocation, accommodation 645
 aspiration, cataract surgery 526
 brunescence 507, 507
 characteristics 509
 clarity/transparency 499
 cortex 499
 CT 94
 development 499–500
 differential diagnosis 509
 dimensions 500
 cataracts and 105, 106
 embryology 499
 embryonic nucleus 499
 examination 32
 expulsion, trauma 325
 extraction
 extracapsular 526, 532, 536
 intracapsular 511, 526, 532, 532
 extraocular displacement, after kick 765
 extrusion, severe trauma 150
 fetal nucleus 499
 fragments in vitreous 533, 533
 fungi and 371, 372
 implant, selection, retinoscopy 40, 41
 inflammation 105
 luxation *see* lens luxation
 nuclear sclerosis 500, 501, 509
 nucleus 499, 624, 625
 opacities 499, 507
 persistent pupillary membrane 446
 at posterior nodal point 644
 retro-illumination 17, 17
 slit-lamp biomicroscopy 18
see also cataracts
 position 510
 posterior nodal point and 643, 644
 refractive index 15
 resorption 504
 retropulsion, in lens luxation 511, 515
 surgical removal, in lens capsule rupture 516
 suture lines (Y sutures) 509, 513
 terminal differentiation 499
 trauma 105, 325
 ultrasound 105
 vesicles 508
 yellow discoloration 507, 507
 yellow pigments 624, 625, 644, 655
- lens bow 499, 500
- lens capsule 499, 500
 accommodation mechanism and 644

- anterior
 - cysts 505, 505–507, 506
 - Purkinje–Sanson reflex 16, 16
- anterior capsulotomy 527–528
- anterior subepithelial cysts 505, 505–507, 506, 516
 - rupture 506
- perforation, foreign bodies 330
- in phacoemulsification and aspiration 528, 530
- pigment deposits (“rests”), equine recurrent uveitis 462
- posterior
 - opacification after cataract surgery 534, 536, 536, 537
 - Purkinje–Sanson reflex 16, 16
 - tears, in cataract surgery 533, 533
- rupture 515–517, 516
 - cataract surgery complication 534, 535
 - clinical appearance 515–516
 - diagnosis/differential diagnosis 515, 516
 - treatment, prognosis 516–517
- ultrasound 103, 105, 105
- lens coloboma 149, 502, 504, 515, 515, 516
- lens subluxation vs. 510–511
 - notch/step in 502, 516
- lens diseases/disorders 499, 500–537
 - acquired 507–517
 - see also cataracts
 - congenital 500–507
- lens epithelial cells (LECs) 499, 500
 - functions 499
- lens fiber cells 499
- lens fibers, primary/secondary 499
- lens-induced uveitis (LIU) 520
 - hypermature cataracts 517, 520
 - phacoemulsification 517
- lens luxation 510–515, 532
 - anterior 510, 515
 - causes 510
 - clinical appearance 510
 - differential diagnosis 510–511
 - glaucoma 550
 - posterior 510, 511, 515
 - primary (hereditary) 510
 - trauma causing 607
 - treatment 511, 515
 - ultrasound 101, 105, 106, 109
- lens material, leakage 330
- lens removal surgery 516
- lens subluxation 14, 502, 504, 510–515, 514
 - causes 510, 514
 - chronic, post-traumatic 514
 - clinical appearance 510
 - congenital bilateral 510
 - definition 510
 - differential diagnosis 510–511
 - lens coloboma vs. 510–511
 - post-traumatic 514
 - post-traumatic cataract and 523
 - treatment 511, 515
- lenticonus 504
- lenticular nuclear sclerosis 32, 570
- lentiglobus 504
- lentivirus, equine infectious anemia 738
- leopard complex gene (*LP*) 474, 586, 587, 667
 - heterozygous (*LP/lp*) horses 667, 668, 669
 - homozygous (*LP/LP*) horses 667, 668, 669, 670
 - ERU in Appaloosa horses 674
 - incorrect classification 668
 - importance, breeding/management 670
 - physical traits associated 667, 668, 668, 669
- leopard complex spotting 667
 - breeds with 667, 668
- LP* gene see leopard complex gene (*LP*)
- TRPM1* gene 667
- leopard spots 667, 668
- Leptospira* 470
 - antibodies 472, 473, 581, 672, 746
 - antigenic relationship with cornea 472, 473, 672
 - blindness due to, broodmares and 811
 - classification 471–472
 - ERU see equine recurrent uveitis (ERU)
 - life cycle, and elimination 470
 - serovars in horses 746
 - uveitis, chorioretinal changes 589–590
- Leptospira biflexa* 471, 472
- Leptospira interrogans* 470, 471, 746
 - antibodies, to lipoproteins of 472, 473
 - chorioretinitis 592
 - cross-reactivity with cornea 472
 - serogroups, and serology 471–472
 - serovars, vaccines and 477, 747
 - in vitreous 581
- Leptospira interrogans* serogroup Australis 458
- Leptospira interrogans* serogroup Grippotyphosa 458, 471, 581, 746
- Leptospira interrogans* serogroup Pomona 458, 463, 471, 471, 472, 590, 672, 746
- Appaloosa horses 474
- vaccine 477
- leptospirosis 470–473, 746–747
 - acute signs 470–471, 471–472, 746
 - antibiotic treatment 479, 747
 - Appaloosa horses 474
 - causative agent 470, 471, 746
 - clinical signs 746, 746
 - ERU and see equine recurrent uveitis (ERU)
 - infection route 470
 - infection source 470, 746
 - seropositivity rates 470–471, 746
 - treatment 479, 747
 - uveitis and 472–473
 - vaccination 477, 747
- lethal mutation 665
- lethal white foal syndrome (LWFS) 681
 - breeds, and inheritance mode 663
 - gene mutation 663, 681
- lethal white overo syndrome see lethal white foal syndrome (LWFS)
- leucocoria 606
- leukocytes
 - corneal injury response 266
 - infiltration of ulcerated stroma 339, 341
 - migration, after corneal injury 266–267
 - see also specific cell types
- leukoencephalomalacia, equine see equine leukoencephalomalacia
- leukoma 276, 277
- levator anguli oculi medialis muscle 189, 190, 190, 697
 - innervation 697
 - paralysis/paresis 712
- levator nasolabialis 134
 - innervation 697
- levator palpebrae superioris 189, 190, 190, 697
 - innervation 697
- levothyroxine 762
- lidocaine 10, 155
- light
 - ability to detect 619–620
 - absorption 15
 - adaptation 620–622, 623–625
 - to bright light 624–625, 625
 - to dim light 623–624, 624
 - to intensity 620–621, 622–623
 - bright see bright light
 - conversion to electrical impulses, retina 691
 - diffraction 642
 - dim see dim light
 - green, chromatic aberrations 643, 643
 - intensity variation, awareness 620
 - level, spherical aberrations 642
 - optical aberrations 642–643
 - perception 616, 619–623, 636
 - adapting to different intensities 622, 623–625
 - photons 619, 654
 - principles of illumination 15–17
 - red, chromatic aberrations 643, 643
 - reflection 15, 16
 - planes of 16
 - Tyndall effect 31, 31
 - scattering, glare and 644
 - sensitivity 620, 621, 623
 - iris hypoplasia 449
 - sneeze reflex (human) 715
 - transmission 15
 - normal horse, examination 15
 - triggering trigeminal mediated headshaking 714–715
 - wavelengths 15
 - color vision and 651, 651
- lighting see illumination, for examination
- lightning strike 323, 765
- light source 5, 6
 - anterior chamber examination 30, 31
 - dazzle response testing 25
 - direct ophthalmoscopy 19, 20
 - indirect ophthalmoscopy 21
 - pupillary light reflex testing 23
- limbal stem cells 258, 269, 407–408

- limbus 253
 - carcinoma *in situ* 290
 - cell types 258
 - circumferential lacerations 325, 333
 - corneal grafts close to 415
 - crypts 258
 - dendritic cells, MHC II expression 262
 - distance to pars plana 9
 - dorsal
 - dermoid 275, 275
 - iris prolapse 326
 - endothelial cells 266
 - epithelial cells 258
 - transplantation 407
 - exposure, examination 11, 11
 - hemangiosarcoma 298
 - lymphoid follicles/lymphocytes 262
 - mast cell tumors 300
 - melanoma 298, 299, 300
 - pigment, conjunctival graft 395
 - rupture 151
 - trauma 325, 333
 - squamous cell carcinoma 227, 227, 675, 675
 - pathogenesis, and breeds 228, 675
 - treatment 232, 232, 289, 294
 - stem cells 258, 269, 407–408
 - stromal opacity, non-lacerating blunt
 - trauma 331
 - vascularization 278, 341
 - wound healing 266
- limb weakness, botulism 732
- limiting membrane, neurosensory retina 691
- linear keratopathy 282, 282–283, 283
- linear perspective 633
- linkage disequilibrium (LD) 664
- lipid emulsion, intravenous 767
- Lipizzaner horses
 - cataracts 509
 - EHV-2 and EHV-5 in 318
 - melanoma 236
 - ophthalmic lesion, frequency 74
- lipocalin 254
- lipofuscin accumulation, retinal pigment
 - epithelium 724, 725
- lipoxigenase 388
- lissamine green stain 35, 38, 256
- Listeria* (spp.), infectious keratitis 339
- Listeria monocytogenes*, blepharitis 206
- liver failure 767, 771
- local anesthesia
 - for corneal surgery 391
 - for cytological sampling, corneal 14
 - for ocular examination 11–15
- loci (locus), gene 664
- locoweed poisoning 304
- locus coeruleus 701, 702
- long ciliary nerve 215
- long (L) cone 651
- loss-of-function mutation 665
- loud noises, blind horses 798, 804
- LP* gene *see* leopard complex gene (*LP*)
- lubricants
 - evaporative keratopathies 303
 - keratoconjunctivitis sicca 305
 - orbital disease 164
 - petroleum-based 164
- luliconazole, keratomycosis 376
- lumican, amniotic membrane 401
- luminance 618, 619, 619–623, 621
 - color cues removed 620, 621
 - color vs. 620, 620, 621
 - definition 620
 - visual acuity affected by 637, 638
- Lyme disease 581, 744–746
 - clinical signs 744, 745
 - treatment 745–746
- lymphangioma, corneal 297
- lymphangiosarcoma, corneal 297
- lymphatic drainage, from eye 544
- lymph node abscess, strangles 743, 743, 744
- lymphocytes
 - ERU 468, 468
 - see also* B lymphocyte(s); T lymphocyte(s)
- lymphocytic follicles *see* lymphoid follicles
- lymphocytic hyperplasia, corneal SCC vs. 292, 292
- lymphocytic nodules, ERU 468, 468
- lymphoid follicles 262
 - ERU 468, 468
- lymphoma 237, 486
 - conjunctival 237
 - corneal *see* corneal lymphoma
 - diagnosis 486
 - diffuse large B-cell 237, 734
 - extraocular 236
 - evaluation 763–764
 - intracorneal 301
 - intraocular 486–487
 - multicentric 763
 - ocular 301–302
 - ocular manifestations 486, 762–763
 - orbital involvement 763
 - pathogenesis 487
 - T-cell-rich large B-cell (TCRLBCL) 763, 763
 - uveal 486–487
- lymphosarcoma 161–162
 - adnexal 236–237
 - conjunctival 236, 237
 - corneoscleral 301–302
 - metastases in posterior segment 606
 - orbital 161, 161–162
 - third eyelid 236, 237
- L-lysine supplementation, putative viral
 - keratitis 320
- lysosomal proteases 262
- lysosomal storage disease 595
- lysozyme, in precorneal tear film 254
- m**
 - MacKay–Marg tonometer 43
 - macrolides, *Rhodococcus equi* infection 773
 - macrophage(s) 262
 - acute corneal graft rejection 415
 - corneal injury response 267
 - corneal wound healing 259, 262
 - equine infectious anemia 738
 - viral arteritis 737
- magnetic resonance imaging (MRI) 95–99
 - advantages/disadvantages 99
 - contrast medium 97
 - CSF 97
 - CT vs. 94, 99
 - dacryocystorhinography (MR-DCG) 100
 - fluid-attenuated inversion recovery (FLAIR)
 - sequences 97
 - gradient echo (GE) pulse sequences 97
 - image planes 97
 - indications/conditions 97
 - optic neuropathy 704
 - before orbital surgery 166
 - sinus and nasal cavity neoplasia 161
 - sinusitis 160
 - trauma 765
 - vestibular disease 730
 - inversion recovery (IR) sequences 97
 - Larmor frequency 95
 - magnetic field strength 97
 - normal anatomy 98, 99
 - oblique dorsal plane 97
 - oblique sagittal plane 97
 - posterior segment examination 580
 - principles 95, 97
 - proton density (PD)-weighted images 97
 - safety 97
 - short tau inversion recovery (STIR)
 - sequences 97
 - signal intensity, order 97
 - spin echo (SE) pulse sequences 95–96
 - T1 (spin–lattice) relaxation time 95, 97, 98
 - T2 (spin–spin) relaxation time 95, 97, 98
- magnification, corneal surgery 392
- magnification aids, corneal surgery 392
- major histopathology complex (MHC) 262, 673
 - adnexal SCC 228
 - antigen presentation 415
 - corneal transplant rejection 415
 - ERU in German Warmbloods 747
 - genes 673
 - MHC-I 415
 - antigen presentation 465, 673
 - cells expressing 262
 - ERU in Appaloosa horses 474, 673
 - MHC-II 415, 673
 - cells expressing 262
 - microsatellite, *TRPM1*, ERU 674
 - microsatellites 674
 - sarcoids and 223
- malaris muscle 189, 190, 190
- malignant rhabdoid tumor, orbital 163
- mandible 135
 - manipulation 137–138
- mandibular “tables” 10
- mannitol 765
- mare reproductive loss syndrome (MRLS) 766, 766

- maspin 307
 mast cell(s) 51, 300
 degranulation, eosinophilic keratitis 316
 mast cell tumors 300–301, 301, 763–764
 masticatory myositis 158
 mastocytoma 300
 mastocytosis 300–301, 301
 matrix metalloproteinase 2 (MMP-2) 267, 467
 inhibitor, amnion stromal matrix 400
 matrix metalloproteinase 9 (MMP-9) 267, 312, 467
 inhibitor 355, 400
 matrix metalloproteinases (MMPs) 263, 267, 339
 corneal wound healing 267, 269
 inhibition, bacterial corneal infection
 healing 355
 overexpression, recurrent erosion 335
 reducing, corneal ulceration treatment 352
 mature horses *see* geriatric horses
 maxilla 135
 maxillary bones
 fractures 149
 protrusion, in sinusitis 159
 maxillary nerve 189
 maxillary osteotomy 160
 maxillary sinus 134, 135, 139
 cysts 160
 rostral *see* rostral maxillary sinus (RMS)
 sinusitis 159, 160
 size, increasing 150
 trephination 179
 maze testing 26, 26–27, 700
 M cells 262
 MCOA syndrome *see* multiple congenital ocular anomalies (MCOA) syndrome
 M (middle) cone 651
 medial canthal (palpebral) ligament 190, 190
 medial canthus 188, 189–190
 in habronemiasis 207
 normal 2
 pigmentation lacking 227, 228
 resection, enucleation 172, 174
 squamous cell carcinoma 228
 swelling, epizootic lymphangitis 750
 medications *see* drug(s)
 medulla oblongata 700, 712
 rostral 695, 697, 703, 712
 disorders affecting 712–713
 medullary rays 692
 medulloepithelioma 450
 anterior uvea 450, 450
 ciliary body 450
 metastasis 450
 nonteratoid 450
 optic nerve 705
 orbital 163–164
 teratoid 450, 606, 606
 vitreous 606
 megalocornea 275–276, 276, 671
 megaloglobus 547
 congenital 584
 megalophthalmos 146
 meibomian glands 188, 188–189, 191
 cilia entering/exiting 209, 210, 676
 function 189
 lipid layer of precorneal tear film from 254
 orifice 188, 188
 meibomianitis 256, 302
 meiosis 664, 665
 melanin 443
 synthesis 671
 melanin granules 53
 melanocytes 258
 absence, in *LP/LP* horses 668
 TRPM1 role 668
 melanocytosis, *LP* gene and 668
 melanoma 484–486, 734
 adnexal 235, 235–236
 choroidal 606
 conjunctival 163, 235, 236
 corneal *see* corneal melanoma
 epibulbar 298, 299
 geriatric horses 235–236
 iris *see* iris, melanoma
 limbal 298, 299, 300
 medulloepithelioma vs. 450
 metastases 236
 orbital 163
 prevalence and factors predisposing to
 235–236
 ultrasound 108
 uveal *see* uveal melanoma
 melanopsin 692
 melanopsin-containing RGCs 692
 melanosomes 671
 melastatin 1 (MLSN1) 668
 see also TRPM1 gene
 melting ulcers *see* keratomalacia (melting ulcers)
 menace response 25, 187, 565, 700–701
 age of development 701
 assessment 25, 700–701
 deficit/loss 25, 701
 causes 25
 West Nile virus encephalitis 728
 eliciting 700, 701
 glaucoma 549
 neuroanatomic pathway 695, 700–701, 702
 visual acuity testing 636–637, 700
 Mendelian modes of inheritance 666
 meningioma
 optic nerve 705
 orbital 163–164
 retrobulbar 705
 meningitis 729, 729
 bacterial 770
 fungal infections causing 729
 secondary, after trauma 765
 meningoencephalitis
 bacterial, neonatal foals 770
 septic 729, 729
 mental mapping 801–803, 802, 804
 mepivacaine, for examination 10
 mesenchymal stem cells (MSCs) 465, 479
 autologous therapy *see* autologous mesenchymal stem cells (MSCs)
 functions 479
 messenger RNA (mRNA) 664
 metal fragment, in orbit 154
 metastatic neoplasia
 adnexal SCC 189, 226, 235
 to eye 762
 lymphomas 762–763
 medulloepithelioma 450
 melanoma 236
 orbital 163
 posterior segment 606, 607
 prognosis, management 764
 uveal 487
 methazolamide, glaucoma 556
 methylcellulose gel 577
 methylene blue 35
 metronidazole, orbital disease 165
 miconazole 373, 374, 376
 microagglutination titers (MAT), leptospirosis 473
 microbial culture *see* culture
 microbiology, advanced diagnostic tests 54
Micrococcus carouzelicus 54
 microcornea 275, 275
 microfilaremia 753
 microfilariae 320, 321, 453
 microfilaricide therapy 751–752
 microflora, gut, autoimmune reaction in
 ERU and 465
 microflora, ocular surface 338
 bacterial 263, 264
 fungal 264, 265, 266, 358
 topical antibiotics/corticosteroids effect 360
Micronema deletrix *see* *Halicephalobus gingivalis*
 microphakia 105, 106, 502, 503, 503, 504
 cataract surgery contraindication 521
 microphthalmos 141–142
 colobomatous 141
 complicated 141–142
 congenital 149
 long-term prognosis, heritability 142
 phthisis bulbi vs. 141–142
 treatment 142
 micropulse transcleral cyclophotocoagulation
 (MP-TSCP) 559
Microsporum 206
 midbrain lesions 139, 140
 middle (M) cone 651
 middle cranial fossa 693, 696, 697, 699, 700
 middle cranial fossa syndrome 708, 710,
 713–714, 714
 causes, clinical signs 713, 714
 treatment, prognosis 714
 mineralization, corneal 281, 281–282
 mineralized crystals, cytology interpretation 52, 53
 Miniature horses
 corneal measurements 256, 257
 iris coloboma 449
 minimum resolution acuity 635, 648
 minimum resolvable acuity 635, 648

- minocycline 313
 - corneal ulceration 354
 - equine recurrent uveitis 479
 - IMMK treatment 312–313
 - Lyme disease 745
 - miosis 629
 - Horner's syndrome 215, 215, 708
 - reflex, putative viral keratitis 319
 - toxic plants causing 768
 - missense mutations 665
 - mitochondria 666
 - mitochondrial inheritance 666
 - mitomycin C (MMC) 233
 - adnexal SCC 230, 233–234
 - corneal scarring reduction 271
 - corneal SCC 292, 295
 - corneoscleral lymphosarcoma 302
 - postsurgical 418
 - Mittendorf's dot 505
 - molar extraction 180
 - molars 137, 180
 - moldy corn disease (equine)
 - leukoencephalomalacia 723
 - "molecular mimicry" 472, 473
 - Moll-like glands 189
 - monochromatic aberrations 642
 - monocyte(s), in ERU 465
 - monocyte chemotactic and activating factor (MCAF) 267
 - monocyte chemotactic protein (MCP)-1 266, 267
 - moon blindness *see* equine recurrent uveitis (ERU)
 - Moraxella* spp.
 - blepharitis 206
 - corneal/conjunctival surface microflora 263
 - Morgan horses
 - congenital cataracts 501, 678
 - USEF rules 795
 - motion detection 625–629, 635, 655
 - central vs. peripheral retina 625–626
 - importance 626
 - during movement 626, 626
 - performance animals 793
 - smooth pursuit movements 628–629
 - stabilizing reflexes 626, 627–628
 - tracking an object 626
 - during trotting 626, 626
 - motion-in-depth detection 635
 - motion parallax 634
 - motor cortex, primary 701
 - motor nerves, eyelid supply 697
 - motor neuron disease, equine *see* equine motor neuron disease (EMND)
 - mouse bioassay (MBA) 732
 - mouth, opening, restricted 158
 - movement
 - eye *see* eye(s), movements
 - perception 619, 620, 654
 - see also* motion detection
 - moxidectin 322, 751–752
 - habronemiasis 753
 - toxicity 767
 - moxifloxacin 354, 389
 - MPLS (mare reproductive loss syndrome) 766, 766
 - MRI *see* magnetic resonance imaging (MRI)
 - MUC 5AC 255
 - mucins 255
 - glycocalyx 255, 256
 - transmembrane 255
 - mucopurulent discharge
 - diagnosis/investigations 197
 - eyelid lacerations 212, 213
 - keratoconjunctivitis sicca 198, 218
 - nasolacrimal duct atresia 193, 193, 194
 - nasolacrimal duct obstruction 192, 193, 196, 196, 197
 - Mucor*, corneal/conjunctival surface microflora 264, 265
 - mucosal immune system 255, 262
 - mule
 - distal nasolacrimal orifice 192
 - globe dimensions 133
 - Müller cells 566, 587, 691, 692
 - number 647
 - see also* retinal Mueller glial cells (RMG)
 - Müller's muscle 189, 190, 190
 - innervation 700
 - loss of sympathetic tone 189
 - Müller's superior tarsal muscle 697
 - multiple congenital ocular anomalies (MCOA)
 - syndrome 275–276, 445, 448, 585–586
 - abnormalities found 585
 - breeding advice 586, 672, 811
 - breeds associated 585, 662, 670, 671
 - clinical appearance 585, 671, 671
 - congenital cataracts 501
 - cysts 585, 671, 671
 - diagnosis 585
 - gene variants 662, 671, 672
 - heritability 585, 586, 662
 - MCOA phenotype 671, 672
 - pathogenesis 671, 672
 - promelanosome protein (*Pmel*) gene
 - mutation 586, 662, 671–672
 - retinal detachment 585, 585
 - retinal dysplasia 584, 585, 704
 - treatment 586
 - muscle atrophy 158
 - ceroid/lipofuscin accumulation 724
 - equine protozoal myeloencephalitis 721, 722
 - muscle enzymes 725
 - muscle fasciculations 728, 758
 - muscle relaxants, cataract surgery 524
 - muscle wasting, PPID (equine Cushing's disease) 759
 - muscle weakness, in hyperkalemic periodic paralysis 758
 - mutations 664–665
 - gain/loss of function 665
 - inheritance modes 666
 - missense 665
 - see also* individual genes
 - muzzles, of blind horses 803, 803
 - mycosis, guttural pouch 164
 - mycotoxins, pasture-derived 709
 - mydriasis 14–15, 32
 - bilateral, PPID (equine Cushing's disease) 759
 - cataract evaluation 517
 - cataract treatment 517
 - lens examination 32
 - mechanism
 - reciprocal innervation and 698
 - sympathetic input 700
 - neuro-ophthalmic tests before 32
 - ocular fundus examination 14
 - posterior segment evaluation 32–33, 565
 - pre-cataract surgery 524
 - prepurchase examination 77
 - time for and duration 14, 32
 - toxic plants causing 768
 - see also* pupil, dilation
 - mydriatics
 - cataract surgery 524, 525
 - equine recurrent uveitis 478
 - glaucoma 555, 556
 - regulations, for performance animals 794
 - stromal abscesses 388
 - topical 13, 353
 - myelin 567, 567, 568
 - nerve fibre layer lacking 692
 - myelination 692, 693
 - optic nerve 567, 567, 568, 693
 - myeloencephalitis, equine protozoal *see* equine protozoal myeloencephalitis (EPM)
 - myofibroblasts 258, 259, 269, 271
 - myonecrosis 158
 - myopathy, nutritional 158
 - myopia (near-sightedness) 40, 639, 641
 - prevalence 641
- n**
- NAD/EDM *see* neuroaxonal dystrophy/equine degenerative myeloencephalopathy (NAD/EDM)
 - nanophthalmos 141
 - nasal bone, fractures, radiography 92, 92
 - nasal cavity neoplasia 160–161
 - nasal cysts 160
 - nasal discharge, unilateral 160–161, 706
 - nasal epithelium, swelling 193–194
 - nasal length 692
 - nasal puncta 29, 192, 192
 - atresia 192, 193, 193, 194, 194
 - Jones test and 38
 - see also* nasolacrimal puncta
 - nasal vestibule 192, 192
 - nasociliary nerve 189, 215
 - anatomy 697
 - nasofrontal bone, anastomoses, periostitis 158–159, 159
 - nasofrontal suture periostitis 159, 159
 - nasolacrimal disease *see* nasolacrimal system diseases/disorders

- nasolacrimal duct (NLD) 30, 139
 anatomy and physiology 191–192, 192
 atresia 193–195
 congenital 193–195
 dacryocystorhinography 194, 194
 diagnosis 193
 differential diagnosis 194
 surgery 194–195, 195
 treatment 194–195
 canaliculi 133, 134, 139, 191
 cannulation, supplies 62, 62
 course 191–192, 192
 CT dacryocystorhinography (CD-DCG) 100, 101
 dacryocystorhinography 99
 damage
 sinus drainage 138
 sinus trephination 179, 180
 disease *see* nasolacrimal system diseases/
 disorders
 endoscopic examination 62
 epiphora 147
 examination 30
 flushing 193
 hemorrhage 196
 inflammation 196, 197
 irrigation 61–62, 62, 197
 normograde 61, 62, 62
 procedure and catheters 61–62
 retrograde 61–62
 supplies required 62, 62
 laceration, repair 169
 lacrimal puncta *see* lacrimal puncta
 length 192
 nasal puncta *see* nasal puncta
 obstruction *see* nasolacrimal duct (NLD)
 obstruction
 orifice 192, 193
 patency evaluation 29, 36, 193, 194, 194
 periostitis in region of 159
 puncture, in trephination of maxillary
 sinus 179, 180
 strictures 197
 tear flow through 147
 trauma 196
 nasolacrimal duct obstruction 29, 147, 192
 acquired 194, 196–198
 causes 196
 differential diagnosis 197
 foreign material 196, 197
 prognosis 197–198
 treatment 196, 197
 congenital 192, 193, 194
 dacryocystorhinography 99, 193, 194
 environmental control 198
 investigations 194, 197
 irrigation 197
 difficulty 62, 197
 mucopurulent discharge 192, 193, 196, 196
 NLD atresia *vs.* 194
 in orbital fractures 167
 recurrent or severe 198
 nasolacrimal openings 192, 193
 nasolacrimal puncta 29, 192
 atresia 192, 193, 194
 surgical opening 194–195
 examination 29, 30
 in irrigation 62, 62, 63
 occlusion, cauterization 199
 see also lacrimal puncta; nasal puncta
 nasolacrimal “sac” 191, 192
 nasolacrimal system 187
 anatomy and physiology 191–192
 dacryocystorhinography 99, 99–100
 distal orifice 192
 drainage portion 191–192
 examination 29, 30
 patency assessment 29, 36, 193, 194, 194
 Jones test 36, 38–39, 39, 62, 193, 197
 radiography 59, 61
 secretory components 191
 nasolacrimal system diseases/disorders
 139, 187–252
 acquired 196–199
 congenital 192–195
 economic impact 187
 future research 239
 prevalence 187
 radiography 92
 natamycin 374, 374–376
 keratomycosis 374–375
 stromal abscesses 389
 national regulations 792–797
 National Thoroughbred Racing Association
 (NTRA) 792, 793, 793
 Nd:YAG laser *see* neodymium-yttrium aluminum
 garnet (Nd:YAG) laser
 near response 629, 645
 near-sightedness *see* myopia (near-sightedness)
 nematodes, migration, orbital 157
 neodymium-yttrium aluminum garnet
 (Nd:YAG) laser
 corpora nigra cysts 447
 iridal cysts 448, 448
 transscleral cyclophotocoagulation 557
 uveal melanoma 486
 neonatal encephalopathy (NE) 770, 770
 neonatal examination 1
 neonatal isoerythrolysis (NI) 771
 clinical signs 771, 771
 neonatal maladaptation 770
 neonatal maladjustment syndrome 583, 770, 770
 neonates *see* foals
 neoplasia
 adnexal *see* adnexal diseases/disorders
 corneal 288–302
 cytology 53
 exophthalmos due to 142–143
 extraocular 762–764, 763
 most common 108
 nasal cavity 161
 ocular and clinical signs 762–763, 763
 orbital *see* orbital neoplasia
 posterior segment 606, 607
 sinus *see* sinus neoplasia
 treatment response, assessment 220
 ultrasound 108
 uveal 484–487
 working horses, developing world 76
 see also individual tumor types
Neospora hughesi 721
Nerium oleander (oleander) 768
 nerve blocks 11–12, 12, 13
 auriculopalpebral *see* auriculopalpebral block
 corneal surgery 391–392
 frontal (supraorbital) 11–12, 13
 infratrochlear nerve 12, 13
 lacrimal nerve 12, 13
 for ocular examination 11–12, 12
 palpebral branch of facial nerve 11, 12
 retrobulbar *see* retrobulbar nerve block
 for slit-lamp biomicroscopy 18
 supraorbital 11–12
 upper eyelids 11, 12, 12
 zygomatic nerve 12, 13
 nerve fiber layer (NFL) 691, 692, 692
 thickness 692
 nerve growth factor (NGF) 258
 nervous tissue tumors 163
 neural reflex, fetal 770
 neural representation, blindness 802–803
 neurapraxia 713
 neuroanatomic pathway *see under*
 neuro-ophthalmology
 neuroaxonal dystrophies 726
 neuroaxonal dystrophy/equine degenerative
 myeloencephalopathy (NAD/EDM) 597,
 726, 726
 clinical signs 726, 726
 neuroborreliosis 745
 neurodegenerative disease, PPID 759, 761
 neuroectodermal cells 261
 neuroendocrine tumors 734
 orbital 163
 neurofilament medium (NF-M) 467
 neurogenic keratoconjunctivitis sicca (NKCS) 198,
 218, 709, 711
 causes 218, 711
 clinical appearance, diagnosis 218, 711, 711
 differential diagnosis 218, 711
 in equine protozoal myeloencephalitis 721
 facial nerve paresis/paralysis 712
 lesion site 218, 711
 treatment and prognosis 218
 neurokinin 1 (NK1) 260
 neurological disorders
 air embolism causing 766
 ocular examination in 1
 strabismus cause 708–715
 neuromodulation
 headshaking 734
 phototrigeminal headshaking 715
 neuromuscular blocking agents 392
 neuronal ceroid lipofuscinosis 595, 596

- neurons
 - first-order 214
 - second-order 215
 - third-order 215
 - neuro-oncological ventral antigen 1 (Nova-1) 587
 - neuro-ophthalmic disorders
 - clinical presentation 704–715
 - future research 715
 - neurologic causes
 - post-retinal visual deficits 704–708
 - see also specific conditions*
 - pathological nystagmus 708–715
 - strabismus, causes 708–715
 - systemic, ocular manifestations 721–737
 - see also nystagmus; strabismus*
 - neuro-ophthalmology 691–720
 - anatomy and function 691–700
 - disorders *see* neuro-ophthalmic disorders
 - examination 23–27, 700–704
 - aim 700
 - corneal reflex 26, 703, 703–704
 - dazzle reflex 25, 703
 - maze testing 26, 26–27
 - menace response 25
 - before mydriasis 32
 - palpebral reflex 25–26, 701
 - pupillary light reflexes 23–25, 25, 701–702
 - swinging light test 701, 702–703
 - vestibulo-ocular reflex 704
 - vision 700–701
 - pathways
 - for conscious vision 694–695, 695
 - for menace response 701, 702
 - for palpebral reflex 701, 703
 - for parasympathetic innervation 698–699, 699
 - for pupillary light reflex 698, 699
 - for sympathetic innervation 699, 699–700
 - for vestibulo-ocular reflex 696, 696
 - neuroplasticity 801
 - visual cortex, blind horses 801–802
 - neuropraxia, of optic nerve 764
 - neuroretinal rim (NRR), optic nerve head 545, 546
 - neurosensory retina (NSR) 566
 - anatomy and function 568, 691–693
 - atrophy, after trauma 604
 - cell types 691–692, 692
 - see also individual cell types (see page 691)*
 - examination 573
 - fluid collection between RPE and 592
 - folding 583–584, 584
 - ganglion cell layer 691, 692, 692
 - layers 691
 - nerve fiber layer 691, 692, 692
 - nonattachment 584, 584
 - photoreceptor layer 691, 692
 - in retinal dysplasia 583–584
 - rosette formation 583–584, 584
 - separation from RPE *see* retinal detachment
 - thickness 568
 - neurotransmitters, cornea 260
 - neutrotrophic keratitis 711–712, 712
 - neutrotrophic keratopathies 261
 - neutral point, color vision 652, 653, 654
 - neutrophil(s) 51
 - activation, in equine recurrent uveitis 465, 468
 - chemoattractants 339
 - corneal injury response 266, 267
 - after corneal microbial invasion 339
 - cytology interpretation 51, 52, 52
 - deep fungal stromal abscesses 369
 - focal chemoattraction, ocular surface and cornea 387–388
 - locomotion/migration 266–267
 - proteases/peroxides and radicals released 339
 - stromal abscess pathogenesis 389–390
 - ulcerative keratomycosis 364
 - neutrophil elastase (NE) 255, 267
 - inhibition, in corneal bacterial infection 355
 - neutrophilia 773
 - “next-generation DNA sequencing” 54
 - nictitans *see* third eyelid (nictitans; nictitating membrane)
 - nictitans gland 191, 191, 218
 - anatomy 191
 - aqueous tear production 191
 - prolapsed 219
 - nictitating membrane *see* third eyelid
 - night blindness, congenital stationary *see* congenital stationary night blindness (CSNB)
 - night vision
 - control (TRPM1 channels) 587
 - poor, in CSNB 586, 587
 - poor, in retinal degeneration 595
 - nociception, perception 698
 - nodal point, posterior 643, 643–644
 - nodular lymphocytic conjunctivitis (NLC) 237–238, 238
 - bilateral 237–238
 - nonpigmented epithelium (NPE), ciliary body 441, 442, 443
 - nonspecific inflammatory response syndrome (SIRS) 317, 317
 - nonsteroidal anti-inflammatory drugs (NSAIDs)
 - cataract surgery 524, 525, 532
 - chronic use, complications 556
 - corneal ulceration 353
 - cyclooxygenase inhibition, in SCC 235
 - equine influenza 742
 - glaucoma 556
 - IMMK treatment 312, 313
 - nasolacrimal disease 195, 196
 - nasolacrimal duct atresia surgery 195
 - orbital cellulitis 157
 - post-direct corneal suturing 393
 - postoperative, cataract surgery 532
 - stromal abscesses 390
 - topical
 - after cataract surgery 532
 - equine recurrent uveitis 477, 478
 - putative viral keratitis 320
 - ulcerative keratomycosis 377
 - uveitis control in corneal ulceration 355
 - West Nile viral encephalitis 728
 - norepinephrine 216
 - nose nets, photic head shaking 715
 - nostril, ipsilateral, reduced airflow from 147
 - NSAIDs *see* nonsteroidal anti-inflammatory drugs (NSAIDs)
 - nuclear factors of activated T lymphocytes (NFATs) 312
 - nuclear sclerosis 500, 501, 509
 - nucleotides 661
 - nucleus intermediolateralis 699
 - nutritional myopathy 158
 - nutritional support 158
 - nyctalopia 586
 - nyctalopin (NPX) gene mutations 587
 - nystagmus 141
 - bilateral, after skull fractures 764
 - central vestibular disease 730
 - CNS disease causing 141
 - continuous 708
 - direction 708
 - fast phase direction 708
 - neuroanatomic pathways 696
 - pathologic 141, 708–715
 - pathological jerk 708
 - pathological vertical 708
 - physiologic 141, 696, 704
 - lack, intracranial neoplasia 734
 - physiological jerk 708
 - positional 708
 - resting (spontaneous) 708
- O**
- object differentiation 629
 - object overlay 633
 - obstacle course 700
 - occipitospheoid suture line 167
 - ocular amyloidosis 287
 - ocular angiography 124–125
 - anterior segment 124, 125, 125
 - dyes used 124, 125
 - normal sequence 125
 - posterior segment 124–125
 - sodium fluorescein 125
 - ocular biopsy *see* biopsy
 - ocular conformers, indications 177
 - ocular cups 70
 - ocular discharge *see* discharge, ocular
 - ocular discomfort, signs 511
 - ocular disease *see* ophthalmic disease
 - ocular examination *see* examination
 - ocular fundus *see* fundus
 - ocular irritation *see* irritation
 - ocular muscles *see* extraocular muscles; *individual muscles*
 - ocular pain
 - acute anterior uveitis 452
 - acute glaucoma 548
 - blind eyes 816–817
 - cornea and eyelids 29
 - corneal culture and 48

- corneal ulcers 352
- deep stromal ulceration 416
- enucleation for 816, 817
- epiphora due to 197
- examination 8–9, 28, 29
- glaucoma 548, 560, 816–817
- onchocerciasis 321
- putative viral keratitis 318, 319
- rose bengal staining 37–38
- ocular perfusion pressure 545
- ocular photography *see* photography
- ocular reflex, prepurchase examination 77
- ocular surface
 - components 253
 - defense mechanisms 339
 - dimensions 253
 - disruption 335–338
 - see also* corneal ulceration
 - microflora *see* microflora, ocular surface
 - see also* conjunctiva; cornea; limbus; precorneal tear film (PTF)
- ocular temperature *see* temperature, eye
- ocular trauma *see* trauma
- ocular ultrasonography *see* ultrasonography/ultrasound
- oculocardiac reflex 166
- oculokinetic reflexes 138
- oculomotor nerve (CN III)
 - anatomy 696, 696–697
 - branches 697
 - dysfunction 98, 708
 - examination **24**
 - eyelid innervation 189
 - function 694
 - lesions
 - equine protozoal myeloencephalitis 721
 - strabismus 140
 - motor fibres 699
 - MRI 98
 - parasympathetic fibers 698–699
 - anisocoria 708
 - parasympathetic nucleus 698
 - somatomotor nucleus 696, 696
- oculovestibular reflex 10
- off-label (extralabel) prescribing 794, 796–797
- ointments 63, 63, 274
- older horses *see* geriatric horses
- oleander ingestion 768
- ON-bipolar cells 587
 - in CSNB 667, 670
- Onchocerca* (spp.)
 - acute uveitis due to 453
 - intermediate host/vector 321
- Onchocerca cervicalis* 206, 320, 321, 751
 - conjunctival depigmentation 321, 322, 751, 751
 - keratitis due to 320, 321, 322, 751
 - life cycle 321
 - prevalence 320, 751
- onchocerciasis 751–752
 - acute/chronic presentations 321
 - clinical signs 751, **751**, 751
- conjunctivitis 321, 751
 - diagnosis 751
 - differential diagnosis 322
 - keratitis 320, 321, 322
 - treatment 751–752
 - uveitis 321, 453, 751
- ophthalmic artery 137
 - thrombosis 164
- ophthalmic disease
 - frequency in horses 74–76, **75**
 - performance animals 793–794
 - regulations, performance horses 794
- ophthalmic dyes 35–39
 - see also* individual dyes
- ophthalmic examination *see* examination
- ophthalmic instruments *see* equipment/instruments
- ophthalmic tests, reference ranges **9**
- ophthalmic vein, dorsal 137
- ophthalmology examination form **7, 8**
- ophthalmoparesis 713
- ophthalmoplegia
 - external 713
 - internal 713, 714
- ophthalmoscope
 - direct 17, 18, 19, 21, 570
 - indirect 21, 570, 571
- ophthalmoscopy 19–23, 565
 - direct 5, 17, 19–20
 - advantages/disadvantages 19
 - field practice 5
 - indications 19–20
 - light source 19, 20
 - optic nerve and retinal vessels 570
 - posterior segment 570, 571, 572
 - power source 19–20
 - technique 20
 - transilluminator method 19, 20
 - indirect 5, 17, 19, 20, 21–22
 - advantages/disadvantages 19, 21
 - binocular 21, 22
 - lenses 21, 22, 570, 571, 572
 - light source 21, 22, 570
 - monocular 20, 21, 22
 - PanOptic, for undilated pupil 21, 22, 570
 - posterior segment 570, 571, 572
 - refractive error 22
- ocular fundus 19, 20, 21
 - smartphone 22–23
 - posterior segment 572, 573
- optical aberrations 642–643
 - chromatic *see* chromatic aberrations
 - spherical *see* spherical aberration
- optical coherence tomography (OCT) 121–124
 - corneal diseases/disorders 123
 - corneal dystrophy 123–124
 - corneal stromal abscess 123, 124
 - corneal thickness measurement 122–123
 - corneal ulcers 123
 - heterochromic iridocyclitis with secondary keratitis 123
 - indications/uses 122
- iris masses 123
- methods 121
- normal cornea 122, 122
- optic nerve head 122
- peripapillary chorioretinal scars 124, 124
- principles 121
- retina 122, 122
- spectral-domain (Fourier-domain) *see* spectral-domain optical coherence tomography (SD-OCT)
- time-domain (TD-OCT) 121
- optic canal 693, 693
- optic chiasm 693–694, 695, 698
 - anatomy 693, 694
 - compression, PPID (equine Cushing's disease) 759
 - lesions/disorders 704, 707
 - MRI 98
- optic disc *see* optic nerve head (ONH)
- optic fissure, late/incomplete closure 141
- optic foramen 134, 134
- optic nerve (CN II) 545
 - abnormalities **598**, 598–606
 - anatomy and physiology 566–567, 567, 569, 692–693, 693, 695
 - astrocytoma **598**, 602, 606, 606, 705
 - atrophy **598**, 600–602, 601, 705
 - causes 600
 - clinical appearance, diagnosis 601, 601
 - toxoplasmosis 748
 - treatment and prognosis 601–602
 - avulsion 707
 - axon number 566–567
 - axoplasmic flow disruption, glaucoma 545, 546
 - circumpapillary ring 568, 568, 569
 - coloboma **598**, 598–599, 599
 - color **571**
 - dazzle reflex 25
 - degeneration 595, 595, 601, 601, 603
 - blood loss causing 603, 604
 - chorioretinitis 589, 591–592
 - dimensions, glaucoma 546
 - direct ophthalmoscopy 570
 - dural sheath, trauma 764
 - equine motor neuron disease 597, 597
 - examination **24**
 - ganglion cell density 647
 - hypercellularity 601
 - hyperemic 605
 - after trauma 601, 603
 - hypoplasia **598**, 600
 - hypotension 705
 - hypoxemia 602–603
 - hypoxia 705
 - inflammatory disorders 705
 - information overload for brain 618
 - intralaminar, in glaucoma 546, 546
 - lesions 565, 704
 - menace response deficit 25
 - meningioma 705
 - myelination 567, 567, 568, 693

- optic nerve (CN II) (*cont'd*)
 - neoplasia 705
 - neuropaxia 764
 - notch on 566, 567
 - origin, point of 692
 - pallor 595, 601, 601, 602
 - pedunculated mass protruding from 602
 - peripapillary ring around 568, 568, 569
 - prelaminar *see* optic nerve head (ONH)
 - regions 693
 - in retinal degeneration 595
 - retinal ganglion cell axons 693
 - schwannoma 602
 - stretching, traumatic neuropathy 705–706
 - striations, myelin 567, 567, 568
 - surface 566–567
 - transection, orbital proptosis 155, 156
 - trauma 601, 607
 - optic nerve atrophy after 601, 601
 - ultrasound 103, 103
- optic nerve head (ONH) 545
 - anatomy and physiology 545, 546, 566, 566, 569, 692, 693
 - area centralis rotunda anatomy 692
 - atrophy (“cupping”) 155, 546, 546, 549
 - “butterfly” lesions temporal to 459, 460
 - central optic cup *see* central optic cup (CUP)
 - colobomas 106, 598, 599, 707
 - color 33, 692
 - congestion 577
 - direct ophthalmoscopy 20
 - in equine recurrent uveitis 470, 470
 - examination 20, 32–33
 - fibrinous traction bands from 460, 461
 - hemorrhages, in foals 577
 - light reflection 15
 - neonatal foals 577
 - normal 568, 569, 574, 575
 - optical coherence tomography (OCT) 122
 - orange-red, in posterior ERU 459–460
 - shape 692, 693
 - size estimation 20
 - strain at, factors affecting 547
 - thickness 122
 - ultrasound 103
- optic neuritis 598, 604–606, 705
 - causes 604–605
 - clinical appearance, diagnosis 605, 605–606, 705
 - cryptococcosis 749
 - exudative 598, 604, 605, 705
 - infectious 705
 - noninfectious 705
 - retrobulbar 605–606
 - treatment 705
- optic neuropathy 704–705
 - acquired 704
 - causes 704, 705
 - compressive 705, 706
 - ischemic *see* ischemic optic neuropathy
 - neurologic signs 704
 - proliferative 598, 602, 603, 705, 707
 - toxic 707
 - traumatic 155, 598, 603–604, 604, 705, 707
- optic papilla *see* optic nerve head (ONH)
- optic radiation 694
 - lesions 704, 707–708
- optic tract 694, 695
 - axons, anatomy 703
 - lesions 704, 707–708
- optokinetic nystagmus system 627, 629
 - activation 627, 628
- optokinetic system 626, 627, 629
 - simulation 627
- ora ciliaris retinae 441, 566
- oral cavity 137–138
- oral examination 27
- oral speculum 138
- orbicularis oculi muscle 189, 190, 190, 697
 - auriculopalpebral block paralysing 11
 - contraction, palpebral reflex 701
 - corneal reflex 703, 703
 - innervation 697, 701
- orbit 133–186
 - anatomy and physiology 133–138, 134, 135
 - biopsy of contents 139
 - bones 133–134, 135
 - deformation 148
 - buccal cavity separated from 137–138
 - contents, anatomy 108, 134, 136
 - CT 94, 94
 - diagnostics 138–139
 - dimensions 133
 - diseases *see* orbital diseases
 - enlargement, postnatal 141
 - examination 27
 - floor of 134
 - in fractures 169
 - foramina 133–134, 134
 - clinical importance 134
 - efferent 134
 - fractures *see* orbital fractures
 - innervation 136
 - lymphosarcoma invasion 237
 - metastases 163
 - muscles 136, 136
 - periosteum (periorbitum) 134
 - positioning 133
 - radiographic evaluation 91
 - soft-tissue damage, management 169
 - space-occupying lesions 161–163
 - prominent nictitans 146, 219
 - structures adjacent to 137–138
 - structures perforating 134, 136
 - surgery *see* orbital surgery
 - trauma *to see* orbital trauma
 - ultrasound examination 101, 103, 108–109
 - vascular abnormalities 148–149
 - external 149, 149
 - vascular supply 137, 137
- orbital abscess 156, 157
- orbital cavity 133
- orbital cellulitis 154, 156–157
- causes 156
- clinical appearance 157
- culture 139
- diagnosis 157
- exophthalmos due to 144
- granulomas 157
- microorganisms 156, 157
- treatment and prognosis 157
- orbital dermoids 148
- orbital diseases
 - abscess 156, 157
 - acquired 149–156
 - clinical signs 149
 - clinical signs 140–148, 149
 - globe location abnormalities 141–146
 - globe position abnormalities 139–141, 140
 - globe size abnormalities 141–146
 - miscellaneous 146–148
 - nystagmus 141
 - congenital 148–149
 - corneal complications 164
 - cosmetic and vision impact 133, 139
 - CT 95
 - economic costs 139
 - future research 180
 - iatrogenic 164
 - impact on equine industry 139
 - infectious 156–158
 - mass lesions *see* orbital mass lesions
 - metastatic 163
 - mycotic 156
 - noninfectious inflammatory 158–159
 - nutritional myopathy 158
 - parasitic 157–158
 - parenteral medications 153, 164–165
 - periostitis 159
 - preventive management 139
 - prophylactic antimicrobials 165
 - pseudotumors 159
 - surgery *see* orbital surgery
 - systemic medications 153, 164–165
 - threats to livestock 139
 - topical medications 156, 164
 - traumatic 149
 - treatment, general 164–165
 - see also individual diseases*
- orbital fat 133
 - herniation 53
 - iatrogenic prolapse 154
 - loss (cachexia), entropion due to 199
 - prolapse 50, 53, 154–155, 155
 - third eyelid protrusion 219, 219
 - resorption, enophthalmos due to 144
- orbital fissure 94, 134, 134, 696, 699, 699, 700, 713
- orbital floor *see* orbit, floor of
- orbital foreign bodies 154, 158
- orbital fractures 28, 149
 - blow-out 332
 - callus formation 168
 - closed reduction 168
 - comminuted 152, 154

- CT 94, 95, 168, 168
 depressed 167
 displaced 149, 154, 168
 enophthalmos due to 144
 in facial trauma 152
 flat bones 169
 healing 168
 imaging 167–168
 kicks causing 149, 167
 management 154
 minor 154
 open 149, 152
 open repair 154, 168
 retrobulbar bony fragments 149
 surgery 154, 167–169
 complications 168, 168, 169
 orbital implants 177, 177–178, 178
 orbital lymphosarcoma 161, 161–162
 orbital mass lesions
 biopsy, culture 139
 exophthalmos due to 143, 144, 601, 601
 lymphosarcoma causing 161, 161–162
 strabismus 139
 surgery 166–167
 ventral, neoplasia 162
 see also orbital neoplasia
 orbital muscles **136**
 ultrasound 103
 orbital neoplasia 161–164, 734
 adenocarcinoma 162, 163
 angiosarcoma 163
 clinical appearances 161, 161, 162, 162
 diagnosis 162
 exophthalmos due to **138**
 hemangiosarcoma 163
 malignant rhabdoid tumor 163
 medulloepithelioma 163–164
 melanoma 163
 meningioma 163–164
 neuroendocrine tumors 163
 osteosarcoma 163
 periosteum (periorbitum) removal 134
 prognosis 163
 squamous cell carcinoma 161, 161
 surgery 166, 167
 treatment 162–163
 tumor types 161, 162
 see also orbital mass lesions
 orbital proptosis 155–156
 clinical appearance 155, 155
 prognosis 156
 treatment 155–156
 orbital prosthesis 142, 170
 see also intraorbital prosthesis (ISP)
 orbital rim, bony 133–134, 134, 150
 dorsal, fractures 167, 167
 fractures 149, 150, 167, 167, 168
 surgery 167, 168
 inferior, fractures 167
 surgical exploration in orbital disease 166
 trauma 149, 150
 orbital surgery 165–180
 closure, large skin defects 176–177
 cosmetic conformer 177–178
 enucleation *see* enucleation
 equipment/instruments 166
 evisceration *see* evisceration
 exenteration *see* exenteration
 exploration 166–167
 complexity and cautions 166
 before enucleation closure 174
 indications 166
 hydroxyapatite orbital implantation 177, 177–178
 mass removal 166–167
 for orbital fractures 167–169
 radical resection of eyelid skin and globe
 176–177
 related procedures 178–180
 retrobulbar blockade *see* retrobulbar nerve block
 skin flaps/grafts 177
 for skull fractures (flat bones) 169
 for soft-tissue damage 169
 tarsorrhaphy 165, 165
 orbital trauma 149
 CT 94, 95
 muscular attachments in 137
 rim, bony 149, 150
 ultrasound 101, 108
 orbital tumors *see* orbital neoplasia
 orbitopalpebral sulcus 188, 188
 ripping along/trauma 212, 213
 orbitotomy
 diagnostic 166
 dorsal, procedure 166
 orbivirus 739
 organophosphate poisoning 768
 orientation, form perception 650, 650–651
 osteoarthropathy, temporohyoid *see* temporohyoid
 osteoarthropathy
 osteoplastic flap, frontonasal 160
 osteopontin (OPN) 467
 osteosarcoma, orbital 163
 over-the-counter drugs 794
 oxygen, cornea, supply to 260
 oxygen therapy 770
- P**
 P2 myelin protein 737
 p53 gene 676
 p53 mutation
 overexpression 229, 676
 sarcomas 222
 squamous cell carcinoma 676
 adnexal SCC 229
 p53 protein 229
 function 676
 pachymeningitis, idiopathic 705
 pachymetry, ultrasonic 46–47
 corneal thickness 46–47, 122, 134, 256
 pain *see* ocular pain
 Paint horse, lymphosarcoma 237
 paired box protein (PAX)-6 679
 palatine bone 134, 134
 palpebrae *see* eyelid(s)
 palpebral blink *see* blinking; palpebral reflex
 palpebral conjunctiva *see* conjunctiva, palpebral
 palpebral fissure 189–190
 lateral, in third eyelid chemosis 219
 normal 2
 palpebral ligaments 190
 palpebral muscles 190
 palpebral nerve block 11, 12
 palpebral reflex 25–26, 701, 712
 eliciting 701
 in facial nerve paresis/paralysis 712
 neuroanatomic pathway 701, 703
 see also blinking
 palpebral veins 137
 pannus 307, 313–314, 314
 panophthalmitis 156, 536
 pan-ophthalmoplegia 713
 PanOptic ophthalmoscope 570, 572, 573
 panoramic view 629, 631, 632, 655
 panuveitis 156, 451, 456
 cataract surgery complication 534, 535
 equine recurrent uveitis 457, 458
 Lyme disease 745
 Rhodococcus equi infection 772
 in systemic diseases 592
 ultrasound 108
 papilla, optic *see* optic nerve head (ONH)
 papillomaviruses, adnexal SCC 229
 paracentesis
 aqueous *see* aqueous paracentesis
 vitreous *see* vitreous paracentesis
 paralysis
 facial nerve *see* facial nerve paresis/paralysis
 hyperkalemic periodic *see* hyperkalemic periodic
 paralysis (HYPP)
 paranasal sinuses 135
 fracture communication, facial trauma 152
 paraorbital neoplasia 161, 163
 parasitic infections
 acute uveitis due to **453**
 blepharitis **204**, 206
 chorioretinitis 592
 conjunctivitis **204**
 keratitis 320–322
 optic neuritis due to 605
 of orbit 157–158
 systemic 733, 751–754
 see also individual parasites
 parasympathetic nervous system 214, 218, 303
 afferent pathways 698
 efferent fibers/pathways 698–699
 innervation of eye 698–699, 699
 postganglionic fibers 699
 preganglionic fibers 698–699
 parasympathomimetic drugs, glaucoma
 555, 556
 paresis, facial nerve *see* facial nerve paresis/
 paralysis
 parotid duct transposition 199, 305

- pars intermedia dysfunction 144
- pars plana 441, 445, 543
 - dimensions 557
 - limbus distance to 9
- pars plana vitrectomy (PPV) 608
 - chronic uveitis 482
 - equine recurrent uveitis 482–484
 - complications 483, 484, 484
 - leptospirosis-associated ERU 482, 484
 - patient selection 482, 484
 - prognosis 483–484
 - surgical technique 482–483, 483
- pars plicata 441, 445, 543
 - dimensions 557
 - see also* ciliary processes
- partial incision keratectomy 394
- partial stylohyoid osteotomy (PSHO) 736
- pasture-derived mycotoxins 709
- path integration 802
- pathogen-associated molecular patterns (PAMPs) 360
- pathological jerk nystagmus 708
- pathological nystagmus 708
- pathological vertical nystagmus 708
- pathologic glare 644
- PATN1* gene 667, 674
- pattern recognition receptors (PRRs) 261, 262, 360
- PAX-6* gene 679
- PCR *see* polymerase chain reaction (PCR)
- PDGFA 677
- pectinate ligaments 30, 31, 442, 543, 550
 - high-resolution ultrasound 550, 551, 552
 - tearing, trauma 331, 331
- pedicle grafts, conjunctival *see* conjunctival grafts
- pedigree analysis 666
- pellucid marginal degeneration (PMD) 280, 677–678
- pemphigus foliaceus 754–756, 755, 755, 756
- pemphigus vulgaris 754, 755, 756
- penetrance 665
- penetrating injuries *see* trauma
- penetrating keratoplasty (PK) 391, 403–407
 - advantages 404
 - amniotic membrane transplants with 407
 - anesthesia 405
 - complications 407
 - conjunctival grafts with 405, 405
 - corneal SCC 293, 297
 - corneal sensory denervation after 404
 - corneal sutures 403, 404
 - corneal ulceration with iris prolapse 385
 - for descemetocoele 416
 - donor cornea preservation 405
 - donor graft, placement/suturing 404, 405
 - frozen donor cornea 405
 - full-thickness 404
 - graft failure 407
 - graft rejection 403, 407
 - hemorrhage minimization 405
 - indications 403, 404–405
 - iris prolapse after melting ulcer rupture 386
 - iris prolapse treatment 418
 - lesion size, measurement 405
 - limitations 403–404
 - melting ulcers 386
 - outcomes 404, 407
 - postoperative care 407
 - principles 403–404
 - procedure 404, 404–405, 405
 - stromal abscesses 391, 404, 404
 - success rate (human) 403
 - surgical technique 405–407, 406
 - donor cornea, handling/suturing 406, 406–407
 - terminology 403
- penicillin
 - Lyme disease 745
 - strangles 744
- penicillin G, orbital disease 164
- penicillin V, nasolacrimal disease 196
- Penicillium* 206, 358
 - corneal/conjunctival surface microflora 264, 265, 266
 - yellow sweet clover infected, ingestion 768
- penitrem-A 768
- pentoxifylline 756
- percutaneous electrical nerve stimulation (EPNS), headshaking 734
- perforating, terminology, in penetrating keratoplasty 403
- perforating trauma 606
 - corneal *see* corneal lacerations
- performance animals
 - enucleation (unilateral), effect 793–794
 - fatalities/injuries 793
 - national/international regulations 792
 - ophthalmic disease 793–794
 - medications used 794
 - regulations on 794
 - regulatory agencies 792–793, 793
 - risks for horse and riders 793
 - see also* racehorses
- perfusion pressure, ocular 545
- pergolide mesylate 762
- perinatal asphyxia syndrome (PAS) 770
- periocular biopsy 54–55, 55
- periocular dermatitis 70, 71
- periocular injection, corneal disease
 - treatment 272, 274
- periocular lacerations 205
- periocular sarcoids 221
- periocular sinus region, examination 27
- periocular squamous cell carcinoma 233, 675
- periocular tissues, examination 27–28
- periodic ophthalmia *see* equine recurrent uveitis (ERU)
- periorbital nasal and sinus diseases 159–164
- periorbital sinuses 138
 - cysts 142
 - diseases 138, 139
 - drainage 138
 - fractures exposing, management 169
- periorbitum, anatomy 134
- periostitis 158–159
 - nasofrontal suture 158–159, 159
- peripapillary region 567, 568, 569
 - chorioretinitis lesions 587, 588, 588–589, 592
- depigmentation 574, 577, 588, 589, 592, 601, 602
- direct ophthalmoscopy 570
- examination, interpretation 576–577
- lesions 576–577
- pigment variation 577, 577
- white exudates, traumatic optic neuropathy 604, 604
- peripheral visual field, motion detection 625
- peripherin 2 466
- peritomy 152
 - transconjunctival enucleation 170, 171
- persistent hyaloid artery (PHA) 504
- persistent hyperplastic primary vitreous/tunica vasculosa lentis (PHPV/PHTVL) 504, 505
- persistent pupillary membrane (PPM) 444, 445–446, 446
 - cataracts and 501, 505
- petroleum-based lubricants 164
- phacoemulsification 518, 519, 526
 - advances in techniques 523
 - aphakia after 518, 519
 - chronic lens-induced uveitis 517
 - chronic uveitis before, results 519
 - corneal edema after 395
 - IOL implants after 41, 526
 - lens capsule rupture 516
 - method 528
 - vision retention 519
- phacoemulsification with aspiration
 - technique 526, 527–530, 529–531
 - anterior capsulotomy 527–528, 529
 - aspiration 529, 530
 - capsulorhexis 527, 528
 - clear corneal incisions 527, 527, 528, 534
 - complications 534, 535
 - one-handed method 528
 - postoperative complications 533–534, 534, 537
 - procedure 528–530, 529
 - trilaminar corneal incision 527, 527, 528, 529
 - two-handed method 528, 529, 529
 - viscoelastic substance 528, 530
- phacofragmentation 526
 - see also* phacoemulsification
- phagocytosis 255, 267, 339
- pharyngitis, strangles 743
- phenol red thread (PRT) test 34–35
- phenotype 665, 666
- phenylbutazone
 - equine recurrent uveitis 478, 478
 - onchocerciasis 752
 - stromal abscesses 390
 - ulcerative keratomycosis 377
- phenylephrine 13
 - in corneal surgery 393
 - equine dysautonomia 709, 733
 - equine recurrent uveitis 477, 478

- Horner's syndrome testing 216
 topical 15
 ulcerative keratomycosis 377
 uveitis control in corneal ulceration 355
 phenylephrine HCl 216
 phosphate buffer, calcium salt precipitation and 281–282
 phosphorylated neurofilament heavy subunit (pNFH) 726
 photic blink reflex *see* dazzle reflex
 photic headshaking 598
 photic trigeminal mediated headshaking 714–715
 clinical signs, diagnosis 715, 733
 etiopathogenesis 715, 733–734
 management 715, 734
 photoablation, diode laser, nasolacrimal duct atresia surgery 194
 photoactive drug, injection 233, 234
 photodynamic therapy (PDT) 233
 adnexal SCC 230, 233, 234, 235
 complications 233
 corneolimbic SCC 230
 sarcomas 224
 photography
 cropping, to enhance 61
 digital 58, 59, 60, 61
 measuring device used in 60
 staging to optimize 60
 taking from various angles 60
 tips for 59
 photons 619, 654
 photophobia
 aniridia 679
 bacterial keratitis 341
 equine viral arteritis 737
 glaucoma 548
 meningitis 770
 prolonged mydriasis-induced 517
 pyrrolizidine alkaloids 767
 Setaria infection 753
 toxic plants causing 767, 768
 ulcerative keratomycosis 363
 photopigment, photoreceptor bleaching and reversal 622
 photoreceptor layer 691, 692
 photoreceptors 566, 691
 bleaching 622
 hyperpolarization 667
 light adaptation 621, 622–623
 light perception 15, 619, 620
 optimally tuned to specific wavelengths 619
 resolvable object size 646
 sensitivity to light, changes 622
 size, visual acuity 646
 spacing, visual acuity 646
 spatial summation 622
 temporal summation 622
 visual streak 646, 647
 see also cones; rods
 photosensitizers 233
 PHPV/PHTVL 504, 505
 phthisis bulbi 145, 146
 Appaloosa horses 474, 673
 causes 145
 end-stage uveitis 455, 456
 entropion and 211
 enucleation for 211, 816
 evisceration for 174
 microphthalmos *vs.* 141–142
 after perforating lacerations 334
 third eyelid elevation 219
 phycomycosis 157
 physical examination 3, 7, 27
 physical fitness, indicator, infrared thermography 117
 physiological jerk nystagmus 708
 physiologic nystagmus 141, 696, 704, 734
 pigmentary keratopathy 314, 314
 pigmentation
 choroid 573, 574
 ciliary body 441, 442, 443
 corneal *see* cornea, pigmentation
 increased *see* hyperpigmentation
 iris 23, 31–32
 lethal white foal syndrome 681
 loss/reduced *see* depigmentation
 third eyelid 2
 TRPM1 role 667, 668
 uvea tract, glare defense 644
 yellow, lens 624, 625
 pigmented epithelium, ciliary body 441, 442, 443
 pigment epithelium-derived factor (PEDF) 263, 268, 388
 decrease, in ERU 466
 pigment retinopathy 597
 in NAD/EDM 726
 pilocarpine 305
 accommodation elicited by 645
 glaucoma 555, 556
 neurogenic keratoconjunctivitis sicca 218
 pineal gland 467
 in equine recurrent uveitis 467, 470
 pinealitis 467, 470
 “pinkie Arab” 208
 piroplasmosis 747–748
 clinical signs 748, 748
 piroxicam, adnexal SCC 234–235
 pituitary adenoma 759
 pituitary gland mass 699
 pituitary pars intermedia dysfunction (PPID) 759–762
 clinical signs 759, 759, 760, 761
 diagnosis, tests 761–762
 management 761, 762
 pathogenesis 759
 pathology 759, 760
 PK *see* penetrating keratoplasty (PK)
 place cells 802
 placentitis 278
 plants, toxic *see* toxic plants
 plaques, fungal, thick pigmented 366, 366, 367
 plasmapheresis 771
 “plasma staining” 309, 310
 platelet-derived growth factor (PDGF) 266, 267–268, 269
 platinum coils, photic headshaking 715
 PLR *see* pupillary light reflex (PLR)
PMEL gene 671, 672
 breeding advice, MCOA phenotype 672
 missense mutation, exon 11 671–672
 mutations 586, 662, 671, 672
 pneumocephalus 153
 pneumophthalmos 153
 pneumotonomography 46
 poll trauma 149, 167, 764
 polo, unilateral blind horses 794, 816
 polyenes 373–374, 374
 keratomycosis 373–374, 374–376
 polyethyleneimine (PEI) 271
 polygenic characteristic 665, 666
 polymerase chain reaction (PCR) 54
 botulism 732
 equine herpesvirus-2 infection 54, 741
 interpretation 54
 keratomycosis 371, 373
 leptospirosis-associated ERU 473, 581, 746
 nested *vs.* quantitative (qPCR) 54, 371
 primary epithelial disease 306
 sarcoma diagnosis 222
 strangles 743
 polymorphism 664–665
 see also mutations
 polymorphonuclear cells (PMN) 262
 corneal injury response 267, 339
 stromal healing 270
 after corneal microbial invasion 339
 migration, after injury 339
 recruitment and activation 262, 339
 see also eosinophil(s); mast cell(s); neutrophil(s)
 polyneuritis equi 736–737
 clinical signs 736, 737
 diagnosis 737
 Ponazuril 723
 pons 698
 Ponzo illusion 616, 616
 posaconazole 376
 positional nystagmus 708
 positional strabismus 708
 positioning, for examination 7–9
 positive reinforcement behavior modification training (PRBMT) 810
 positive reinforcement training 63, 63
 blind horses 810
 postanesthetic cortical blindness 707, 708
 posterior capsular opacification 534, 536, 536, 537
 posterior capsular tears 533, 533
 posterior chamber
 aqueous humor flow into 543
 tan-yellow exudates, in MPLS 766
 ultrasound 103
 posterior ciliary arteries 136
 posterior ciliary veins 137

- posterior collagenous zones *see* retrocorneal fibrous membranes (RCFMs)
- posterior ethmoidal nerve, block 715
- posterior iris epithelium 441, 442
- posterior lamellar keratoplasty (PLK) 407, 409–412
- complications 412
- deep stromal abscess 384, 403, 407, 409, 410, 414–415
- donor graft 411
- indications 403, 409
- keratomycosis 377
- modification, standing surgery 412
- outcomes 407, 410, 412
- post-operative care 412
- surgical technique 411, 411
- posterior nodal point 643, 643–644
- opacities, impact 644
- posterior segment
- abnormalities 565
- assessment 565
- in MCOA syndrome 585
- in acute uveitis 453
- anatomy and physiology 566–569
- in chorioretinitis 589
- coloboma 598
- diagnostic tests 577
- ERU histopathology 469, 469–470, 470
- examination 32–33, 565, 570–580, 571, 608
- advanced diagnostics 577–580
- biomicroscopy 570
- clinical 570–573
- CT and MRI 580
- electroretinography 578
- fluorescein angiography 578, 580, 580
- interpretation 573–577
- ophthalmoscopy (direct/indirect) 570, 571, 572
- optical CT 578, 579
- smartphone ophthalmoscopy 572, 573
- ultrasonography 105, 106–107, 577, 578
- visual evoked potentials 578
- future research 608
- histology 570
- injury, blunt trauma 325, 606–608, 607
- lesions, in posterior ERU 459
- ocular angiography 124–125
- in ocular trauma 606–608
- surgery 566, 608
- trauma 325, 606–608, 607
- see also* choroid; fundus; retina; sclera
- posterior segment diseases 580–606
- inheritance 565
- neoplasia 606, 607
- prevalence 565
- significance/impact of 565
- posterior synechia *see* synechia, posterior
- posterior tunica vasculosa lentis (TVL) *see* hyaloid artery
- posterior uveitis *see* uveitis, posterior
- postganglionic lesions 215
- postganglionic neurons 215, 218, 303
- parasympathetic nervous system 699
- sympathetic nervous system 699, 700
- post-inflammatory strictures, muscle, strabismus due to 140–141
- post-retinal visual deficits, neurologic causes 704–708
- potassium, in hyperkalemic periodic paralysis 758
- povidone-iodine 374, 392
- PPIB gene 680
- PPID *see* pituitary pars intermedia dysfunction (PPID)
- PPM *see* persistent pupillary membrane (PPM)
- Prascend pergolide tablet 762
- precorneal tear film (PTF) 189, 253–256
- albumin 364
- anatomy 253, 254–255
- aqueous layer (middle) 254, 254
- decreased production, effect 255–256
- production 191
- assessment 256
- closed eye 253–254
- components 253, 254, 254–255, 364
- disorders/abnormal, staining 36, 37, 38, 361
- disruption/loss 255–256
- ulcerative keratomycosis 363, 363
- distribution over cornea 305
- drainage, normal 190
- fluorescein staining 35, 35–36
- foreign body in 327
- formation/production 187, 191, 218
- function 253, 254, 255, 256, 261
- defense/barrier role 339
- immune surveillance, impairment 256
- instability 305
- fungal-associated 360, 360–361, 361
- fungal keratitis pathogenesis 358
- rose bengal staining 361
- layers 254, 254–255
- lipid layer (outer) 254, 254
- secretion 189
- mucus layer (inner) 254, 255
- formation 191
- instability, rose bengal retention 361
- mucin defect, rose bengal staining 36, 37
- mucins 255
- poor structure, keratoconjunctivitis sicca 304
- proinflammatory/angiogenic molecules 262
- proteases, elevated 267, 269
- in bacterial infection 355
- qualitative deficiency 303
- quantitative deficiency 303
- see also* keratoconjunctivitis sicca (KCS)
- replacement frequency 253
- rose bengal staining 36–37, 38, 361
- stability 254
- testing 35–36
- Thelazia lacrymalis* in 322, 322
- topical drug administration 273
- volume and thickness 253
- predescemetocytes 270, 350, 350, 352
- prednisolone
- adnexal lymphosarcoma 237
- equine recurrent uveitis 477, 478
- preganglionic fibers 215, 218, 303
- parasympathetic nervous system 698–699
- sympathetic nervous system 699
- preganglionic lesions 215, 216, 709
- premelanosome protein (PMEL) 671
- gene mutation 586, 671
- premelanosome protein 17 (PMEL17) 276
- premolars 137, 180
- prepurchase examination 1, 76–79, 77
- guidelines 77
- ocular reflex testing 77
- ophthalmic portion 77
- pupil dilation and 77
- report 77–79, 78
- significance of findings 78, 78
- prescription drugs
- performance horses 794
- see also* drug(s)
- presphenoid bone 693
- pretectal olivary nucleus (PON) 698
- primary epithelial disease 305–306, 306
- secondary disease vs. 305
- primary neuroectodermal intraocular tumors 450
- primitive neuroectodermal tumor, retinoblastoma 606
- procaine penicillin, orbital disease 164
- prognathism 180
- prolapse
- iris *see* iris prolapse
- nictitans gland 219
- orbital fat *see* orbital fat
- third eyelid *see* third eyelid (nictitans; nictitating membrane)
- uvea 151, 515, 607
- proliferative optic neuropathy (PON) 602, 603
- promoters 664
- pro-opiomelanocortin-derived (POMC) peptides 759
- proparacaine 10, 12–13
- proptosis, orbital *see* orbital proptosis
- prostaglandin analogs, glaucoma 555, 556
- prosthesis 177–178
- black 175, 178, 179
- corneal-scleral 177, 177, 178, 179
- hydroxyapatite orbital implant 152, 177, 177–178, 178, 179
- intraocular 152
- intrasceral *see* intrasceral prosthesis (ISP)
- preparation 178, 179
- see also* implants
- proteases 262
- corneal 267
- elevated, corneal stroma/tear film 267, 269
- microbial/host-derived 339
- in ulcerative keratomycosis 377
- proteoglycans 258, 259
- proton density (PD) 95, 97

- protozoal disease
 blepharitis and conjunctivitis **203**
 myeloencephalitis *see* equine protozoal myeloencephalitis (EPM)
 systemic 721–723, 747–749
- Pseudomonas* (spp.)
 antibiotics for 354
 corneal ulcers 339, 343, 354, 357
 keratitis 262
 melting ulcer 340
- Pseudomonas aeruginosa* 255, 339
 antibiotic sensitivity 354
 exotoxins/endotoxins 339
- “pseudo-polycoria” 449
- pseudoptosis 205
- pseudotumors
 conjunctival 237–238, 238
 orbit 159
- ptaquiloside 767
- Pteridium aquilinum* (bracken fern) toxicity 767
- pterygium burr 395
- pterygoid canal 218
- pterygopalatine ganglion 303, 715
- pterygopalatine nerve, anatomy 697
- ptosis 215
 bilateral, grass sickness
 (dysautonomia) 732–733
 evaporative keratopathy and 303
 facial nerve paralysis 217, 217
 Horner’s syndrome 215, 215
 temporohyoid osteoarthropathy 735
- pulmonary adenocarcinoma 163, 487, 606
- punch biopsy 55
- punctum (puncta)
 lower eyelid, cannulation 62
 see also lacrimal puncta; nasal puncta;
 nasolacrimal puncta
- pupil 441
 asymmetry 708
 bright light 645, 646
 constriction 23, 625, 625
 anatomy 698
 disparity 25
 parasympathetic system role 698, 699
 pupillary light reflex 701
 spherical aberrations 642
- corpora nigra cysts occluding 447, 447
- dilated, in glaucoma 549
- dilation 14, 14
 in aniridia 444
 induction, time for 14
 light adaptation 623
 mechanism 698
 parasympathetic system role 698, 699
 prepurchase examination 77
 stressful environments 701
 uveitis control in corneal ulceration 355
 see also mydriasis
- direct response to light 23, 623, 625, 625
- division into segments, in bright light 625, 625
- examination 28, 32
- fixed dilated 549, 603
- horizontal elongation, vision in dim light 623
- indirect (consensual) response to light 23
- large, spherical aberrations 642
- normal 24
- obstruction, secondary glaucoma 548
- parasympathetic innervation regulating response 698, 699
- position 623, 645
- pupillary light reflex *see* pupillary light reflex (PLR)
- reciprocal innervation 698
- at rest 646
- shape 623, 623, 645
 low light intensity 23, 623
 optical consequences 625, 645–646
- size
 assessment 23
 changes, with light intensity 622, 622, 625, 625
 diffraction impact 642
 range 622, 622
 spherical aberrations and 642, 645
 unequal (anisocoria) 23, 25, 708–709
 visual acuity affected by 637, 645
- symmetry 25
 assessment 23
 sympathetic regulation of response 698
- two segments, constriction 625, 625, 642, 646, 646
- pupillary apertures, multiple 645, 646, 646
- bright light and 645, 646
- pupillary escape 23
- pupillary light reflex (PLR) 151, 701–702
 assessment 701–702
 bilateral, lesions and 704
 cataract evaluation 517
 chromatic 701, 715
 consensual (indirect) 23–25, 151, 701
 absent 151
 cortical vs. subcortical lesions 704
 diphasic 701
 direct 23, 701
 evaluation 23–25
 factors reducing 702
 neuroanatomic pathways 698, 699
 in optic nerve abnormalities **598**
 pupil symmetry examination 23
 qualitative 701
 reduced/absent 151, 702, 704
 bacterial meningitis in neonatal foals 770
- pupillary membrane 446
 persistent *see* persistent pupillary membrane (PPM)
- Purkinje cells 701
- Purkinje–Sanson reflexes 16, 16, 29
- Purkinje shift 620, 620
- purpura hemorrhagica 743, 744
- pyogranulomas, *Rhodococcus equi* infection 772, 772, 773
- pyrantel toxicosis 707
- pyrexia, screening, infrared thermography 116
- pyrimethamine 723
- pyrrolizidine alkaloids 767
- pythiosis 157
- q**
- Qa factor, antibodies 771
- quarantine 139
 equine infectious anemia 739
- Quarter Horse
 aniridia 444, 679
 congenital cataracts 501, 501, 678
 HERDA in 47, 757
 hyperkalemic periodic paralysis 680
 lymphoma, ocular manifestations 763, 763
 nuclear cataracts 512
 optic disc colobomas 598, 599
 pemphigus 755, 756
- QuikVue camera 22, 23
- r**
- rabies 728–729
 clinical signs 728, **728**
- racehorses
 enucleation, effect 793–794
 injuries and fatalities 793
 medication and testing 792–793
 ophthalmic disease, regulations 794
 ophthalmic lesion, frequency 74
 regulations 794, **795**
 regulatory agencies 792–793, **793**
 vision 793
 see also performance animals
- Racing Medication and Testing Consortium (RMTC) 792–793, **793**
- radiating glia 691
- radiation
 cell damage mechanisms 287
 safety, equipment 93
- radiation-induced keratopathy 287–288
- radiation therapy (radiotherapy)
 corneal SCC 293–294, **296**
 sarcomas 226
- radiofrequency hyperthermia
 adnexal SCC 232
 corneal SCC 294, **295**
- radiofrequency (RF) pulse 95
- radiography
 CT vs. 92, 94
 depression fractures 92, 92
 digital systems 59, 61
 in the field 59, 61
 globe perforation 151
 indications 59
 ionizing radiation exposure risk 92
 limitations 92
 periocular, positioning for 61
 periostitis 159
 sinusitis 160
 skull *see* skull radiography

- radiology 90–92
 - contrast, in the field 61
 - see also specific modalities*
- radiotherapy *see* radiation therapy
- “ramp retina” 644
- ramus communicans 699
- random assortment 664
- random X chromosome inactivation 664
- RCGs *see* retinal ganglion cells (RGCs)
- rebound tonometry 43, 44, 44–45
- reciprocal innervation 698
- rectus muscle 136
 - anterior, attachments 140
 - avulsion 140, 141
- red eye 203
 - acute anterior uveitis 452
 - see also conjunctivitis*
- red-green color deficiency 652
- red maple (*Acer rubrum*) ingestion 768
- red nuclei, midbrain 701
- red wavelength-sensitive cones 651
- reference ranges, ophthalmic tests 9
- referral institutions
 - head support for ocular examination 9
 - ocular examination 2
- reflexes *see individual reflexes*
- refracting surfaces of eye 639
- refraction, aspheric 639
- refractive error 40
 - absence (emmetropia) 639
 - aphakic equine globe 518
 - correction 639
 - cylindrical 642
 - extent, expression 639
 - hyperopic 639
 - myopic 639
 - prevalence/frequency 639
 - visual acuity affected by 637
- refractive index 15
- refractive state, visual acuity 639–642, 641
 - assessment, retinoscopy 39–40, 639
 - cataract surgery 537
 - resting 639–640
 - estimating 641–642
- refractive status, accommodation 644
- regional akinesia 11–12
- regional analgesia 11–12
- regulations
 - ophthalmic disease in performance horses 794
 - medications 796, 796–797
 - USEF rules 794, 795–796
- regulatory agencies 792–793, 793
- reining, blind horses 815
- relative brightness 633
- relative velocity, depth perception 634
- reportable disease 729, 739
- respiratory epithelium, adenocarcinoma 163, 487, 606
- restraint, for examination 9–11, 10
- retina 444
 - abnormalities 566
 - in acute uveitis 453
 - anatomy and physiology 566, 691–693, 692
 - appearance in chorioretinitis 587
 - autoantigens, immune response in ERU 463, 464, 465, 467, 468, 590
 - blood vessels *see* retinal vessels
 - brain processing of information and 617, 617
 - CD4+ lymphocytes in ERU 463, 464, 465, 466, 590, 672
 - cell types 566
 - central
 - color vision 652
 - motion detection 625–626
 - damage, elevated IOP effect 545
 - degeneration *see* retinal degeneration
 - depigmentation 33, 579
 - duplex (rods and cones), light adaptation 620
 - in equine recurrent uveitis 463, 466–468
 - examination 20, 32–33, 566
 - see also* electroretinography (ERG)
 - factors affecting visual acuity 646–648
 - function, disruption 453
 - gray linear folds 587, 588
 - histology 570, 692
 - image stabilization, during movement 626, 627
 - indirect ophthalmoscopy 570
 - inflammation 588
 - see also* chorioretinitis
 - layers 570, 691, 692, 692
 - neuroprotection, reduced in ERU 467
 - neurosensory *see* neurosensory retina (NSR)
 - nonapetal, hyperpigmentation 595, 595
 - object stabilization 626
 - optical coherence tomography (OCT) 122, 122
 - peripapillary
 - in active chorioretinitis 588
 - degeneration, after trauma 764
 - elevated, optic neuritis 605
 - peripheral 625
 - MCOA syndrome 671
 - pigment epithelium *see* retinal pigment epithelium (RPE)
 - protection in bright light 623
 - “ramp” 644
 - reattachment, folds/wrinkles 592
 - Snellen acuity and 637
 - tapetal
 - depigmentation 595, 595
 - pigment in, EMND 597, 597
 - tear 325
 - thickening 573
 - thickness 122
 - trauma 607
 - ultrasound 103
 - vascularization (paurangiotic) 33, 568, 569
- retinal astrocytes 691
- retinal atrophy 584
 - progressive 595
 - Pteridium aquilinum* (bracken fern) toxicity 767
- retinal blood vessels *see* retinal vessels
- retinal degeneration 522, 579, 595–596
 - blood loss causing 603, 604
- causes, and breeds associated 595
- after chorioretinitis 587, 589
- clinical appearance 595
- peripheral cystoid 595
- Pteridium aquilinum* (bracken fern) toxicity 767
- senile 596, 596
- treatment and prognosis 595, 596
- retinal detachment 592–595
 - bullous 592, 592, 593, 594
 - focal 593
- cataracts and 578, 594
- cataract surgery complication 534, 535
- causes 592
- chronicity 107
- clinical appearance 593, 593–594
- complete 592, 593, 594, 595
- congenital 584–585
- foals 593
- in MCOA syndrome 585, 585
- partial 592, 593, 594
- peripapillary 589, 593
- posterior ERU 459, 460, 461, 470
- prognosis 595
- reattachment 592, 594
- reattachment surgery 608
- rhagmatogenous 585, 592
- subretinal space examination 107
- traction 593, 594
- trauma causing 607
- treatment 594–595
- ultrasound 101, 107, 108, 577, 578, 594
- unilateral or bilateral 592
- retinal disinsertion 593
- retinal disorders 582–598
 - histopathology 584
 - lesions, visual deficits, neurologic causes 704–708
- retinal dysplasia 583–584, 704
 - clinical appearance 583–584
 - congenital 584
 - in MCOA syndrome 584, 585
- retinal eccentricity, visual acuity affected by 637
- retinal ganglion cells (RGCs) 570, 691
 - afferent pathway and 698
- axons
 - decussation at optic chiasm 693
 - nerve fiber layer 692, 692
- damage by elevated IOP 546
- decussation, optic chiasm 698
- density 566, 646, 647
 - visual streak 646, 647, 647
- in glaucoma 546
- intrinsically photosensitive (iRGCs) 692, 701
- IOP resistant 546–547
- light adaptation 622
- melanopsin-containing 692, 694
- number 647
 - in optic nerve 647, 693
- in optic tract 694
- in peripheral retina 625
- types 647
- in visual streak 566

- retinal hemorrhages 202, 582–583
 - foals 577, 582, 583, 583
 - focal 583
 - in pars plana vitrectomy in ERU 484
 - punctate 582, 583, 583
 - secondary 583
 - trauma causing 607
 - retinal image
 - blurring 639
 - accommodation mechanism 644, 645
 - movement, optokinetic system and 627
 - objects in front/behind plane of focus 646
 - retinal lesions, visual deficits, neurologic
 - causes 704–708
 - retinal Mueller glial cells (RMG) 463, 467
 - dysfunctional, in ERU 463, 467
 - fibronectin and osteopontin 467
 - role, potassium/water homeostasis 467
 - see also* Müller cells
 - retinal nonattachment 584, 584
 - retinal pigment epithelium (RPE) 566, 573
 - albinism 574
 - cell migration, in chorioretinitis 590, 591
 - ceroid/lipofuscin accumulation 724, 725
 - colobomas 580, 599, 600
 - complement factor B expression 465
 - depigmentation 33, 579
 - equine motor neuron disease 597, 597
 - equine recurrent uveitis 466, 469, 469–470
 - examination interpretation 573
 - function 592
 - hyperplasia, in chorioretinitis 590
 - hypertrophy, after trauma 604
 - neurosensory retina separation *see* retinal detachment
 - over tapetal retina 574, 576
 - periphery of tapetum 574, 575, 576
 - pigment streaks, in MCOA syndrome 585, 585
 - proliferation, MCOA syndrome 585, 585
 - serofibrinous exudate, ERU 469, 469
 - “window defect”, coloboma 599, 600
 - retinal reattachment surgery 608
 - “retinal slip” 629
 - retinal tears
 - giant 593, 594
 - management 594–595
 - retinal detachment association 592
 - trauma causing 607
 - retinal vessels 568, 568, 569
 - direct ophthalmoscopy 570
 - examination 571
 - paurangiotic 33, 568, 569, 576
 - retinitis, focal 588
 - retinitis pigmentosa 637
 - retinoblastoma 606
 - retinopathy
 - pigment 597
 - senile 596, 596, 759
 - retinoscopy 39–41
 - fundic reflex movement 40
 - indications/use 39–40
 - neutralization 40
 - refractive state assessment 39–40, 639
 - spot 40
 - streak 40
 - technique 40, 40
 - retirement of horses, after enucleation 794
 - retractor anguli oculi muscle 189, 190, 190
 - retractor bulbi muscle 136, 136, 697
 - corneal reflex 703, 703
 - function, retained in facial nerve paralysis 217
 - spasm, in hyperkalemic periodic paralysis 758
 - retrobulbar disease, exophthalmos due to 144
 - retrobulbar masses 28
 - differential diagnosis 108
 - episcleral vessel enlargement 148
 - parasitic infections causing 158
 - ultrasound 101, 108
 - retrobulbar nerve block 14, 165
 - cataract surgery 524
 - enucleation 170
 - indications/uses 170
 - methods 170
 - third eyelid surgical therapy 220
 - retrobulbar optic cone, compression 147
 - retrochiasm pathways 693–694
 - retrocorneal fibrous membranes (RCFMs) 123, 284–285, 285, 455–456
 - in heterochromic iridocyclitis with keratitis 456
 - after non-lacerating blunt trauma 331
 - retrocorneal membranes, in deep stromal
 - abscesses 415
 - retro-illumination 16, 17
 - lens examination 32
 - posterior segment examination 33
 - slit-lamp biomicroscopy 18
 - retropharyngeal swelling, strangles 743
 - reverberation artifact 327
 - rhabdoid tumor, orbital 163
 - Rhinosporidium seeberi* 206
 - Rhodococcus equi* 771, 773
 - Rhodococcus equi* infection 771–773
 - anterior uveitis 772, 772
 - chorioretinitis 592
 - clinical signs 772, 772
 - diagnosis 773
 - foals 771–773, 772, 772
 - prognosis 773
 - retinal detachment 593
 - treatment 773
 - rhodopsin 620, 623
 - vitamin A for 764
 - riboflavin (vitamin B2) 356
 - ribonucleic acid (RNA) 664
 - ricketsial diseases, systemic 743–747
 - riders, deaths 793
 - “Ride with Pride” program 814, 814
 - riding, blind horses 810, 813, 813, 817
 - dressage horses 813, 814, 815, 815
 - unilateral sight loss horses 816
 - riding aids, blind horses 810
 - rifampin, *Rhodococcus equi* infection 773
 - RMG *see* retinal Mueller glial cells (RMG)
 - RNA (ribonucleic acid) 664
 - Robinia pseudoacacia* (black locust trees)
 - toxicity 767
 - Rocky Mountain horses
 - congenital cataracts 501
 - corneal measurements 256, 257
 - corneal SCC 288
 - DDDB2* gene and SCC 676
 - glaucoma 548
 - iris coloboma 449
 - MCOA syndrome 448, 670, 670, 671
 - megalophthalmos 146
 - silver coat color 670, 670
 - rods 566
 - density 647, 648
 - in dim light 620, 691
 - function 566, 691
 - light intensities, adjusting to 620
 - loss, in ERU 469, 470
 - number 647–648
 - numerous in horse 42
 - in photoreceptor layer 691
 - scotopic state of eye, in ERG 41–42
 - spherical aberrations and 642–643
 - visual acuity 638
 - Romanowsky-type stains 50, 52
 - romifidine, effect on IOP 45
 - rose bengal staining 35, 36–38, 37, 256, 304
 - fungal-associated PTF instability 360, 361
 - indications for use 36–37
 - strips/solution and application 36
 - rostral alar foramen 134, 134, 697, 698
 - rostral colliculus 703
 - rostral maxillary sinus (RMS) 138
 - trephination 138, 179
 - rostral medulla oblongata *see* medulla oblongata
 - rostral salivary nucleus (RSN) 700
 - rotational horse falls 793
 - RPE *see* retinal pigment epithelium (RPE)
- S**
- saccades 626, 628
 - sacrocaudalis dorsalis muscle
 - biopsy, polyneuritis equi 737
 - neurogenic atrophy 725
 - Saddlebred horses, USEF rules 796
 - sampling
 - for culture 47–48, 48
 - for cytology 48–50, 49
 - Sarcocystis neurona* 217, 721
 - sarcoids 220–226
 - aggressive, frontal bone invasion 221
 - breeds associated 221, 222–223
 - clinical appearance 221
 - diagnosis 221
 - differential diagnosis 221–222
 - fibroblastic 221, 222
 - genetic predisposition 222–223
 - locations 221
 - long-term prognosis 226
 - malevolent/malignant 221
 - methods for definitive diagnosis 221–222
 - mixed 221, 222

- sarcoids (*cont'd*)
 nodular type A, and B 221, 221
 occult 221, 221
 pathogenesis/progression 222
 postoperative appearance 224
 prognosis 223, 226
 recurrence 220, 221, 223, 224, 226
 treatment 223–226
 autologous vaccination 225
 brachytherapy 223, 226, 226
 chemotherapy 223, 224, 225
 cryotherapy 225–226
 electrochemotherapy 225
 hyperthermia 226
 immunotherapy 223, 224–225
 intralesional BCG 224–225, 225
 medical 223, 224
 surgical 223, 223–224
 topical therapy 223, 224
 verrucose 221
- sarcoma, anaplastic 161
- sarmazenil 767
- scalpel blade, blunt end, for samples 48, 49
- scars/scarring
 bullet-hole *see* bullet-hole lesions/scarring
 chorioretinal *see* chorioretinal scars/scarring
 corneal *see* corneal scarring
 eyelid, in eyelash disorders 209, 210
 formation, HERDA 757, 757
 reduction, amniotic membrane role 400
- SCC *see* squamous cell carcinoma (SCC)
- Scheiner's disc 646
- schematic eye 641–642
- Schiotz tonometer 43
- Schirmer tear test (STT) 33–34, 256
 borderline and abnormal values 33
 in facial nerve paresis/paralysis 712
 foals, values 33
 HERDA 758
 indications 33, 34
 keratoconjunctivitis sicca 34, 198, 304
 method 33, 34
 normal values 9, 33, 34, 198
 normal variability in values 34
 STT I 34, 304
 keratoconjunctivitis sicca 304
 normal values 34, 198
 STT II 34, 198, 304
 keratoconjunctivitis sicca 305
 temporohyoid osteoarthropathy 735
- Schlemm's canal, absence in horses 544
- schwannoma 222, 606
 optic nerve 598, 602
- scintigraphy, sinusitis 160
- sclera 134
 anatomy 573
 closure, after evisceration 175
 elevated IOP effect 545
 examination 29–30
 exposure, examination 11, 11
 icteric 29
 equine granulocytic anaplasmosis 747
- toxic plants causing 767, 768
- inner surface 442
- lamina cribrosa *see* lamina cribrosa
- orange tinge 29
- perforation 150
- rupture 134, 150, 205
 trauma causing 607
- thickness 134
- ultrasound biomicroscopy 114
- transposition 399–400
- ultrasound 103
- scleral-based incision, cataract surgery 527
- sclerocornea 276, 276
- sclerotomy, in pars plana vitrectomy in ERU 483
- SCN4A gene 680
- S cone (short; blue wavelength-sensitive cone) 651
- scopolamine 768
- Scopulariopsis* spp. 358
- “seagull” sign 578, 595
- sebaceous glands, eyelids 188, 188–189, 191
- seclusio pupillae 520
- secondary reinforcement (S-RF), blind horses
 training 810
- secretory IgA (sIgA) 255
- secretory leucocyte protease inhibitor (SLPI) 254–255
- secretory phospholipase A₂ 254
- sector iridectomy, in melanoma 486, 486
- sedation
 effect on IOP 45
 for enucleation 170
 for examination 7–9, 10
 for fine-needle aspiration 54
 for periocular radiography 61
 Schirmer tear test (STT) values 34
 for slit-lamp biomicroscopy 18
 standing *see* standing sedation
 for subpalpebral lavage (SPL) system 65
 for tonometry 45
 for ultrasound 104
- sedatives, in ocular examination 9, 10
- seeing 616–618, 655
 brain in 616, 617, 617, 618
 in context 616
 information overload 618
 information processing 617
 visual attention interference, trauma 618
 light/dark perception by horses 616
 object as separate from surroundings 618, 619
 a perception 616
 process/steps in 617, 617–618
see also vision
- Seidel test 36, 38, 150
 AH leakage 36, 38, 38, 150
 bacterial corneal ulceration 350
 conjunctival grafts 395, 397
 corneal laceration 38, 38, 332–333, 333
 direct corneal suturing 393
 iris prolapse surgery 418
see also fluorescein stain/staining
- seizures 734
- selenium deficiency 158
- selenium supplementation 158
- “self-sacrificing dressing” *see* amniotic membrane
 transplants (AMT)
- semicircular canals 695
- senile cataracts 507, 507, 509
- senile retinal degeneration 596, 596
- senile retinopathy 596, 596, 759
- sensory deprivation, “crossmodal” sensory
 processing 801–802
- sensory nerve block, enucleation 170
- sensory nerve supply, eye/surrounding area
 697–698
- sensory processing, “crossmodal” 801–802
- separation anxiety 8
- sepsis
 anaerobic 153
 neonatal 768, 768–770, 769
 bacterial meningitis and 770
 clinical signs 768, 768–769
 “negative” scores 769
 prognosis 769, 770
 scoring systems 769
 treatment 769
- septin 7 464
- sequestrae, corneal 283–284, 284
- serine proteases 267, 339, 355
- serum
 collagenolysis inhibition in corneal bacterial
 infection 353, 355–356
 production and administration 356
- serum amyloid A (SAA)
 equine protozoal myeloencephalitis 723
 habronemiasis 753
- serum proteins, equine recurrent uveitis
 (ERU) 465–466
- Setaria* 753, 753
 clinical signs 753, 753
- Setaria digitata* 753
- Setaria equina* 753
- severe combined immunodeficiency (SCID)
 223, 681
 breeds, inheritance, gene variants 663
- sex chromosomes 664
- shadows, contour/areas 633
- Shetland Pony, USEF rules 796
- short ciliary nerves 699
- short (blue wavelength-sensitive: S) cone 651
- short full thickness eyelid defects *see* coloboma
- signage, stalls/paddocks of blind horses 803
- signal gain 621
- silicone-coated intravitreal devices, in ERU 480
- silicone matrix cyclosporine A delivery
 devices 274
 immune-mediated keratitis 313
- silicone prosthesis, intraocular, blunt trauma 607
- silver (chocolate) coat color 585, 670, 670
 breeding advice 672, 811
 gene involved 671–672
- silver dapple gene 146
- silver* gene 671
- silver sulfadiazine 374, 376
- simple hyperopic astigmatism (SHA) 639

- simple myopic astigmatism (SMA) 639
- single nucleotide polymorphism (SNP) 665
- sinocentesis 160
- sinonasal disease 159–164
 - neoplasia 161
- sinonasal transitional carcinoma 96
- sinoscopy, sinusitis 159–160
- sinus(es)
 - radiographic evaluation 91
 - trauma 149
 - skull radiography 92
 - trephination 178–180
- sinusoscopic lavage 160
- sinus cysts 160
- sinus diseases 139, 159–164
 - neoplastic *see* sinus neoplasia
 - trephination 138, 179
- sinus flap surgery 180
- sinus fracture 169
 - emphysema 147
- sinusitis 158, 159–160
 - causes 159
 - clinical appearance 159
 - dental disease-associated 160, 180
 - diagnosis 159–160
 - optic nerve atrophy 600
 - primary, compressive optic neuropathy 706
 - treatment and prognosis 160
- sinus neoplasia 160–161
 - bone deformation 147
 - clinical appearances 160–161
 - diagnosis, treatment, prognosis 161
- sinusotomy 160
- sinus percussion 147, 149
- sinus trephination 160
- size
 - depth perception 633
 - understanding of concept 648
- skiascopy *see* retinoscopy
- skiascopy bar 40, 40
- skin
 - depigmentation *see* depigmentation
 - hair types 187, 188, 188
- skin disorders, systemic 754–757
- skin expanders 177, 177
- skin flaps/grafts
 - after radical resection of eyelid skin 177
 - split-thickness, sarcoid surgical excision 224
- skin neoplasia *see* melanoma; sarcoids
- skull, anatomy 133–134, 135, 693, 693
- skull fractures 169, 304
 - basilar 764, 765
 - closed displaced 169
 - CT and MRI 765
 - depressed 169
 - open (acute) 169
 - periobital, radiography 92
 - radiography 92
 - secondary meningitis after 765
 - surgery 169
 - treatment and prognosis 765
 - unstable, movement 169
- skull radiography 90–92, 91
 - CT dacryocystorhinography vs. 100
 - digital equipment 90, 92
 - indications 92
 - normal 91
 - sinus and nasal cavity neoplasia 161
 - trauma 92
- “skyline” radiograph 91, 92
- “sleazy/sleezy or slinky” 70, 70
- slit-lamp 17, 18
 - portable monocular 18, 18
- slit-lamp biomicroscopy 17–18, 18
 - corneal examination 16, 18, 29
 - corneal foreign bodies 329, 330
 - corneal ulceration healing 342
 - glare effect, light scattering 644
 - iris examination 32
 - lens lesions 32
 - safety precautions 18
 - sedation and nerve blocks 18
- Smad7 gene, overexpression 418
- smartphone 4
 - eye examination 14, 22–23, 23
 - eye imaging adaptor 22
 - ophthalmoscopy 22–23, 23, 572, 573
 - photography of ocular region, in the field 58, 58, 59
- smartphonoscopy 572, 573
- smell, blind horses 803
- smooth-pursuit movements 626, 628–629
 - moving, or stationary objects 629
- sneeze reflex, photic (human) 715
- Snellen eye chart 635–636, 637, 637, 639
- Snellen value 640
- Snellen visual acuity 637
- sodium channel
 - alpha-subunit, gene mutation 680
 - hyperkalemic periodic paralysis 758
- sodium EDTA, subepithelial mineralization therapy 282
- sodium fluorescein 35–36
 - angiography 125
 - tear film staining 35, 35–36
 - see also* fluorescein stain/staining
- sodium ions, transport 443
- sodium/potassium ATPase pump 453
- soft-tissue damage, orbit, management 169
- solanine 768
- Solanum* plant toxicity 767
- somatomotor nucleus, of oculomotor nerve 696
- sound waves, ultrasound 101
- space-occupying lesions, orbital 161–163
 - elevation of third eyelid 146, 219
- Spanish Trotter Horse racing 117
- spastic entropion 199, 211
- spatial discrimination 648
- spatial information, processing in blind subjects 802–803
- spatial summation 622
- spectral-domain optical coherence tomography (SD-OCT) 47, 121, 121, 704
- corneal thickness measurements 47, 122, 256–257
- future research 715
- handheld, neuro-ophthalmic disorders 715
- normal cornea 122
- posterior segment examination 578, 579
- post-retinal visual deficits 704
- specular microscopes 117
- specular microscopy 117, 117–118
 - noncontact 117
- sphenoid bone 134
- sphenopalatine sinuses 139
 - compressive optic neuropathy and 706
 - CT 94
 - drainage 139
 - infection 139
 - optic nerve atrophy 600
- sphenopalatine sinusitis, infectious 159
- spherical aberration 642, 642
 - positive and negative 642
- spherophakia 503
- spinal cord damage 764
- SPL *see* subpalpebral lavage (SPL) system
- splicing (gene) 664
- spot retinoscopes 40
- squamous cell carcinoma (SCC) 226, 675–676
 - actinic blepharitis as precursor 208
 - adnexal *see* adnexal squamous cell carcinoma
 - breeds, prevalence 662, 675
 - corneal *see* corneal squamous cell carcinoma
 - corneolimbic *see* corneolimbic squamous cell carcinoma
 - eyelid *see* eyelid disorders
 - frequency 226
 - gene variants 662, 676
 - Haflinger horse *see* Haflinger horse (Avelignese horse)
 - inheritance mode 662
 - limbal *see* limbus, squamous cell carcinoma
 - medial canthus 228
 - orbital 161, 161
 - pathogenesis 288–289
 - periocular 233, 675
 - periosteum containing 134
 - prevalence 675
 - sites 675
 - third eyelid *see* third eyelid (nictitans; nictitating membrane)
 - UV radiation association 675
- squeeze procedure 770
- stable-management practice, ERU reduction 476, 476–477
- staining, cytology samples 50
- standing horses
 - CT for 93, 94
 - electroretinography (ERG) in 41, 42
- standing sedation
 - corneal surgery 391
 - deep lamellar endothelial keratoplasty 414
 - enucleation 170
 - orbital foreign bodies 154
 - posterior lamellar keratoplasty 412

- standing sedation (*cont'd*)
 - sinus cyst resection 160
 - sinus trephination 178
 - superficial keratectomy 394
- standing surgery
 - dental 180
 - enucleation 170
 - sedation for *see* standing sedation
 - sinus flap surgery 180
 - sinusotomy 160
 - sinus trephination 178
- Staphylococcus* (spp.)
 - corneal/conjunctival surface microflora 263
 - corneal ulceration 343
 - infectious keratitis 339
 - melting ulcer 340
 - stromal abscesses 387
- Staphylococcus aureus* 255
 - adherence to epithelium 339
 - phagocytosis resistance 339
- staphyloma, congenital 277
- star gazing 140, 586, 586
- stars of Winslow 33, 443, 444, 566, 570, 574, 576
- STAT proteins 466
- stem cell(s)
 - cornea 258, 259
 - limbal 258, 269, 407–408
 - markers 258
 - mesenchymal 465
- stem cell response, limbal 258
- stem cell transplant, mesenchymal *see* autologous mesenchymal stem cells (MSCs)
- stereoaquity 635, 648
- stereomovement 635
- stereopsis (binocular depth perception) 633, 634–635, 793
- Stevens tenotomy scissors 231
- St John's wort (*Hypericum perforatum*) 767–768
- strabismus 139–141
 - acquired 140–141
 - causes 139–141
 - CNS infections/lesions 140
 - neurological 708–715
 - orbital neoplasia 162, 163, 601, 601
 - space-occupying lesions 139
 - trauma 140
 - in central vestibular disease 730
 - definition/description 139, 708
 - dorsomedial, in congenital stationary night blindness 586
- foals 140, 140
- neuromuscular (fixed) 708, 714
 - causes 708
 - direction 708
- persistent congenital 140, 141
- positional 708
 - equine protozoal myeloencephalitis 721, 722
 - peripheral vestibular disease 730
- rotational, in foals 140, 140
- ventral
 - orbital fracture causing 168, 168
- temporohyoid osteoarthropathy 735
 - ventrolateral 721
 - vestibular 708
- strangles 743–744
 - bastard 744
 - blepharitis 206
 - carriers 743
 - clinical signs 743, 743, 743
 - diagnosis 743
 - sequelae/complications 744
 - treatment 744
 - vaccination 744
- streak retinoscopy 40, 639
 - after cataract surgery 532, 537
 - resting refractive state 639–640
- Streptococcus* (spp.)
 - antibiotics for 354, 744
 - β -hemolytic species 339, 343
 - cataract surgery complication 534
 - corneal ulceration 343, 354, 357
 - infectious keratitis 339
 - stromal abscesses 387
- Streptococcus equi* 343
 - antibiotics for 744
 - blepharitis 206
 - corneal bacterial ulceration 343, 354, 357
 - guttural pouch empyema 164
 - M protein 744
- Streptococcus equi* subspecies *equi* 743–744
 - strangles due to *see* strangles
- Streptococcus equi* subspecies *zooepidemicus* 354
- Streptococcus equi* var *equi* 592
- Streptococcus zooepidemicus* 534
- Streptomyces* (spp.), corneal/conjunctival surface microflora 263
- Streptomyces natalensis* 375
- stress, assessment, infrared ocular thermography 117
- striae, after non-lacerating blunt trauma 330
- stromal abscesses 387–389
 - bacterial 387
 - causative microbial species 387–388
 - chronic, with secondary uveitis 387
 - clinical appearance 388–389
 - clinical course (waxing/waning) 388
 - corneal vascularization 388
 - deep *see* deep stromal abscess (DSA)
 - diagnosis 387, 389
 - increasing 388
 - differential diagnosis 389
 - etiology 387
 - familial/genetic predisposition 387
 - full-thickness 367, 387
 - medical therapy 390
 - fungal 366–368, 367–371, 387
 - deep *see* deep stromal abscess (DSA)
 - full-thickness 367
 - superficial 366–367, 367
 - treatment 389
- healing, signs 390
- infrared photography 114, 115
- medical treatment 389
- micropuncture hypothesis 387
- neutrophil chemoattraction 387–388
- optical coherence tomography 123, 124
- pathogenesis 387–388
- prevalence 388
- prognosis 391
- quiescent 388
- recurrence 388
- rupture 388
- satellite 369
- seasonality, frequency 387
- superficial 366–367, 367, 387
- surgical treatment 390–391
 - penetrating keratoplasty 391, 404, 404
- treatment 389–390
- ultrasound 104
- vision threatening 387
- visual outcome 391
- strontium-90
 - corneal SCC 293
 - radiation-induced keratopathy after 287
- structural variants (SVs) 665
- Sturge–Weber disease 148, 149
- stylohyoid
 - fractures 735
 - temporohyoid osteoarthropathy 735, 736
- subalbinotic coat color, tapetum 19, 569, 572
- subconjunctival hemorrhage 200, 202, 205
 - dorsal nasal bulbar 203
- subconjunctival injections 14, 73, 73–74
 - in corneal diseases 274
 - drug types and duration of effect 274
 - indications/advantages 274
- subconjunctival mass, orbital fat
 - herniation 154, 155
- subepidermal clefts 774
- subepithelial keratomycosis (SEK) 362, 362–363, 363
- subpalpebral lavage (SPL) system 64–72
 - after cataract surgery 509, 521, 521
 - choice of eyelid for insertion 64, 64–65
 - complications 71, 72
 - damaged tubing repair 71, 72
 - description 64
 - foals 65, 65
 - footplate 64, 65, 67, 71, 72
 - indications 64, 69
 - conjunctivitis treatment 205
 - corneal ulceration treatment 352–353
 - stromal abscess treatment 389
 - temporohyoid osteoarthropathy 736
- injection port assembly, steps 67, 68, 69, 69
- insertion 64, 65–67, 66, 66, 67, 68
- items required for 65, 65
- kits, and manufacturers 64
- lower eyelid insertion 64, 64, 65
- management 71, 72, 73
- manes, braiding 67, 68, 69

- medication delivery 67, 69, 273
 - patient positioning 65
 - preparation for insertion 65, **65**
 - protecting/covering 70, 70–71
 - removal 71–72, 73
 - repair 71
 - securing 65–67, **66**, 68, 69
 - sedation 65
 - treatment duration 67
 - treatment plan 69
 - treatment schedules 69
 - trocarn insertion 66, 67, 68
 - tubing leaks/holes 71, 72
 - upper eyelid insertion 64, 64, 65
 - subretinal edema 588
 - subretinal hemorrhages 582
 - substance P 260
 - sudomotor pathway 700
 - sulcus, orbitopalpebral *see* orbitopalpebral sulcus
 - sulfadiazine 723
 - sulfamethoxazole, nasolacrimal disease **196**
 - sulfur granules 315, 316, 322, 752
 - summer sores *see* habronemiasis
 - superficial keratectomy (SK) 394
 - amnion graft with 394, 400, 402
 - complications 394
 - conjunctival graft with 394
 - corneal SCC 297, 402
 - in idiopathic primary edema 279
 - indications 394
 - postoperative care 394
 - recurrent corneal erosion 338
 - standing sedation 394
 - stromal abscesses 390–391
 - supplies *see* equipment/instruments
 - suppressor of cytokine signaling-1 (SOCS1) mimetic peptide 478
 - suprachoroidal space 543, 544
 - supraciliary space 543, 544, 544
 - supraciliary trabecular meshwork 543
 - supraorbital block 11–12
 - supraorbital fat pad, bulging 759, 760
 - supraorbital foramen 13, 133, 135
 - supraorbital fossa
 - biopsy of orbital contents 139
 - bulging, African horse sickness 739, 739
 - distension 148, 157
 - fat 144
 - shrinkage 144, 145
 - supraorbital nerve 12
 - block 11–12, 13
 - see also* frontal nerve
 - surface, ocular *see* ocular surface
 - surfactant protein A (SP-A) 255
 - surfactant protein D (SP-D) 255
 - surgeon's knots 393
 - surgery *see specific procedures and indications*
 - surgical glue, iris prolapse 418
 - surgical planning, CT for 95, 95, 167–168
 - surgical site infections (SSIs), risk factors 170
 - Surgilube 104
 - suspensions (drug) 273
 - suture(s)
 - absorbable, corneal surgery 391
 - corneal 334–335, 391
 - temporary repair of entropion 200, 200, 200–201
 - sutureless techniques, amniotic membrane
 - transplant 402
 - suture lines, lens 513
 - swamp cancer *see* habronemiasis
 - sweat glands
 - innervation 700
 - modified (Moll-like) 189
 - swinging light (flashing) test 701, 702–703
 - sympathetic nervous system 214–215
 - denervation, enophthalmos associated 145
 - first-order neurons 699, 699
 - innervation of eye 698, 699, 699–700
 - postganglionic fibers 699, 700
 - preganglionic neurons 699
 - second-order neurons 699, 699
 - synaptotagmin-1 467, 587
 - synechiae
 - anterior 104, 524
 - iris prolapse surgery 417
 - iris–iris 509
 - posterior 104, 517, 518, 524
 - cataract surgery complication 534, 536
 - in chronic uveitis 455
 - in ERU 458, 459, 461, 462, 548
 - ultrasound 105
 - synophthalmia (unusual cyclopia) 142
 - systemic diseases, ocular manifestations
 - 721–791
 - bacterial 729, 731, 732, 743–747
 - blindness due to **723**
 - conjunctival disease due to **738**
 - dermatologic 754–757
 - endocrine 759–762
 - exophthalmos due to **740**
 - facial nerve dysfunction due to 721, **722**
 - fungal 724, 749–751
 - genetic 757–759
 - Horner's syndrome due to **722**
 - miscellaneous disorders 762–768
 - neonatal manifestations 768–774
 - see also* foals, neonatal
 - neoplasia 734–735, 762–764
 - neuro-ophthalmic 721–737
 - parasitic 733, 751–754
 - protozoal 721–723, 747–749
 - rickettsial 743–747
 - uveitis (anterior/posterior) due to **742**
 - viral 726–729, 737–743
 - systemic lupus erythematosus 756, **756**, 757
- t**
- tacrolimus (FK506), IMMK treatment 312
 - tactile sensory input, blind horses 803, 803
 - talin 1 465
 - tapetal reflexes 23, 25, 32, 33
 - tapetum 19, 33, 443, 444, 568, 573–574, 624
 - absence 443, 574
 - anatomy 568, 568–569, 569
 - of carnivores 623–624
 - color 33, 568, 569, 573–574
 - blue, blue-green 33, 574, 574, 575, 576
 - changes 33
 - yellow/green 33, 623, 624
 - color-dilute horses 569, 574, 576
 - color variations 569, 572, 574, 575, 576, 623
 - iris and coat color 574
 - constituents, and evolution 624
 - dim light vision 623, 624, 624, 655
 - examination 32–33
 - function 568–569
 - hemorrhages, foals 577
 - histology 570
 - hyperpigmentation 587
 - hyper-reflectivity **571**, 573, 584, 587, 595
 - hypoplasia 574, 575
 - hyporeflexivity **571**, 573, 588
 - light scattering 623
 - light wavelength reflected from 568–569, 623
 - normal 568, 569
 - periphery, RPE pigmentation 574, 575, 576
 - pigmented freckles, nevi 574
 - reflectivity 568, 623–624, 624
 - examination **571**
 - as reflector 623–624, 624
 - RPE pigmentation obscuring 574, 575
 - thickness, variations 574
 - undeveloped 19, 33
 - yellow 33, 574
- tapetum fibrosum 33, 568
- tapetum lucidum 623, 624, 624, 655
 - see also* tapetum
- targeted lamellar keratoplasty 402–407
 - procedures 403
- targeted posterior stroma transplantation 409–412
- target movement, visual acuity affected by 637
- tarsal glands *see* meibomian glands
- tarsal plate 188
 - defects 27
 - functions 188
- tarsopalpebral grafts 396
- tarsorrhaphy 165, 165
 - after facial nerve injury in trauma 154
 - indications 165
 - in orbital proptosis treatment 155–156
 - permanent partial, in facial nerve paralysis 217
 - temporary *see* temporary tarsorrhaphy
- tarsus *see* tarsal plate
- tattooing
 - cornea 175
 - eyelid, to protect from SCC 230
- T-cell(s) *see* T lymphocyte
- T-cell lymphoma 763, 763
- T-cell receptor 312
- tear(s)
 - artificial *see* artificial tears
 - fibronectin source 267
 - flow, course 191–192

- tear(s) (*cont'd*)
- flow through nasolacrimal duct 147
 - overflow *see* epiphora
 - production
 - circadian rhythm 305
 - glands 191
 - production, testing
 - phenol red threat test 34–35
 - Schirmer tear test 33–34
 - proteases, excessive 267
 - “tear catchers” 70, 71
 - tear-deficient keratopathies 302, 303–305, 304
 - diagnosis 304–305
 - management, prognosis 305
 - pathogenesis 303–304
 - see also* keratoconjunctivitis sicca (KCS)
 - tear film *see* precorneal tear film (PTF)
 - tear film breakup time (TFBUT) 35–36, 38, 46, 256
 - assessment method 46
 - keratoconjunctivitis sicca 305
 - normal reference range 9, 46
 - tear-deficient keratopathy 303
 - tear overflow *see* epiphora
 - tectonuclear axons 703
 - tectotegmental spinal tract 699
 - temperature
 - examination in field practice setting 3
 - eye 116, 117
 - physical fitness assessment 117
 - rectal temperature relationship 116
 - stress affecting 117
 - eye surface, infrared thermography 116, 116
 - temporal bone 133, 134, 135
 - trauma 764
 - zygomatic process fractures 167
 - temporal summation 622
 - temporary tarsorrhaphy 165, 165
 - conjunctival grafts 398
 - entropion 199, 200
 - facial nerve paresis/paralysis 217, 713
 - facial nerve trauma 154
 - hydroxyapatite orbital implant insertion 178
 - partial, after evisceration 175
 - penetrating keratoplasty 407
 - temporohyoid joint 735, 736
 - temporohyoid osteoarthropathy (THO) 304, 304, 735–736
 - clinical signs 735, 735, 735
 - diagnosis 735, 736
 - keratoconjunctivitis sicca in 304, 735
 - medical vs. surgical treatment 736
 - Tennessee Walking horses 587
 - aniridia 679, 679
 - CSNB cause in 670
 - Tenon's capsule
 - conjunctival graft 395, 396
 - in evisceration procedure 175
 - removal, conjunctival grafts 395, 396, 397
 - tension pneumocephalus 153
 - teratoid medulloepithelioma 450, 606, 606
 - terbinafine, keratomycosis 376–377
 - Tesla, unit 97
 - tetanolysin 731
 - tetanospasmin 731
 - tetanus 146, 731
 - bilateral third eyelid elevation 219
 - clinical signs 731, 731
 - tetanus antitoxin 731
 - tetanus vaccination 731
 - after enucleation 173
 - after eyelid laceration repair 212
 - sinus fractures 169
 - tetracaine, for examination 10
 - tetracyclines
 - cautions on IV use 165
 - corneal bacterial infection 355, 355
 - Lyme disease 745
 - orbital disease 165
 - for recurrent (chronic nonhealing) erosion 338
 - thalamus, anatomy 694
 - Theileria equi* (*Babesia equi*) 747
 - Thelazia lacrymalis* 206, 304, 320
 - intermediate host/vector 321
 - keratitis due to 320, 321, 322
 - in precorneal tear film 322, 322
 - therapeutics, ophthalmic 61–74, 615
 - goals 615
 - nasolacrimal duct irrigation 61–62, 62
 - topical medication *see* topical medication
 - thermal injury, corneal 323–324
 - thermokeratoplasty 279, 394, 395, 616
 - recurrent corneal erosion 338
 - thiaminases 767
 - thiamine deficiency 729, 729
 - third eyelid (nictitans; nictitating membrane) 2, 146, 147, 188, 191, 218
 - aberrant/ectopic cilia 219
 - anatomy 191, 191, 218
 - cartilage 191, 191
 - chemosis 219
 - conjunctiva covering 191, 218
 - damage, repair 169
 - disorders 218–220
 - clinical appearance, diagnosis 218–219
 - differential diagnosis 220
 - long-term prognosis 220
 - methods for definitive diagnosis 220
 - treatment 220
 - elevated 146, 219, 219
 - bilateral, causes 219
 - causes 219
 - Horner's syndrome 215, 215, 708
 - hyperkalemic periodic paralysis 758
 - systemic illness causing 728
 - see also* prominence (*below*)
 - erosion 219
 - examination 27–28, 191
 - flaps 395
 - “flashing”, tetanus 731
 - foreign bodies 326, 329
 - gland *see* nictitans gland
 - inflammation 219
 - lacerations 219, 220
 - lymphosarcoma 236, 237
 - nonpigmented 2, 219
 - partial removal 220
 - pigmentation 2, 218
 - pigment lacking 2, 219
 - position disorders 219, 220
 - prolapse
 - rabies 728
 - systemic illness causing 728
 - prominence (protrusion) 146, 147
 - enophthalmos 144–145
 - Horner's syndrome 215, 215, 708
 - orbital cellulitis 157
 - orbital neoplasia 161, 162, 162
 - removal
 - iatrogenic fat prolapse after 154–155
 - transconjunctival enucleation 172, 174
 - resection 220
 - squamous cell carcinoma 218, 219, 227, 227, 228, 228, 231, 675
 - surgical treatment 231
 - surgical therapy 220
 - in T-cell lymphoma 763, 763
 - trauma 219, 220
 - third eyelid gland *see* nictitans gland
 - THO *see* temporohyoid osteoarthropathy (THO)
 - Thoroughbreds
 - congenital cataracts 678
 - pemphigus 755
 - persistent pupillary membrane 505
 - racing injury database 793
 - racing with one blind eye 794
 - sarcoids 223
 - three-dimensionality, perception 620, 648
 - three-order neuron pathway 699, 699–700
 - thrombocytopenia 738
 - thrombospondins 263
 - thymidine analogues, putative viral keratitis 320
 - thymine 661
 - thyroid carcinoma 487
 - tight intercellular junctions
 - corneal endothelium 259, 260
 - corneal epithelium 257, 268
 - nonpigmented epithelium of ciliary body 441, 443
 - tigilanol tiglate 763
 - time-domain optical coherence tomography (TD-OCT) 121
 - timolol maleate, glaucoma 555
 - tissue glues, iris prolapse 418
 - tissue inhibitor of metalloproteinases (TIMP)-2 467
 - tissue plasminogen activator (TPA)
 - in anterior chamber 417
 - corneal trauma 329, 332, 417
 - iris prolapse 417, 418
 - Lyme disease 746
 - persistent fibrin, post-cataract surgery 533, 535
 - T lymphocyte(s) 51

- activation 415
 - acute corneal graft rejection 415
 - in ERU 465
- acute corneal graft rejection 415
- adnexal lymphosarcoma 237
- CD3+
 - adnexal SCC 228
 - equine recurrent uveitis 466
- CD4+ helper (Th) cells 262
 - acute corneal graft rejection 415
 - autologous mesenchymal stem cell therapy
 - effect 479
 - autoreactive, anergy after sustained-release CsA 482
 - autoreactive, in ERU 463, 464, 465, 672
 - bystander activation, putative viral keratitis 318
 - changes/dysregulated in ERU 464, 672
 - equine recurrent uveitis 463, 464, 466
 - formin-like 1 (FMNL1) deficiency 464
 - immune-mediated keratitis 307
 - increased IFN γ expression in ERU 464
 - lineages (Th1, Th2, Th17) 262, 464
 - Th1 and Th17 in experimental autoimmune uveitis 479
 - Th1 in ERU 464, 466, 467, 672
 - Th17, in ERU 464, 466, 672
- CD8+ (cytolytic) 262
 - acute corneal graft rejection 415
 - immune-mediated keratitis 307
- CD31, equine viral arteritis 737
- Fas ligand binding 259
- lacking, SCID 681
- lymphocytic nodules, ERU 468, 468
- memory cells 262
- regulatory (Tregs) 262
 - remission of inflammation in ERU 464, 465
- tobramycin 354
- Toll-like receptor (TLR) 257, 261, 262, 312, 360
- tonography 46
- tonometry 32, 42–46
 - applanation 43, 44–45
 - digital (palpation) 43
 - direct 43
 - factors affecting 44–45
 - handheld tonometers 43, 44
 - indentation 43
 - indications 43
 - indirect 43
 - instruments 43, 43
 - measurement methods 43, 43, 44
 - portable tonometers 43, 43
 - rebound 43, 44, 44–45
 - reproducibility 44
 - sedation 45
 - sequential/repeat, use of same tonometer 45, 46
- Tonopen-Avia® tonometer 43
- Tonopen XL® tonometer 43, 44
- TonoVet PLUS® tonometer 43, 44, 44, 45
- TonoVet® tonometer 43, 44, 45
- topical anesthesia
 - cornea, ultrasound 104
 - subpalpebral lavage system insertion 65
- topical medication 62–64
 - amphiphilic drugs, corneal disease 273
 - application, steps 63
 - bioavailability of drugs 273–274, 389
 - compliance 272
 - contamination of multidose bottle 273
 - for corneal diseases 272, 273–274
 - entropion 200
 - eyedrop application 273
 - gels 273
 - half-life of drugs 273
 - in idiopathic primary edema 279
 - liquid forms 63
 - novel methods 274
 - ointment forms 63, 63, 274
 - old, risks of using 63
 - for orbital/globe disease 156, 164
 - polypharmacy formulations 273
 - positive reinforcement training for 63, 63
 - preparation 63
 - solutions 273
 - SPL system, delivery 67, 69, 273
 - spraying, using insulin syringe 273
 - stromal abscesses 389
 - suspensions 273
 - see also individual drugs
- topical ophthalmic dyes 35
- toric (toroidal) cornea 639
- touch, blind horses 803, 803
- toxic plants 767–768
 - clinical signs 767, 767–768
- toxins, equine leukoencephalomalacia 724
- Toxoplasma gondii* 748
- toxoplasmosis 748, 748–749
- trabecular cells 442
- trabecular meshwork 442
 - anatomy 543, 544
 - aqueous humor outflow 543, 544
 - obstruction, acute anterior uveitis 453
- traction bands, retinal detachment 593, 594
- trail horses, blind 813, 813
- training, blind horses see blindness/blind horses
- traits
 - polygenic 666
 - simple (Mendelian) 666
- transcorneal tension, measurement 43
- transforming growth factor beta (TGF- β) 268, 400
- transforming growth factor beta 1 (TGF- β 1) 258
- transient receptor potential cation channel,
 - subfamily M, member 1 (TRPM1) gene see *TRPM1* gene
- transillumination 16, 16
 - cataracts 16, 16
 - ciliary body cyst 14
 - cornea examination 29
 - direct 32
 - lens examination 14
 - ocular fundus 16, 17, 19
 - posterior segment examination 33
- Purkinje–Sanson reflexes 16, 16
- slit-lamp biomicroscopy 18
- transilluminator method
 - direct ophthalmoscopy 19, 20
 - indirect ophthalmoscopy 20
- transitional carcinoma, sinonasal 96
- transmission of light 15
- transscleral cyclophotocoagulation (TSCP) 557, 557, 558, 566
- trapped horses 798
 - blind horses 803, 817
- trauma 764–765, 765
 - blunt see blunt trauma
 - causes 764
 - clinical appearance and diagnosis 607, 607
 - clinical signs 764, 764
 - conjunctivitis/blepharitis due to 204
 - corneal see corneal trauma
 - cranial, optic neuropathy due to 603–604, 604
 - diagnosis of injury 765
 - eyelid see eyelid trauma
 - eyelid lacerations see eyelid lacerations
 - facial see facial trauma
 - globe see globe, trauma
 - head see head trauma
 - Horner's syndrome due to 215
 - intraocular inflammation 516
 - investigations/radiology 765
 - iris prolapse 324, 325, 326, 335, 417
 - lens 105, 325
 - lens capsule rupture 515, 516
 - lens luxation due to 607
 - limbus rupture 325, 333
 - optic nerve see optic nerve (CN II)
 - orbital see orbital trauma
 - penetrating injuries 606
 - ultrasound 109
- perforating 606
- posterior segment 325, 606–608, 607
- prevalence 764
- prevention, practical/stable-management practices 476, 476
- retina 607
- skull radiography 92
- susceptibility 212
- third eyelid 219, 220
- treatment 607–608, 765
- ultrasound 106, 109
- see also individual structures and injuries
- traumatic optic neuropathy 598, 603–604, 604, 705, 707
- treat feeding 63–64
- trephination
 - indications 179
 - sinus disease 138, 179
 - sinuses 178–180
- Treponema* 470
- triamcinolone acetamide
 - equine recurrent uveitis 478, 478
 - subconjunctival injection 478
 - suprachoroidal injection 478, 479

- triazoles **374**
 - trichiasis 208, 209, 209
 - cause 210
 - surgical treatment 210
 - Trichophyton* 206
 - trifluorothymidine, putative viral keratitis 320
 - trifluridine 318
 - Trifolium hybridum* (alsike clover) 767
 - trigeminal ganglion
 - anatomy 698
 - EHV-2 latency 318–319
 - trigeminal mediated headshaking, photic *see* photic trigeminal mediated headshaking
 - trigeminal nerve (CN V)
 - anatomy and function 697, 698
 - branches 697, 698
 - examination **24**
 - eyelid innervation 189, 189
 - headshaking 733
 - in hypothyroidism 762
 - mandibular branch 697–698, 698
 - maxillary branch 697, 698
 - in neurogenic keratitis 711
 - ophthalmic branch 189, 189, 215, 697, 698, 711
 - trauma, keratoconjunctivitis sicca 198
 - vibrissae as tactile stimuli via 187
 - trigeminal neuropathy 711
 - photic trigeminal mediated headshaking 714
 - trilostane 762
 - trimethoprim, nasolacrimal disease **196**
 - trimethoprim sulfonamide (TMPs), orbital disease 164
 - trismus 731
 - trochlear nerve (CN IV)
 - anatomy 697
 - examination **24**
 - function 694
 - motor nucleus 696, 697
 - Trombicula autumnalis* 733
 - tropicamide 32
 - accommodation mechanism 645
 - cataract evaluation 517
 - evaluation before cataract surgery 523
 - for examination **10, 14**
 - posterior segment evaluation 565
 - TRPM1, as melastatin 1 668
 - TRPM1* gene 587, 667
 - congenital stationary night blindness 587, 667
 - ERU in Appaloosa horses 674
 - functions 667, 668, 674
 - immune 674
 - knockout mice 668
 - polymorphisms 667
 - trypan blue 35, 38
 - Trypanosoma evansi* 733
 - trypanosomiasis 733, **733**
 - tubuloacinar gland (nictitans gland) 191, 218
 - tumor necrosis factor α (TNF α) 259, 266
 - tumors *see* neoplasia
 - tumor suppressor gene
 - Melastatin 1 (MLSN1) 668
 - mutations, SCC 675
 - turbinates, ethmoid 138
 - two-dimensional photos, information transfer 648
 - tympano-occipital fissure 699, 700
 - Tyndall effect 31, 31
- U**
- UBM *see* ultrasound biomicroscopy (UBM)
 - ulcer(s), or ulcerations
 - corneal *see* corneal ulceration
 - melting *see* keratomalacia (melting ulcers)
 - ulcerative keratitis
 - amniotic membrane transplant 401
 - assessment 35
 - bacterial 343
 - clinical appearance 343
 - diagnostic techniques 343, 347, 350, 352
 - differential diagnosis 343
 - Gram-negative species **344–345**
 - Gram-positive species **346–347**, 352
 - medical therapy 352–356, **353**
 - see also* corneal ulceration, bacterial
 - cytology 48–49, 343
 - sampling collection methods 49, 49–50
 - staining of slides 50
 - frequency 74
 - fungal *see* ulcerative keratomycosis
 - inflammatory cell features 49
 - iridocyclitis in 354
 - management 200
 - see also* corneal ulceration
- ulcerative keratomycosis 357–360, 361, 363–366
 - causative species 358
 - clinical forms 363–364
 - clinical signs 363, 365
 - continuum, preliminary phases 363
 - corneal ulcers in 363, 363, 364
 - corticosteroids associated 358, 360
 - diagnosis 365, 371–372
 - differential diagnosis 372–373
 - fungal species **359**
 - groove/furrow 364, 365
 - histology 364
 - pathogenesis 358, 360
 - prevalence, factors influencing 358, 360
 - prognosis 387
 - proteases in 377
 - treatment 365, 365–366, **374, 375**, 376, 377
 - combination therapy **375**
 - surgical 377, 384
 - see also* keratomycosis
- ultrasonic pachymetry 46–47
- ultrasonography/ultrasound 100–110
 - abscesses 108
 - acoustic enhancement 110
 - “acoustic shadow” 110
 - advantages 100
 - air entrapment, artifact 109
 - amplitude-mode (A-scan) 102, 102
 - anechoic structures 103
 - artifacts interpretation 109–110, 110
- asteroid hyalosis 106–107
- Baum's bumps 109, 110, 110
- blunt trauma, non-lacerating 330, 331
- brightness-mode (B-scan) 102, 103
- cataracts 105, 105
 - after cataract surgery 532
 - before cataract surgery 523–524, 537
- ciliary body cysts 448
- comparison of eyes 103
- cornea 103, 104
- corneal ulceration 104
- cysts 108
- dacryoadenitis 108–109
- Descemet's membrane detachment 330
- Doppler 102, 103
- echoes 101
- exophthalmos 108
- eye tumors 108
- in the field 58–59, 61
- foreign bodies 108, 109
- general features 101–103
- globe, offset device for 104, 104
- globe, ruptured 109
- head injuries 765
- high-frequency *see* high-frequency ultrasound
- high-resolution *see* high-resolution ultrasound
- hyperechoic structures 103
- hypoechoic structures 103
- indications 58, 100–101, 104–105, 577
- intraocular masses 101, 107–108, 108
- iris hypoplasia 450
- lens 103, 105, 106
- lens luxation 101, 105, 106, 109
- lens subluxation 105
- limitations 103
- linear transducer vs. sector/convex 102
- MCOA syndrome 585
- melanoma 108
- ocular acoustic echoes, normal 103, 103
- ocular injury in facial trauma 152
- ocular trauma 106, 109, 330, 331
- optimal transducer (7.5/10-MHz) 102
- orbit 108–109, 162
- orbital exploration, surgical 166
- orbital neoplasia 162
- orbital trauma 108
- panuveitis 108
- posterior segment 106–107, 577, 578
- posterior segment coloboma 599
- principles 101–102
- probes 58, 59, 110
 - high-frequency 110, 111
- real-time B-mode before fine-needle aspiration 139
- reduplication echoes 109
- refraction 101
- retinal detachment 101, 107, 108, 577, 578, 594
- retrobulbar neoplasms 101, 108
- reverberation artifacts 109, 110, 327
- sedation 104
- shadowing 110

- specific ocular structures 103
- technique 103–104
- time gain compensation (TGC) 102
- transcorneal approach 103, 104
- transducers 102, 104, 104, 111
- transpalpebral approach 103, 151
- tumors 108
- vitreal degeneration 106
- vitreal pseudomembranes 107
- vitreous 566
- vitreous cavity 106
- vitreous hemorrhage 107, 108
- vitreous inflammation 107
- waves, velocity 101
- ultrasound biomicroscopy (UBM) 110–114
 - anterior segment 111
 - central corneal thickness measurement 114
 - corneal foreign bodies 329
 - corneo-limbral SCC 112
 - corpora nigra 111
 - high-frequency 102
 - indications 110–111
 - limitations 111
 - normal appearances in 110–111, 111
 - scleral thickness measurement 114
 - water bath use 111
- ultraviolet (UV) radiation
 - adnexal SCC association 228–229
 - cones sensitive to 651
 - DNA damage, corneal SCC 288
 - SCC pathogenesis 228, 288, 675
 - UV-A, collagen cross-linking, corneal ulcer healing 356
- unilateral sight loss 815–816
 - acuity/depth perception of unilateral sight 816
 - adaptation to 815
 - causes 815
 - equestrian competition 816
 - handling horses with 815
 - regulations affecting 794
 - sport horses 816, 816
- United States of America (USA), regulatory agencies 792, 793
- United States Equestrian Federation (USEF) 792, 793, 794
 - rules on performance horses, vision loss 794, 795–796
- United States Trotting Association Rules and Regulations 794
- uracil 664
- USDA piroplasmosis treatment program 748
- uvea 134
 - see also uveal tract
- uveal coloboma 449
- uveal cysts 446
 - anterior 446–449, 450
 - differential diagnosis 447, 448, 450
 - locations 446
 - see also ciliary body, cysts; corpora nigra, cysts; iridal cysts
- high-resolution ultrasound 113, 113
- infrared photography 115
- uveal diseases
 - acquired 451–484
 - congenital 444–450
 - inflammatory see uveitis
 - metastatic neoplasia 487
 - neoplasia 484–487
- uveal inflammation see uveitis
- uveal lymphoma 486–487
- uveal melanoma 484, 484–486, 485
 - clinical signs/appearance 484, 484–485
 - differential diagnosis 448, 485
 - histology 485, 485–486, 486
 - pathogenesis 485
 - treatment 486
- uveal prolapse 515
- uveal trabecular meshwork (UTM) 543, 551
- uveal tract 441
 - anatomy and physiology 441–444
 - anterior
 - ERU histopathology 468, 468–469, 469
 - medulloepithelioma 450, 450
 - melanoma 484, 484–485
 - see also ciliary body; iris
 - blood supply/circulation 444, 445
 - diseases see uveal diseases
 - exudates, in ERU 468
 - inflammation see uveitis
 - infrared photography 114
 - perfusion, decrease in elevated IOP 545
 - pigmentation, glare defense 644
 - posterior 442
 - see also choroid
 - prolapse 151, 515, 607
 - traumatic 607
 - see also choroid; ciliary body; iris
- uveitis 451–484
 - acute active 451, 451, 452, 452–455, 461
 - causes 453, 453–454
 - clinical diagnostic decision tree 451
 - clinical signs 451, 452, 452
 - diagnostic test decision tree 454
 - leptospirosis and 472–473
 - therapeutics decision tree 454
 - treatment 453, 455
 - anterior 451
 - absent in IMMK 307
 - acute, clinical signs 451, 452, 452, 452
 - in bacterial corneal ulcers 343, 350, 354–355, 357, 387
 - cataracts 507
 - causes 452
 - ciliary cleft collapse 551, 554
 - control in bacterial corneal ulcers 354–355
 - deep fungal stromal abscess 368
 - foreign bodies causing 328, 330
 - iris fungal abscess 372
 - in lens capsule rupture 516
 - melting ulcers and 389
 - neonatal sepsis 768–769, 769
 - onchocerciasis 321, 751
 - Rhodococcus equi* infection 772
 - systemic illness causing 742
 - ulcerative keratomycosis 378
- Appaloosa breed 473–474
- autoimmune 464, 465
- cataracts due to 507, 508
- causes 451
- chronic 451, 451, 455–457, 519
 - cataract surgery complication 534, 535
 - clinical diagnostic decision tree 451
 - clinical signs 455, 455
 - diagnostic test decision tree 454
 - leptospirosis and 473
 - pars plana vitrectomy 482
 - persistent 455
 - therapeutics decision tree 454
- clinical diagnostic decision tree 451
- clinical signs 451, 768, 772
- definition 451
- diagnosis 451
- endogenous, subepithelial mineralization in 281, 281
- end-stage 455, 456
- equine leukocyte antigen and 673
- equine recurrent see equine recurrent uveitis (ERU)
- experimental autoimmune (EAU) 464, 465, 466
- “flare-up”, stromal abscess treatment 390
- history taking 451
- insidious
 - enucleation 816
 - lens luxation with 510
- in lens capsule rupture 515
- lens-induced see lens-induced uveitis (LIU)
- leptospirosis and 472–473
- in Lyme disease 581, 745
- mare reproductive loss syndrome 766
- mechanism of inflammation 354
- onchocerciasis 751
- panuveitis see panuveitis
- peracute 766
- posterior 451
 - neonatal sepsis 769
 - onchocerciasis 751
 - systemic illness causing 742
- pupil dilation and 14
- recurrent 387, 451, 451, 457
 - clinical diagnostic decision tree 451
 - diagnostic test decision tree 454
 - phthisis bulbi due to 146
 - therapeutics decision tree 454
 - see also equine recurrent uveitis (ERU)
- reflex 320
- Rhodococcus equi* infection 772, 772
- secondary
 - chronic stromal abscess 389
 - neonatal sepsis 770
- septic, neonatal foals 768
- subacute 451, 451
 - clinical diagnostic decision tree 451
 - diagnostic test decision tree 454

- uveitis (*cont'd*)
 - leptospirosis and 472–473
 - therapeutics decision tree **454**
 - after transscleral cyclophotocoagulation 558
 - treatment, decisions 476–477
 - unilateral, infrared thermography 117
 - uveodermatologic syndrome 208
 - uveoscleral outflow 46
 - V**
 - Vaccaria pyramidata* (cow cockle) 767
 - vaccine/vaccination
 - autologous, sarcoid treatment 225
 - corneal melanoma treatment 299
 - EHV-1 741–742
 - EHV-4 741–742
 - in equine recurrent uveitis, spacing 476
 - influenza (equine) 742
 - Leptospira* 477, 747
 - rabies 729
 - strangles 744
 - tetanus *see* tetanus vaccination
 - West Nile viral encephalitis 728
 - vago-sympathetic trunk lesion, Horner's syndrome 710
 - vagus nerve (CN X) 700
 - variable expressivity 665
 - varnish roaning 667, 668
 - vascular congestion, reduced 452
 - vascular endothelial cells 263
 - vascular endothelial growth factors (VEGFs) 263, 268
 - corneal vascularization 263, 271–272
 - decreased, glucocorticoid action 312
 - VEGF-A 388, 390
 - vascularization
 - corneal *see* corneal vascularization
 - limbal 278, 341
 - perilimbal 279
 - retina (paurangiotic) 33, 568, 569
 - vascular pannus 271
 - vascular supply *see* blood supply/circulation
 - vascular tumors, corneal 297–298
 - vascular tunic *see* choroid
 - vasculitis, infectious diseases causing 140
 - vasoactive intestinal peptide-1 (VIP-1) 260
 - VEGF-A 388, 390
 - Venezuelan equine encephalitis **726**, 726–727
 - venous air embolism 765–766
 - venous malformations, superficial 149
 - venous stasis, episcleral vascular congestion causing 147, 148
 - venting, USEF rules **795**
 - ventral oblique muscle 697
 - vergence eye movements 626, 629
 - Verhoeff's stain 284
 - vernal keratoconjunctivitis (VKC) 316
 - vernier (alignment) acuity 648
 - vertebral nerves 700
 - vesicles, lens 508
 - vestibular disease 729–731
 - bilateral 730
 - central 729, 730, **730**
 - infectious causes of signs 730
 - paradoxical 730
 - diagnosis 730–731
 - peripheral 140, 729–730, **730**
 - clinical signs 730, **730**, 730
 - vestibular ganglion 695
 - vestibular system (VS) 627, 695
 - central 695, 696
 - components, anatomy 695, 696
 - equilibrium, role 695
 - motion detection 627
 - peripheral 695
 - vestibulocochlear nerve (CN VIII) 695, 697, 700
 - anatomy 712
 - dysfunction
 - temporohyoid osteoarthropathy 735, **735**, 735
 - vestibular disease 730, **730**
 - examination **24**
 - in keratoconjunctivitis sicca 148
 - vestibular division 695
 - vestibulo-ocular reflex (VOR) 626, 627, 629, 704
 - assessment 704
 - neuroanatomic pathway 696, 696, 704
 - simulation 627, 704
 - veterinarians
 - judging suitability of horse for use 615
 - recommendations on riding blind horse 815
 - responsibility, medications for performance horses 794
 - vibrissae 2, 187, 188
 - function 187
 - Vicryl 415
 - viral infection(s)
 - acute uveitis **453**
 - chorioretinitis 592
 - conjunctivitis **204**, 205
 - encephalitis **726**, 726–727
 - epitheliotropic virus 318
 - optic neuritis 605
 - polyneuritis equi 737
 - systemic, ocular manifestations 726–729, 737–743
 - see also specific viruses*
 - viral keratitis, putative *see* keratitis
 - virulence 339
 - viscoelastic material/solution
 - cataract surgery 528, 530, 533
 - corneal surgery 393
 - in penetrating keratoplasty 405
 - visible light 619, 619
 - vision 615–660
 - assessment 23–27, 565, 615, 700
 - before cataract surgery 522–523
 - difficulties/complexity 615, 655
 - maze testing 26, 26–27, 700
 - menace response *see* menace response
 - assessment stimuli 637
 - contrast 637, 638
 - luminance 637, 638
 - binocular 566, 632, 793
 - in bright light, adaptations 624–625
 - after cataract surgery 537
 - color *see* color vision
 - in congenital stationary night blindness 586
 - definition 615
 - dichromatic 566
 - digital camera comparison 616–617
 - in dim light 623–625, 655
 - shape discrimination 624
 - see also* dim light
 - diseases affecting 615
 - double 139
 - evolution 624, 625, 654
 - after globe perforation 151, 152
 - history taking, before cataract surgery 522
 - impairment, microphthalmic eyes 141
 - importance of understanding of 615
 - information overload 618
 - information processing *see* information processing
 - light adaptation 620–621, 622–623
 - loss
 - behavior indicating 637
 - in ERU 474, **475**, 476
 - resistance, in glaucoma 546–547, 568
 - transient 708
 - see also* blindness/blind horses; visual deficit
 - monocular 793
 - motion detection *see* motion detection
 - after neonatal sepsis 769
 - neuro-ophthalmic examination 700–701
 - night *see* night vision
 - ocular adaptation 623–625
 - panoramic view 631, 632, 655
 - poor in low light, in CSNB 586, 587
 - spatial, performance animals 793
- visual acuity 626, 635–648
 - accommodation *see* accommodation, lens
 - age affecting 638
 - assessment
 - behavioral testing 623
 - optokinetic nystagmus activation 627, 628
 - stimuli for 637
 - in bright light 638, 647
 - definition 635
 - diffraction 642
 - in dim light 623, 637, 638, 648
 - distortion 639
 - evaluation 635
 - factors influencing 637–638
 - glare and *see* glare
 - high, cone:ganglion cell ratio 647
 - measurement 635–636
 - menace response and 636–637
 - on/above ground, effect 636
 - motion detection and 626
 - optical aberrations *see* optical aberrations
 - optical factors 638–639
 - optimizing, ganglion cell density 647
 - optokinetic nystagmus testing 627

- posterior nodal point 643, 643–644
 - pupil shape 645–646
 - pupil size, effect of 637, 645
 - reduced, dim light 623
 - refractive state 639–642
 - reporting 636
 - retinal factors affecting 646–648
 - temporal visual streak 646
 - terminology 636, **640**
 - unilateral sight 816
 - visual attention 618, 618
 - visual centre 647
 - visual cortex 701
 - lesions 704, 707–708
 - neuroplasticity, blindness 801–802
 - retrochiasm pathways to 693–694, 695
 - visual cues, importance, herd animals 798
 - visual deficit
 - anisocoria with 708
 - assessment 700
 - equine protozoal myeloencephalitis 721
 - menace response deficiency 25, 700
 - optic neuropathy 704, 705
 - posterior nodal point opacities 644
 - posterior segment lesions 565
 - post-retinal, neurologic causes 704–708
 - PPID (equine Cushing's disease) 759
 - see also* vision, loss
 - visual discrimination 636, 648
 - light level affecting 638
 - orientation basis 650, 650–651
 - shape, dim light 624
 - visual evoked potentials (VEPs) 42
 - flash-stimuli (FVEP) 42
 - posterior segment examination 578
 - recording with ERG 42
 - visual field 133, 566, 628, 629–635, 633, 655
 - horizontal 629
 - menace response assessment 700
 - monocular, horizontal meridian 629
 - overlap between eyes 139, 632
 - peripheral, motion detection 625
 - total horizontal 629
 - visual pathways 617–618, 691
 - dysfunction 691
 - poor understanding of 618
 - visual perception
 - axons in lateral geniculate nucleus 694
 - neuroanatomic pathways 694, 695, 700
 - visual perspective, field of view and 629–635, 630
 - visual pigments, families 651
 - visual resolution, limits, optokinetic nystagmus 627
 - visual sensitivity
 - saccades 628
 - vergence eye movements 629
 - visual “shortcuts” 626–627, 627
 - visual streak 23, 566, 628, 646, 647, 655, 692
 - cone density 652
 - ganglion cell density 646, 655
 - lesions, visual acuity 637
 - rods, visual discrimination impaired in bright light 638
 - sensitivity, visual acuity 646–647, 647
 - tapetal location, dim light vision 647
 - temporal, visual acuity 646
 - visual system, evolution 624
 - visual texture 635, 636
 - Visudyne 234
 - vitamin A
 - corneal scarring (postsurgery) reduction 418
 - deficiency 586, 764
 - chronic 764
 - clinical signs 764, **764**
 - functions 764
 - neurogenic keratoconjunctivitis sicca 218
 - vitamin B2 (riboflavin) 356
 - vitamin E
 - deficiency 158, 597
 - chronic, equine motor neuron disease 724, 725
 - NAD/EDM 726
 - supplementation 158
 - equine motor neuron disease 725
 - NAD/EDM 726
 - vitamin E-deficient myopathy 725
 - vitamin K-dependent coagulation factors 768
 - vittiligo 208, 209
 - conjunctival, onchocerciasis 751, 751
 - vitreal collagen 581
 - vitreal degeneration (syneresis) 581–582, 582
 - posterior ERU 459, 460
 - posterior lens luxation with 515
 - ultrasound 106
 - vitreal hemorrhage 607
 - in pars plana vitrectomy in ERU 484
 - ultrasound 107, 108
 - vitreal membranes, thickened 581, 582
 - vitreal pseudomembranes, ultrasound 107
 - vitrectomy 608
 - complications 608
 - ERU 482–484
 - pars plana *see* pars plana vitrectomy (PPV)
 - vitrectomy contact lens, in ERU 483, 483
 - vitreous
 - abnormalities 566
 - anatomy and physiology 566
 - calcium-phosphate crystals 582, 583
 - color changes 566
 - degeneration *see* vitreal degeneration (syneresis)
 - diseases 580–582
 - in equine recurrent uveitis 466–468, 581, 608
 - examination 32–33
 - extrusion 150
 - floaters 33, 582
 - foreign body 327
 - hemorrhage *see* vitreal hemorrhage
 - hyaloid artery remnants 581, 581
 - IgA, in ERU 581
 - inflammation (hyalitis) 581, 582
 - posterior equine recurrent uveitis 459
 - ultrasound 107
 - injection, after paracentesis 57–58, 58
 - Leptospira interrogans* in 581
 - liquefaction
 - in acute uveitis 453
 - in posterior ERU 460, 460
 - medulloepithelioma 606
 - opacities, posterior ERU 459, 460, 460
 - reverberation artifact 327
 - “seagull” sign 578, 595
 - ultrasonography 566, 578
 - yellow discoloration, posterior equine recurrent uveitis 459, 460
 - yellow-green discoloration 570, 581, 582
 - zones 566
 - vitreous cavity
 - MRI 97, 98
 - ultrasound 106
 - vitreous chamber
 - CT 94
 - ultrasound 103
 - vitreous humor, volume 136
 - normal reference range **9**
 - vitreous paracentesis 57, 57–58
 - complications 57
 - indications/uses 57
 - procedure 57, 57–58
 - vittitis, in posterior equine recurrent uveitis 459–460
 - voriconazole **374**, 375, 376
 - intracorneal injection 74
 - keratomycosis 375, 376, 377
 - SPL system unsuitable 70, 353
 - stromal abscesses 389
 - vortex veins 137, 543, 544, 577
 - dorsal 137
 - ventral 137
 - voxels 92
- W**
- wall eyes *see* blue-eyed horses
 - Warmbloods
 - corneal thickness 257
 - DDB2* gene 676
 - middle cranial fossa syndrome 714
 - posterior equine recurrent uveitis 459, 463
 - sarcoids 223
 - see also* German Warmblood horses
 - water buckets, blind horses 804, 804
 - water hemlock ingestion 768
 - wavelengths of light, color vision and 651, 651
 - weakness
 - botulism 732
 - equine motor neuron disease 724
 - hyperkalemic periodic paralysis 758
 - weight
 - head **9**
 - loss, orbital fat resorption, enophthalmos 144
 - Welch Allyn PanOptic ophthalmoscope 570, 572, 573
 - welfare concerns, ocular disease and 76
 - wellness visits 1
 - Western equine encephalitis **726**, 726–727

Western show ring events, blind horses 815
 West Nile virus, transmission 727–728
 West Nile virus encephalitis 727, 727–728
 clinical signs 727, 728
 diagnosis 728
 prevention and management 728
 white spotting mutations 668
 whole genome sequencing (WGS) 54
 wild onion ingestion 768
 wind, stressor for blind horses 804
 Winslow, stars of 19
 withers, fistulous 746
 Wnt signaling 467
 working horses
 blind horses 811–813, 813
 ophthalmic conditions frequency 76, 76
 wound healing
 cascade, corneal 266
 corneal *see* corneal wound healing
 wound management, blepharitis 207, 208

X

X chromosome 664
 mutations on, inheritance 666
 random inactivation 664
 xeroderma pigmentosum (humans) 676
 xeromycteria 711
 X-linked dominant inheritance 666
 X-linked recessive inheritance 666
 X-ray *see* radiography
 X-ray attenuation, CT 92
 XXTERRA™, sarcoids 224
 xylazine
 effect on IOP 45
 for examination 9, 10

Y

Y chromosome 664
 yellow pigments, lens 624, 625, 644, 655
 yellow sweet clover ingestion 768
 Y sutures 32

Z

Zeiss-like glands 189
 zonulae occludens 257
 zonular fibers 14, 32, 441, 442
 accommodation 644, 645
 formation problem 510
 rupture, elevated IOP effect 545
 zonular ligaments
 degeneration, lens luxation 510
 fibrin deposits 514
 zoonotic disease 729
 zygomatic arch fractures 149
 zygomatic bone 133, 134, 135
 zygomatic branch, auriculopalpebral nerve 217
 zygomatic nerve 12, 13, 700
 anatomy 697
 block 12, 13
 zygomatic process, frontal bone
 fractures 167, 167, 168
 resection 166

